Pyrrolopyrazine kinase inhibitors

This application is entitled to the benefit of U.S. provisional patent application Ser. No. PCT/CN2011/001489 filed on Sep. 1, 2011, the disclosure of which is incorporated herein by reference.

The present invention relates to the use of novel pyrrolopyrazine derivatives which are JAK and SYK inhibitors and selectively inhibit JAK3 and are useful for the treatment of autoimmune and inflammatory diseases. This application is related to U.S. application Ser. Nos. 13/110,062, filed May 18, 2011, 13/110,053, filed May 18, 2011, 13/040,310, filed March 4, 13/039,433, filed Mar. 3, 2011, 12/378,837, filed on Feb. 20, 2009, 12/378,869, filed on Feb. 20, 2009, 12/378,971, filed on Feb. 20, 2009, 12/378,977, filed on Feb. 20, 2009, and 12/378,978, filed on Feb. 20, 2009, the disclosures of which are incorporated herein by reference.

The JAKs (JAnus Kinases) are a family of cytoplasmic protein tyrosine kinases including JAK1, JAK2, JAK3 and TYK2. Each of the JAKs is preferentially associated with the intracytoplasmic portion of discrete cytokine receptors ( Annu. Rev. Immunol. 16 (1998), pp. 293-322).

JAK/STAT signaling has been implicated in the mediation of many abnormal immune responses such as allergies, asthma, autoimmune diseases such as transplant (allograft) rejection, rheumatoid arthritis, amyotrophic lateral sclerosis and multiple sclerosis, as well as in solid and hematologic malignancies such as leukemia and lymphomas.

Animal studies have suggested that JAK3 not only plays a critical role in B and T lymphocyte maturation, but that JAK3 is constitutively required to maintain T cell function. Modulation of immune activity through this novel mechanism can prove useful in the treatment of T cell proliferative disorders such as transplant rejection and autoimmune diseases.

JAK3 inhibitors are useful therapy as immunosuppressive agents for organ transplants, xeno transplantation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other indications where immunosuppression would be desirable.

SYK (Spleen Tyrosine Kinase) is a non-receptor tyrosine kinase that is essential for B-cell activation through BCR signaling. SYK become activated upon binding to phosphoryated BCR and thus initiates the early signaling events following BCR activation. Mice deficient in SYK exhibit an early block in B-cell development (Cheng et al. Nature 378:303, 1995; Turner et al. Nature 378:298, 1995). Therefore inhibition of SYK enzymatic activity in cells is proposed as a treatment for autoimmune disease through its effects on autoantibody production.

SYK is implicated in allergic disorders including asthma (reviewed in Wong et al. Expert Opin Investig Drugs 13:743, 2004). Therefore, small molecule inhibitors of SYK will be useful for treatment of allergy-induced inflammatory diseases including asthma.

In view of the numerous conditions that are contemplated to benefit by treatment involving modulation of the JAK and/or SYK pathways it is immediately apparent that new compounds that modulate JAK and/or SYK pathways and methods of using these compounds should provide substantial therapeutic benefits to a wide variety of patients. Provided herein are novel pyrrolopyrazine derivatives for use in the treatment of conditions in which targeting of the JAK and/or SYK pathways or inhibition of JAK or SYK kinases, particularly JAK3, and are therapeutically useful for the treatment of auto-immune and inflammatory diseases.

The novel pyrrolopyrazine derivatives provided herein selectively inhibit JAK3 and/or SYK pathways and are useful for the treatment of auto-immune and inflammatory diseases. For example, the compounds of the invention may inhibit JAK3 and SYK. Furthermore, the compounds of the invention may inhibit JAK3 and JAK2, wherein preferred compounds are selective for JAK3 of the JAK kinases, and are useful novel pyrrolopyrazine derivatives for the treatment of auto-immune and inflammatory diseases. Similarly, the compounds of the invention may inhibit JAK3 and JAK1, wherein preferred compounds are selective for JAK3 of the JAK kinases, and are useful novel pyrrolopyrazine derivatives for the treatment of auto-immune and inflammatory diseases. In particular, the bicyclic heteroaryl sidechain off the pyrrolopyrazine core of the compound of Formula I, denoted by variable Q, renders these molecules unexpectedly increasingly selective for JAK3 of the JAK kinases, and/or SYK. In combination with the amido linked sidechains (—C(═O)NRR′) off of the pyrrolopyrazine core, which renders the compounds of Formula I unexpectedly potent over pyrrolopyrazine compounds with sidechains other than amido sidechains at the same position on the pyrrolopyrazine core, the compounds of formula I are both unexpectedly potent and selective for JAK3 of the JAK kinases, and/or SYK.

The application provides a compound of Formula I

wherein:

R is H;

R′ is lower alkoxy or

or R and R′ together form heterocycloalkyl, optionally substituted with —CN;

R 1 is H or R 1a ;

R 1a is lower alkyl, cycloalkyl, lower alkoxyl, hydroxy lower alkyl, or lower haloalkyl;

R 1′ is H or lower alkyl;

or R 1a and R 1′ together form heterocycloalkyl, cycloalkyl, indan-1-yl, phenyl, or heteroaryl, optionally substituted with one or more R 1″ ;

each R 1″ is independently hydroxy, amino, oxo, lower alkyl, —C(═O)NH 2 , —CN, lower haloalkyl, benzyl, cyano lower alkyl, or —NHC(═O)OC(CH 3 ) 3 ;

R 2 is H, hydroxy, —CN, —C(═O)NH 2 , —C(═O)OH, —C(═O)OC(CH 3 ) 3 , R 2a , or R 2b ;

R 2a is lower alkyl, phenyl, phenyl lower alkyl, cycloalkyl, heteroaryl, heterocycloalkyl, heterocycloalkyl lower alkyl, heteroaryl lower alkyl, phenyl lower alkoxy, lower alkoxy, optionally substituted with one or more R 2a′ ;

each R 2a′ is independently hydroxy, —CN, amino, lower alkyl sulfonylamino, lower alkoxy, halo, lower alkyl, cyano lower alkyl, lower haloalkyl, lower alkyl sulfonyl, oxo, halo lower alkoxy, cycloalkyl, —C(═O)OCH 3 ;

R 2b is —C(O)R 3 or —CH 2 C(═O)R 3 ;

R 3 is heterocycloalkyl, optionally substituted with one or more R 3′ ;

each R 3′ is independently —CN, halo, lower alkyl, or lower alkyl sulfonyl;

Q is a 5,6-bicyclic heteroaryl ring system, 6,6-bicyclic heteroaryl ring system, 5,5-bicyclic heteroaryl ring system, 6,5-bicyclic heteroaryl ring system, or 5,7-bicyclic heteroaryl ring system, optionally substituted with one or more Q a or Q b ;

each Q a is independently halo, —CN, hydroxy, or —(CH 2 )—C(═O)Q a′ ;

each Q a′ is independently hydroxy, amino, or heterocycloalkyl, wherein heterocycloalkyl is optionally substituted by one or more Q a″ ;

each Q a″ is independently lower alkyl or lower haloalkyl;

n is 1, 2, or 3;

each Q b is independently lower alkyl, cycloalkyl, lower alkoxy, phenoxy, lower alkyl sulfonyl, heterocycloalkyl, heterocycloalkyl lower alkyl, or heteroaryl lower alkyl, optionally substituted with one or more Q b′ ; and

each Q b′ is independently hydroxy, halo, —CN, amino, heterocycloalkyl, lower alkyl, benzyl, or lower alkyl sulfonyl;

or a pharmaceutically acceptable salt thereof.

The phrase “a” or “an” entity as used herein refers to one or more of that entity; for example, a compound refers to one or more compounds or at least one compound. As such, the terms “a” (or “an”), “one or more”, and “at least one” can be used interchangeably herein.

As used in this specification, whether in a transitional phrase or in the body of the claim, the terms “comprise(s)” and “comprising” are to be interpreted as having an open-ended meaning That is, the terms are to be interpreted synonymously with the phrases “having at least” or “including at least”. When used in the context of a process, the term “comprising” means that the process includes at least the recited steps, but may include additional steps. When used in the context of a compound or composition, the term “comprising” means that the compound or composition includes at least the recited features or components, but may also include additional features or components.

As used herein, unless specifically indicated otherwise, the word “or” is used in the “inclusive” sense of “and/or” and not the “exclusive” sense of “either/or”.

The term “independently” is used herein to indicate that a variable is applied in any one instance without regard to the presence or absence of a variable having that same or a different definition within the same compound. Thus, in a compound in which R″ appears twice and is defined as “independently carbon or nitrogen”, both R″s can be carbon, both R″s can be nitrogen, or one R″ can be carbon and the other nitrogen.

When any variable (e.g., X, X′, or Q) occurs more than one time in any moiety or formula depicting and describing compounds employed or claimed in the present invention, its definition on each occurrence is independent of its definition at every other occurrence. Also, combinations of substituents and/or variables are permissible only if such compounds result in stable compounds.

The symbols “*” at the end of a bond or “------” drawn through a bond each refer to the point of attachment of a functional group or other chemical moiety to the rest of the molecule of which it is a part. Thus, for example:

A bond drawn into ring system (as opposed to connected at a distinct vertex) indicates that the bond may be attached to any of the suitable ring atoms.

The term “optional” or “optionally” as used herein means that a subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs and instances in which it does not. For example, “optionally substituted” means that the optionally substituted moiety may incorporate a hydrogen or a substituent.

The phrase “come together to form a bicyclic ring system” as used herein means join to form a bicyclic ring system, wherein each ring may be made up of either 4-7 carbon atoms or 4-7 carbon and heteroatoms, and may be saturated or unsaturated.

The term “about” is used herein to mean approximately, in the region of, roughly, or around. When the term “about” is used in conjunction with a numerical range, it modifies that range by extending the boundaries above and below the numerical values set forth. In general, the term “about” is used herein to modify a numerical value above and below the stated value by a variance of 20%.

The definitions described herein may be appended to form chemically-relevant combinations, such as “heteroalkylaryl,” “haloalkylheteroaryl,” “arylalkylheterocyclyl,” “alkylcarbonyl,” “alkoxyalkyl,” “cycloalkylalkyl” and the like. When the term “alkyl” is used as a suffix following another term, as in “phenylalkyl,” or “hydroxyalkyl,” this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, “phenylalkyl” refers to an alkyl group having one to two phenyl substituents, and thus includes benzyl, phenylethyl, and biphenyl. An “alkylaminoalkyl” is an alkyl group having one to two alkylamino substituents. “Hydroxyalkyl” includes 2-hydroxyethyl, 2-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 2,3-dihydroxybutyl, 2-(hydroxymethyl), 3-hydroxypropyl, and so forth. Accordingly, as used herein, the term “hydroxyalkyl” is used to define a subset of heteroalkyl groups defined below. The term -(ar)alkyl refers to either an unsubstituted alkyl or an aralkyl group. The term (hetero)aryl or (het)aryl refers to either an aryl or a heteroaryl group.

Compounds of formula I may exhibit tautomerism. Tautomeric compounds can exist as two or more interconvertable species. Prototropic tautomers result from the migration of a covalently bonded hydrogen atom between two atoms. Tautomers generally exist in equilibrium and attempts to isolate an individual tautomers usually produce a mixture whose chemical and physical properties are consistent with a mixture of compounds. The position of the equilibrium is dependent on chemical features within the molecule. For example, in many aliphatic aldehydes and ketones, such as acetaldehyde, the keto form predominates while; in phenols, the enol form predominates. Common prototropic tautomers include keto/enol (—C(═O)—CH-Δ-C(—OH)═CH—), amide/imidic acid (—C(═O)—NH-Δ-C(—OH)═N—) and amidine (—C(═NR)—NH-Δ-C(—NHR)═N—) tautomers. The latter two are particularly common in heteroaryl and heterocyclic rings and the present invention encompasses all tautomeric forms of the compounds.

Technical and scientific terms used herein have the meaning commonly understood by one of skill in the art to which the present invention pertains, unless otherwise defined. Reference is made herein to various methodologies and materials known to those of skill in the art. Standard reference works setting forth the general principles of pharmacology include Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10 th Ed., McGraw Hill Companies Inc., New York (2001). Any suitable materials and/or methods known to those of skill can be utilized in carrying out the present invention. However, preferred materials and methods are described. Materials, reagents and the like to which reference are made in the following description and examples are obtainable from commercial sources, unless otherwise noted.

The term “acyl” as used herein denotes a group of formula —C(═O)R wherein R is hydrogen or lower alkyl as defined herein. The term or “alkylcarbonyl” as used herein denotes a group of formula C(═O)R wherein R is alkyl as defined herein. The term C 1-6 acyl refers to a group —C(═O)R contain 6 carbon atoms. The term “arylcarbonyl” as used herein means a group of formula C(═O)R wherein R is an aryl group; the term “benzoyl” as used herein an “arylcarbonyl” group wherein R is phenyl.

The term “alkyl” as used herein denotes an unbranched or branched chain, saturated, monovalent hydrocarbon residue containing 1 to 10 carbon atoms. The term “lower alkyl” denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms. “C 1-10 alkyl” as used herein refers to an alkyl composed of 1 to 10 carbons. Examples of alkyl groups include, but are not limited to, lower alkyl groups include methyl, ethyl, propyl, i-propyl, n-butyl, i-butyl, t-butyl or pentyl, isopentyl, neopentyl, hexyl, heptyl, and octyl, and are optionally fully or partially deuterated.

When the term “alkyl” is used as a suffix following another term, as in “phenylalkyl,” or “hydroxyalkyl,” this is intended to refer to an alkyl group, as defined above, being substituted with one to two substituents selected from the other specifically-named group. Thus, for example, “phenylalkyl” denotes the radical R′R″—, wherein R′ is a phenyl radical, and R″ is an alkylene radical as defined herein with the understanding that the attachment point of the phenylalkyl moiety will be on the alkylene radical. Examples of arylalkyl radicals include, but are not limited to, benzyl, phenylethyl, 3-phenylpropyl. The terms “arylalkyl”, “aryl alkyl”, or “aralkyl” are interpreted similarly except R′ is an aryl radical. The terms “heteroaryl alkyl” or “heteroarylalkyl” are interpreted similarly except R′ is optionally an aryl or a heteroaryl radical.

The term “haloalkyl” as used herein denotes a unbranched or branched chain alkyl group as defined above wherein 1, 2, 3 or more hydrogen atoms are substituted by a halogen. The term “lower haloalkyl” denotes a straight or branched chain hydrocarbon residue containing 1 to 6 carbon atoms, wherein 1, 2, 3 or more hydrogen atoms are substituted by a halogen. Examples are 1-fluoromethyl, 1-chloromethyl, 1-bromomethyl, 1-iodomethyl, difluoromethyl, trifluoromethyl, trichloromethyl, tribromomethyl, triiodomethyl, 1-fluoroethyl, 1-chloroethyl, 1-bromoethyl, 1-iodoethyl, 2-fluoroethyl, 2-chloroethyl, 2-bromoethyl, 2-iodoethyl, 2,2-dichloroethyl, 3-bromopropyl or 2,2,2-trifluoroethyl.

The term “alkylene” as used herein denotes a divalent saturated linear hydrocarbon radical of 1 to 10 carbon atoms (e.g., (CH 2 ) n ) or a branched saturated divalent hydrocarbon radical of 2 to 10 carbon atoms (e.g., —CHMe- or —CH 2 CH(i-Pr)CH 2 —), unless otherwise indicated. Except in the case of methylene, the open valences of an alkylene group are not attached to the same atom. Examples of alkylene radicals include, but are not limited to, methylene, ethylene, propylene, 2-methyl-propylene, 1,1-dimethyl-ethylene, butylene, 2-ethylbutylene.

The term “alkoxy” as used herein means an —O-alkyl group, wherein alkyl is as defined above such as methoxy, ethoxy, n-propyloxy, i-propyloxy, n-butyloxy, i-butyloxy, t-butyloxy, pentyloxy, hexyloxy, including their isomers. “Lower alkoxy” as used herein denotes an alkoxy group with a “lower alkyl” group as previously defined, and are optionally fully or partially deuterated.

The term “hydroxyalkyl” as used herein denotes an alkyl radical as herein defined wherein one to three hydrogen atoms on different carbon atoms is/are replaced by hydroxyl groups.

The term “cycloalkyl” as used herein refers to a saturated carbocyclic ring containing 3 to 8 carbon atoms, i.e. cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl. “C 3-7 cycloalkyl” as used herein refers to an cycloalkyl composed of 3 to 7 carbons in the carbocyclic ring.

The term “cycloalkenyl” refers to a partially unsaturated carbocyclic containing 5 to 7 carbon atoms unless otherwise specified and having a carbon-carbon double bond within the ring. For example, C 5-6 cycloalkenyl refers to a cycloalkenyl group having from 5 to 6 member atoms. In certain embodiments cycloalkenyl groups have one carbon-carbon double bond within the ring. In other embodiments, cycloalkenyl groups have more than one carbon-carbon double bond within the ring. However, cycloalkenyl rings are not aromatic. Cycloalkenyl groups may be optionally substituted with one or more substituent. Examples of cycloalkenyl include, but are not limited to, cyclopentenyl and cyclohexenyl.

The term “halogen” or “halo” as used herein means fluorine, chlorine, bromine, or iodine. The term “amino” as used herein encompasses —NR 2 , wherein each R group is independently H or lower alky, wherein lower alkyl is as defined herein. Examples of amino groups include dimethylamino, methylamino and NH 2 .

As used herein, the term “aryl” means a monocyclic or bicyclic (also referred to as “biaryl”), substituted or unsubstituted carbocyclic aromatic group. Examples of aryl groups are phenyl, naphthyl and the like.

The term “heteroaryl” as used herein means a monocyclic, bicyclic, or tricyclic radical of 5 to 18 ring atoms having at least one aromatic ring containing four to eight atoms per ring, incorporating one or more N, O, or S heteroatoms, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl radical will be on an aromatic ring. As well known to those skilled in the art, heteroaryl rings have less aromatic character than their all-carbon counter parts. Thus, for the purposes of the invention, a heteroaryl group need only have some degree of aromatic character. Examples of heteroaryl moieties include monocyclic aromatic heterocycles having 5 to 6 ring atoms and 1 to 3 heteroatoms include, but is not limited to, pyridinyl, pyrimidinyl, pyrazinyl, pyrrolyl, pyrazolyl, imidazolyl, indolyl oxazol, isoxazole, thiazole, isothiazole, triazoline, triazolyl, thiophenyl, furanyl, thiadiazole and oxadiaxoline which can optionally be substituted with one or more, preferably one or two substituents selected from hydroxy, cyano, alkyl, alkoxy, thio, lower haloalkoxy, alkylthio, halo, haloalkyl, alkylsulfinyl, alkylsulfonyl, halogen, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, and dialkylaminoalkyl, nitro, alkoxycarbonyl and carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, arylcarbamoyl, alkylcarbonylamino and arylcarbonylamino. Examples of bicyclic moieties include, but are not limited to, quinolinyl, indazolyl, isoquinolinyl, benzofuryl, benzothiophenyl, benzoxazole, benzisoxazole, benzothiazole, pyrrolopyridinyl, pyrrolopyrazinyl and benzisothiazole.

The term “5,6-bicyclic heteroaryl ring system” as used herein denotes a partially saturated or unsaturated 5,6-bicyclic ring system containing at least one N, O, or S heteroatom, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl ring system will be on the 5-membered ring. Examples include, but are not limited to: 1H-indazol-3-yl, 4,5,6,7-tetrahydro-1H-indazol-3-yl, 1H-indol-3-yl, 5,6,7,8-Tetrahydro-imidazo[1,5-a]pyridin-1-yl, imidazo[1,5-a]pyridin-1-yl, indazol-1-yl, 1H-pyrazolo[3,4-b]pyridin-3-yl, 1H-pyrazolo[4,3-b]pyridin-3-yl, imidazo[1,2-a]pyridin-3-yl, 2-oxy-4,5,6,7-tetrahydro-1H-indazol-3-yl and benzoimidazol-1-yl, each of which may be optionally substituted.

The term “6,6-bicyclic heteroaryl ring system” as used herein denotes a partially saturated or unsaturated 6,6-bicyclic ring system containing at least one N, O, or S heteroatom, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl ring system will be on a 6-membered ring containing at least one N, O, or S heteroatom. Examples include, but are not limited to: isoquinolin-1-yl and isoquinolin-8-yl, each of which may be optionally substituted.

The term “5,5-bicyclic heteroaryl ring system” as used herein denotes a partially saturated or unsaturated bicyclic ring system containing at least one N, O, or S heteroatom, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl ring system will be on a 5-membered ring containing at least one N, O, or S heteroatom. Examples include, but are not limited to: 1H-thieno[3,2-c]pyrazol-3-yl, 1,4,5,6-tetrahydro-cyclopentapyrazol-3-yl, and 5,6-dihydro-4H-cyclopentapyrazol-1-yl, each of which may be optionally substituted.

The term “5,7-bicyclic heteroaryl ring system” as used herein denotes a partially saturated or unsaturated bicyclic ring system containing at least one N, O, or S heteroatom, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl ring system will be on a 5-membered ring containing at least one N, O, or S heteroatom. Examples include, but are not limited to: 1,4,5,6,7,8-hexahydro-cycloheptapyrazol-3-yl, each of which may be optionally substituted.

The term “6,5-bicyclic heteroaryl ring system” as used herein denotes a partially saturated or unsaturated 6,5-bicyclic ring system containing at least one N, O, or S heteroatom, the remaining ring atoms being carbon, with the understanding that the attachment point of the heteroaryl ring system will be on the 6-membered ring, which optionally contains one or more N, O, or S heteroatoms. Examples include, but are not limited to: 1H-indol-7-yl, 1H-pyrrolo[2,3-c]pyridin-7-yl, 1H-indazol-4-yl, and 1H-indazol-7-yl, each of which may be optionally substituted.

The term “heterocycloalkyl”, “heterocyclyl” or “heterocycle” as used herein denotes a monovalent saturated cyclic radical, consisting of one or more rings, preferably one to two rings or three rings, of three to eight atoms per ring, incorporating one or more ring carbon atoms and one or more ring heteroatoms (chosen from N, O or S(═O) 0-2 ), wherein the point of attachment can be through either a carbon atom or a heteroatom, and which can optionally be independently substituted with one or more, preferably one or two or three substituents selected from hydroxy, oxo, cyano, lower alkyl, lower alkoxy, lower haloalkoxy, alkylthio, halo, haloalkyl, hydroxyalkyl, nitro, alkoxycarbonyl, amino, alkylamino, alkylsulfonyl, arylsulfonyl, alkylaminosulfonyl, arylaminosulfonyl, alkylsulfonylamino, arylsulfonylamino, alkylaminocarbonyl, arylaminocarbonyl, alkylcarbonylamino, arylcarbonylamino, unless otherwise indicated. Examples of heterocyclic radicals include, but are not limited to, azetidinyl, pyrrolidinyl, hexahydroazepinyl, oxetanyl, tetrahydrofuranyl, tetrahydrothiophenyl, oxazolidinyl, thiazolidinyl, isoxazolidinyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, isoindolinyl, dihydroisoquinolinyle, tetrahydropyranyl, tetrahydrocarbolinyl, imidazolinyl, thiomorpholinyl, quinuclidinyl and imidazolinyl.

The phrase “organ rejection” includes acute allograft or xenograft rejection and chronic allograft or xenograft rejection in the setting of vascularized and/or non-vascularized (e.g. bone marrow, pancreatic islet cells) transplants.

The term “excipient” as used herein refers to a compound that is useful in preparing a pharmaceutical composition, generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes excipients that are acceptable for veterinary use as well as human pharmaceutical use. The compounds of this invention can be administered alone but will generally be administered in admixture with one or more suitable pharmaceutical excipients, diluents or carriers selected with regard to the intended route of administration and standard pharmaceutical practice.

“Pharmaceutically acceptable” means that which is useful in preparing a pharmaceutical composition that is generally safe, non-toxic, and neither biologically nor otherwise undesirable and includes that which is acceptable for veterinary as well as human pharmaceutical use.

A “pharmaceutically acceptable salt” form of an active ingredient may also initially confer a desirable pharmacokinetic property on the active ingredient which were absent in the non-salt form, and may even positively affect the pharmacodynamics of the active ingredient with respect to its therapeutic activity in the body. The phrase “pharmaceutically acceptable salt” of a compound means a salt that is pharmaceutically acceptable and that possesses the desired pharmacological activity of the parent compound. Such salts include: (1) acid addition salts, formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like; or formed with organic acids such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, 1,2-ethane-disulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo[2.2.2]-oct-2-ene-1-carboxylic acid, glucoheptonic acid, 3-phenylpropionic acid, trimethylacetic acid, tertiary butylacetic acid, lauryl sulfuric acid, gluconic acid, glutamic acid, hydroxynaphthoic acid, salicylic acid, stearic acid, muconic acid, and the like; or (2) salts formed when an acidic proton present in the parent compound either is replaced by a metal ion, e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion; or coordinates with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like.

Inhibitors of JAK3 and/or SYK

The application provides a compound of Formula I

A compound of Formula I

wherein:

R is H;

R′ is lower alkoxy or

or R and R′ together form heterocycloalkyl, optionally substituted with —CN;

R 1 is H or R 1a ;

R 1a is lower alkyl, cycloalkyl, lower alkoxyl, hydroxy lower alkyl, or lower haloalkyl;

R 1′ is H or lower alkyl;

or R 1a and R 1′ together form heterocycloalkyl, cycloalkyl, indan-1-yl, phenyl, or heteroaryl, optionally substituted with one or more R 1″ ;

each R 1″ is independently hydroxy, amino, oxo, lower alkyl, —C(═O)NH 2 , —CN, lower haloalkyl, benzyl, cyano lower alkyl, or —NHC(═O)OC(CH 3 ) 3 ;

R 2 is H, hydroxy, —CN, —C(═O)NH 2 , —C(═O)OH, —C(═O)OC(CH 3 ) 3 , R 2a , or R 2b ;

R 2a is lower alkyl, phenyl, phenyl lower alkyl, cycloalkyl, heteroaryl, heterocycloalkyl, heterocycloalkyl lower alkyl, heteroaryl lower alkyl, phenyl lower alkoxy, lower alkoxy, optionally substituted with one or more R 2a′ ;

each R 2a′ is independently hydroxy, —CN, amino, lower alkyl sulfonylamino, lower alkoxy, halo, lower alkyl, cyano lower alkyl, lower haloalkyl, lower alkyl sulfonyl, oxo, halo lower alkoxy, cycloalkyl, —C(═O)OCH 3 ;

R 2b is C(O)R 3 or —CH 2 C(═O)R 3 ;

R 3 is heterocycloalkyl, optionally substituted with one or more R 3′ ;

each R 3′ is independently —CN, halo, lower alkyl, or lower alkyl sulfonyl;

Q is a 5,6-bicyclic heteroaryl ring system, 6,6-bicyclic heteroaryl ring system, 5,5-bicyclic heteroaryl ring system, 6,5-bicyclic heteroaryl ring system, or 5,7-bicyclic heteroaryl ring system, optionally substituted with one or more Q a or Q b ;

each Q a is independently halo, —CN, hydroxy, or —(CH 2 )—C(═O)Q a′ ;

each Q a′ is independently hydroxy, amino, or heterocycloalkyl, wherein heterocycloalkyl is optionally substituted by one or more Q a″ ;

each Q a″ is independently lower alkyl or lower haloalkyl;

n is 1, 2, or 3;

each Q b is independently lower alkyl, cycloalkyl, lower alkoxy, phenoxy, lower alkyl sulfonyl, heterocycloalkyl, heterocycloalkyl lower alkyl, or heteroaryl lower alkyl, optionally substituted with one or more Q b′ ; and

each Q b′ is independently hydroxy, halo, —CN, amino, heterocycloalkyl, lower alkyl, benzyl, or lower alkyl sulfonyl;

or a pharmaceutically acceptable salt thereof.

The application provides the compound of Formula I, wherein R is H.

The application provides the compound of Formula I, wherein R′ is

The application provides the compound of Formula I, wherein R is H and R′ is

The application provides the compound of Formula I, wherein R 1′ is H or lower alkyl.

The application provides the compound of Formula I, wherein R 1″ is H or lower alkyl R is H, and R′ is

The application provides the compound of Formula I, wherein R 1 is lower alkyl.

The application provides the compound of Formula I, wherein R 1 is lower alkyl, R 1′ is H or lower alkyl, R is H, and R′ is

The application provides the compound of Formula I, wherein both R 1 and R 1′ are H.

The application provides the compound of Formula I, wherein R is H, R′ is

and both R 1 and R 1′ are H.

The application provides the compound of Formula I, wherein R 2 is —C(═O)R 3 .

The application provides the compound of Formula I, wherein R 2 is —C(═O)R 3 , R 1 is lower alkyl, R 1′ is H or lower alkyl, R is H, and R′ is

The application provides the compound of Formula I, wherein R 2 is lower alkyl, optionally substituted with one or more R 2a′ .

The application provides the compound of Formula I, wherein R 2 is lower alkyl, optionally substituted with one or more R 2a′ , R 1 is lower alkyl, R 1′ is H or lower alkyl, R is H, and R′ is

The application provides the compound of Formula I, wherein Q is a 5,6-bicyclic heteroaryl ring system, optionally substituted with one or more Q a or Q b .

The application provides the compound of Formula I, wherein Q is a 5,6-bicyclic heteroaryl ring system, optionally substituted with one or more Q a or Q b , R 2 is lower alkyl, optionally substituted with one or more R 2a′ , R 1 is lower alkyl, R 1′ is H or lower alkyl, R is H, and R′ is

The application provides the compound of Formula I, wherein Q is indazol-3-yl, optionally substituted with one or more Q a or Q b .

The application provides the compound of Formula I, wherein Q a is halo or lower alkyl.

The application provides the compound of Formula I, wherein Q is indazol-3-yl, optionally substituted with one or more Q a or Q b , and Q a is halo or lower alkyl.

The application provides the compound of Formula I, wherein Q b is lower alkyl.

The application provides the compound of Formula I, wherein Q is indazol-3-yl, optionally substituted with one or more Q a or Q b , and Q a is halo or lower alkyl, and Q b is lower alkyl.

The application provides the compound of Formula I, wherein R 1a and R 1′ together form heterocycloalkyl or cycloalkyl, optionally substituted with one or more R 1″ .

The application provides the compound of Formula I, wherein R 1a and R 1′ together form heterocycloalkyl or cycloalkyl, optionally substituted with one or more R 1″ , Q is indazol-3-yl, optionally substituted with one or more Q a or Q b , and Q a is halo or lower alkyl, and Q b is lower alkyl.

The application provides the compound of Formula I, wherein R 1″ is amino or —CN.

The application provides the compound of Formula I, wherein R 1″ is amino or —CN, R 1a and R 1′ together form heterocycloalkyl or cycloalkyl, optionally substituted with one or more R 1″ , Q is indazol-3-yl, optionally substituted with one or more Q a or Q b , and Q a is halo or lower alkyl, and Q b is lower alkyl.

The application provides the compound of Formula I, wherein R 2 is lower alkyl.

The application provides the compound of Formula I, wherein R 2 is lower alkyl, R 1″ is amino or —CN, R 1a and R 1′ together form heterocycloalkyl or cycloalkyl, optionally substituted with one or more R 1″ , Q is indazol-3-yl, optionally substituted with one or more Q a or Q b , and Q a is halo or lower alkyl, and Q b is lower alkyl.

The application provides a compound selected from the compounds listed in Table I.

The application provides a method for treating an inflammatory or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides the above method, further comprising administering an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.

The application provides a method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for inhibiting T-cell proliferative disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for inhibiting T-cell proliferative disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I

The application provides the above method, wherein the proliferative disorder is cancer.

The application provides a method for treating a B-cell proliferative disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an immune disorder including lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes, complications from organ transplants, xeno transplantation, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, and Leukemia, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for preventing or treating all forms of organ rejection, including acute allograft or xenograft rejection and chronic allograft or xenograft rejection, of vascularized or non-vascularized transplants, comprising administering to a patient in need thereof the compound of Formula I.

The application provides a method for inhibiting JAK3 activity comprising administering the compound of Formula I, wherein the compound exhibits an IC 50 of 50 micromolar or less in an in vitro biochemical assay of JAK3 activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 100 nanomolar or less in an in vitro biochemical assay of JAK3 activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 10 nanomolar or less in an in vitro biochemical assay of JAK3 activity.

A method for inhibiting SYK activity comprising administering the compound of Formula I, wherein the compound exhibits an IC 50 of 50 micromolar or less in an in vitro biochemical assay of SYK activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 100 nanomolar or less in an in vitro biochemical assay of SYK activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 10 nanomolar or less in an in vitro biochemical assay of SYK activity.

The application provides a method for treating an inflammatory condition comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the compound of Formula I.

The application provides a method for treating an immune disorder comprising co-administering to a patient in need thereof a therapeutically effective amount of an immunosuppressant compound in combination with the compound of Formula I.

The application provides a pharmaceutical composition comprising the compound of Formula I, admixed with at least one pharmaceutically acceptable carrier, excipient or diluent.

The application provides the above composition, further comprising an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, and an agent for treating immunodeficiency disorders.

The application provides a process for preparing the compound of Formula I.

The application provides the use of the compound of Formula I in the manufacture of a medicament for the treatment of an inflammatory disorder.

The application provides the use of the compound of Formula I in the manufacture of a medicament for the treatment of an autoimmune disorder.

The application provides the use of the compound of any one of claims 1 - 15 in the preparation of a medicament for the treatment of arthritis or asthma.

The application provides the invention as hereinbefore described.

Compounds

Examples of representative compounds encompassed by the present invention and within the scope of the invention are provided in the following Table. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

In general, the nomenclature used in this application is based on AUTONOM™ v.4.0, a Beilstein Institute computerized system for the generation of IUPAC systematic nomenclature. If there is a discrepancy between a depicted structure and a name given that structure, the depicted structure is to be accorded more weight. In addition, if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or portion of the structure is to be interpreted as encompassing all stereoisomers of it.

TABLE I depicts exemplified compounds according to Formula I.

Synthesis

General Schemes

Procedure 1

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

Method A

(2-Bromo-7-hydroxymethyl-pyrrolo[2,3-b]pyrazin-5-yl)-methanol

To a partial suspension of 2-bromo-5H-pyrrolo[2,3-b]pyrazine (5.0 g, 25.2 mmol) in 1,4-dioxane (100 mL) was added 2.0 M aqueous NaOH (25 mL, 50.0 mmol) and 37% aqueous formaldehyde (19 mL, 252 mmol). The dark homogenous reaction mixture was stirred at room temperature overnight. The organics were evaporated under reduced pressure. The aqueous layer was neutralized with 1.0 M HCl and extracted with EtOAc (2×). The combined organics were concentrated to afford 2.6 g of an orange solid. Upon standing, a thick brown precipitate formed in the aqueous layer. The precipitate was collected by filtration and dried. The brown solid was extracted with hot 10% MeOH/EtOAc (3×200 mL). The extracts were combined and evaporated to provide an additional 3.05 g of orange solid. Overall yield was 5.65 g (87%) of (2-bromo-7-hydroxymethyl-pyrrolo[2,3-b]pyrazin-5-yl)-methanol. 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 8.43 (s, 1H), 7.96 (s, 1H), 6.71 (t, J=7.3 Hz, 1H), 5.59 (d, J=7.6 Hz, 2H), 5.10 (t, J=5.3 Hz, 1H), 4.66 (d, J=5.6 Hz, 2H).

(2-Bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol

To a suspension of (2-bromo-7-hydroxymethyl-pyrrolo[2,3-b]pyrazin-5-yl)-methanol (5.65 g, 21.9 mmol) in THF (150 mL) was added a solution of 2.0 M aqueous NaOH (33 mL, 66 mmol). The homogeneous reaction mixture was stirred overnight then the organics were removed under reduced pressure. The aqueous residue was brought to pH 4 with 1.0 M aqueous HCl. The resulting precipitate was collected via filtration and rinsed with H 2 O to afford 3.68 g of a yellow solid. The filtrate was extracted with EtOAc (2×) and the organics were concentrated under reduced pressure to provide an additional 0.92 g of yellow solid. Overall yield was 4.60 g (92%) of (2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol. 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.19 (br. s., 1H), 8.33 (s, 1H), 7.85 (s, 1H), 4.96 (t, J=5.3 Hz, 1H), 4.62 (d, J=4.9 Hz, 2H).

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

A stock solution of Jones reagent (2.67 M) was prepared by carefully adding concentrated H 2 SO 4 (2.3 mL) to CrO 3 (2.67 g) then diluting to 10 mL with H 2 O. To a partial suspension of (2-bromo-5H-pyrrolo[2,3-b]pyrazin-7-yl)-methanol (4.6 g, 20.1 mmol) in acetone (300 mL) was slowly added Jones reagent (9 mL, 24.0 mmol). During the addition the starting material gradually dissolved and a thick green precipitate was formed. The reaction mixture was stirred for 15 min then quenched with i-PrOH (2 mL) and filtered over Celite, rinsing with acetone. The filtrate was concentrated to provide 4.76 g of 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a yellow-orange solid that was used without further purification. To a solution of this solid in DMF (50 mL) at 0° C. was added NaH (60% in mineral oil, 1.2 g, 30.1 mmol). The reaction mixture was stirred at room temperature for 30 min then cooled back to 0° C. and 2-(trimethylsilyl)ethoxymethyl chloride (4.3 mL, 24.1 mmol) was slowly added. The reaction mixture was warmed to room temperature and stirred for 1 h then quenched with H 2 O and extracted with EtOAc (3×). The combined organics were washed with H 2 O (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (20% to 30% EtOAc/hexanes) to isolate 3.82 g (53%) of 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.37 (s, 1H), 8.50 (s, 1H), 8.33 (s, 1H), 5.73 (s, 2H), 3.53-3.70 (m, 2H), 0.90-1.05 (m, 2H), 0.00 (s, 9H).

Method B

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine

In a dry round-bottomed flask, 2-bromo-5H-pyrrolo[2,3-b]pyrazine (5.0 g, 25.2 mmol) was dissolved in DMF (50 mL). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 1.22 g, 30.6 mmol). The reaction mixture was warmed to room temperature and stirred for 15 min then cooled back to 0° C. and SEM-Cl (5.4 mL, 30.4 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 1.5 h. The reaction mixture was quenched with 50 mL water and extracted with 150 mL diethyl ether (2×). The combined organic layers were washed twice with 30 mL water and once with 30 mL brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on ˜20 g SiO 2 and chromatographed over 200 g SiO 2 with EtOAc/Hexanes (gradient: 0-15% EtOAc). All fractions containing product were combined and concentrated to afford 6.61 g (80%) of 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine as a pale yellow oil which gradually solidified. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.38 (s, 1H), 7.70 (d, J=3.8 Hz, 1H), 6.76 (d, J=3.8 Hz, 1H), 5.68 (s, 2H), 3.50-3.65 (m, 2H), 0.88-1.03 (m, 2H), 0.00 (s, 9H).

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine (6.58 g, 20.0 mmol) was dissolved in chloroform (pentene stabilized, 120 mL) and chloromethylenedimethyliminium chloride (10.3 g, 80.2 mmol) was added. The reaction mixture was stirred at reflux for 8 h as a steady stream of nitrogen gas was bubbled through the reaction mixture. The dark brown solution was cooled to room temperature and stirred overnight. The reaction mixture was carefully quenched with ˜100 mL saturated NaHCO 3 -solution (caution: exothermic) and then extracted twice with 200 mL diethyl ether. The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was absorbed on ˜20 g SiO 2 and chromatographed over 200 g SiO 2 with EtOAc/Hexanes (gradient: 0-25% EtOAc). All fractions containing product were combined and concentrated to afford 5.92 g (83%) of an approx 3:1 mixture of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde and 2-chloro-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a yellow solid. Bromide: 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.37 (s, 1H), 8.50 (s, 1H), 8.33 (s, 1H), 5.73 (s, 2H), 3.56-3.67 (m, 2H), 0.91-1.02 (m, 2H), 0.00 (s, 9H); Chloride: 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.36 (s, 1H), 8.41 (s, 1H), 8.35 (s, 1H), 5.74 (s, 2H), 3.56-3.67 (m, 2H), 0.91-1.02 (m, 2H), 0.00 (s, 9H).

Procedure 2

2-Bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

In a flask 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (3.11 g, 8.74 mmol) was dissolved in dioxane (120 mL) and H 2 O (30 mL) and the mixture cooled at 0° C. Sufamic acid (5.09 g, 52.4 mmol) was added, followed by a solution of sodium chlorite (1.28 g, 11.4 mmol) and potassium dihydrogen phosphate (14.3 g, 104.9 mmol) in H 2 O (75 mL) via an addition funnel over 15 min. The mixture was allowed to warm to room temperature over 2 h. The resulting yellow solid was filtered off, washed with H 2 O and hexane and dried. The filtrate was then extracted with EtOAc, and the combined organics washed with brine, dried over MgSO 4 and concentrated to give additional product. In total 3.71 g of 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid was obtained as a yellow solid. 1 H NMR (CDCl 3 , 400 MHz): δ (ppm) 8.52 (s, 1H), 8.42 (s, 1H), 5.73 (s, 2H), 3.56-3.65 (m, 2H), 0.90-1.02 (m, 2H), 0.00 (s, 9H).

Procedure 3

2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid methyl ester

2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

To a stirred solution of (2-bromo-7-hydroxymethyl-pyrrolo[2,3-b]pyrazin-5-yl)-methanol (0.525 g, 2.03 mmol) in 200 mL of acetone at 40° C. was added a solution of CrO 3 (0.832 g, 8.32 mmol) and H 2 SO 4 (1.32 g, 13.4 mmol) in water (3 ml). Then the reaction was stirred at 40° C. for 16 hours then filtered through Celite. The filtrate was evaporated at 40° C. under reduced pressure to give 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (0.527 g) as an off-white solid. LCMS: (M+H) + =264; 1 H NMR (300 MHz, DMSO-d 6 ): δ 13.04 (s, 1H), 8.53 (s, 1H), 8.45 (s, 1H), 5.63 (s, 1H).

2-Bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid methyl ester

To a stirred solution of 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (0.527 g, 2.18 mmol) in 50 ml, of methanol was added H 2 SO 4 (1.5 mL) slowly at room temperature. The reaction mixture was stirred at reflux for 16 h. The solvent was evaporated at 40° C. under reduced pressure then the residue was suspended in 5 mL of water and treated with solid NaHCO 3 until pH=7. The solution was extracted with ethyl acetate (90 mL), then the organics were washed with water (20 mL), brine (20 mL) and dried over anhydrous sodium sulfate. The drying agent was removed by filtration and the solvent was evaporated at 40° C. under reduced pressure to give a crude product, which was purified by column chromatography (silica gel, 200-300 mesh, eluting with a mixture of petroleum ether and ethyl acetate (1:1, v/v) to give 2-bromo-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid methyl ester (0.24 g, 43%) as a white solid.

LCMS: (M+H) + =278; 1 H NMR (300 MHz, DMSO-d 6 ): δ 8.62 (s, 1H), 8.48 (s, 1H), 3.91 (s, 3H).

Pharmaceutical Compositions and Administration

The compounds of the present invention may be formulated in a wide variety of oral administration dosage forms and carriers. Oral administration can be in the form of tablets, coated tablets, dragées, hard and soft gelatin capsules, solutions, emulsions, syrups, or suspensions. Compounds of the present invention are efficacious when administered by other routes of administration including continuous (intravenous drip) topical parenteral, intramuscular, intravenous, subcutaneous, transdermal (which may include a penetration enhancement agent), buccal, nasal, inhalation and suppository administration, among other routes of administration. The preferred manner of administration is generally oral using a convenient daily dosing regimen which can be adjusted according to the degree of affliction and the patient's response to the active ingredient.

A compound or compounds of the present invention, as well as their pharmaceutically useable salts, together with one or more conventional excipients, carriers, or diluents, may be placed into the form of pharmaceutical compositions and unit dosages. The pharmaceutical compositions and unit dosage forms may be comprised of conventional ingredients in conventional proportions, with or without additional active compounds or principles, and the unit dosage forms may contain any suitable effective amount of the active ingredient commensurate with the intended daily dosage range to be employed. The pharmaceutical compositions may be employed as solids, such as tablets or filled capsules, semisolids, powders, sustained release formulations, or liquids such as solutions, suspensions, emulsions, elixirs, or filled capsules for oral use; or in the form of suppositories for rectal or vaginal administration; or in the form of sterile injectable solutions for parenteral use. A typical preparation will contain from about 5% to about 95% active compound or compounds (w/w). The term “preparation” or “dosage form” is intended to include both solid and liquid formulations of the active compound and one skilled in the art will appreciate that an active ingredient can exist in different preparations depending on the target organ or tissue and on the desired dose and pharmacokinetic parameters.

Solid form preparations include powders, tablets, pills, capsules, cachets, suppositories, and dispersible granules. A solid carrier may be one or more substances which may also act as diluents, flavoring agents, solubilizers, lubricants, suspending agents, binders, preservatives, tablet disintegrating agents, or an encapsulating material. In powders, the carrier generally is a finely divided solid which is a mixture with the finely divided active component. In tablets, the active component generally is mixed with the carrier having the necessary binding capacity in suitable proportions and compacted in the shape and size desired. Suitable carriers include but are not limited to magnesium carbonate, magnesium stearate, talc, sugar, lactose, pectin, dextrin, starch, gelatin, tragacanth, methylcellulose, sodium carboxymethylcellulose, a low melting wax, cocoa butter, and the like. Solid form preparations may contain, in addition to the active component, colorants, flavors, stabilizers, buffers, artificial and natural sweeteners, dispersants, thickeners, solubilizing agents, and the like.

Liquid formulations also are suitable for oral administration include liquid formulation including emulsions, syrups, elixirs, aqueous solutions, aqueous suspensions. These include solid form preparations which are intended to be converted to liquid form preparations shortly before use. Emulsions may be prepared in solutions, for example, in aqueous propylene glycol solutions or may contain emulsifying agents such as lecithin, sorbitan monooleate, or acacia. Aqueous solutions can be prepared by dissolving the active component in water and adding suitable colorants, flavors, stabilizing, and thickening agents. Aqueous suspensions can be prepared by dispersing the finely divided active component in water with viscous material, such as natural or synthetic gums, resins, methylcellulose, sodium carboxymethylcellulose, and other well known suspending agents.

The compounds of the present invention may be formulated for parenteral administration (e.g., by injection, for example bolus injection or continuous infusion) and may be presented in unit dose form in ampoules, pre-filled syringes, small volume infusion or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, for example solutions in aqueous polyethylene glycol. Examples of oily or nonaqueous carriers, diluents, solvents or vehicles include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), and injectable organic esters (e.g., ethyl oleate), and may contain formulatory agents such as preserving, wetting, emulsifying or suspending, stabilizing and/or dispersing agents. Alternatively, the active ingredient may be in powder form, obtained by aseptic isolation of sterile solid or by lyophilisation from solution for constitution before use with a suitable vehicle, e.g., sterile, pyrogen-free water.

The compounds of the present invention may be formulated for topical administration to the epidermis as ointments, creams or lotions, or as a transdermal patch. Ointments and creams may, for example, be formulated with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Lotions may be formulated with an aqueous or oily base and will in general also containing one or more emulsifying agents, stabilizing agents, dispersing agents, suspending agents, thickening agents, or coloring agents. Formulations suitable for topical administration in the mouth include lozenges comprising active agents in a flavored base, usually sucrose and acacia or tragacanth; pastilles comprising the active ingredient in an inert base such as gelatin and glycerin or sucrose and acacia; and mouthwashes comprising the active ingredient in a suitable liquid carrier.

The compounds of the present invention may be formulated for administration as suppositories. A low melting wax, such as a mixture of fatty acid glycerides or cocoa butter is first melted and the active component is dispersed homogeneously, for example, by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool, and to solidify.

The compounds of the present invention may be formulated for vaginal administration. Pessaries, tampons, creams, gels, pastes, foams or sprays containing in addition to the active ingredient such carriers as are known in the art to be appropriate.

The compounds of the present invention may be formulated for nasal administration. The solutions or suspensions are applied directly to the nasal cavity by conventional means, for example, with a dropper, pipette or spray. The formulations may be provided in a single or multidose form. In the latter case of a dropper or pipette, this may be achieved by the patient administering an appropriate, predetermined volume of the solution or suspension. In the case of a spray, this may be achieved for example by means of a metering atomizing spray pump.

The compounds of the present invention may be formulated for aerosol administration, particularly to the respiratory tract and including intranasal administration. The compound will generally have a small particle size for example of the order of five (5) microns or less. Such a particle size may be obtained by means known in the art, for example by micronization. The active ingredient is provided in a pressurized pack with a suitable propellant such as a chlorofluorocarbon (CFC), for example, dichlorodifluoromethane, trichlorofluoromethane, or dichlorotetrafluoroethane, or carbon dioxide or other suitable gas. The aerosol may conveniently also contain a surfactant such as lecithin. The dose of drug may be controlled by a metered valve. Alternatively the active ingredients may be provided in a form of a dry powder, for example a powder mix of the compound in a suitable powder base such as lactose, starch, starch derivatives such as hydroxypropylmethyl cellulose and polyvinylpyrrolidine (PVP). The powder carrier will form a gel in the nasal cavity. The powder composition may be presented in unit dose form for example in capsules or cartridges of e.g., gelatin or blister packs from which the powder may be administered by means of an inhaler.

When desired, formulations can be prepared with enteric coatings adapted for sustained or controlled release administration of the active ingredient. For example, the compounds of the present invention can be formulated in transdermal or subcutaneous drug delivery devices. These delivery systems are advantageous when sustained release of the compound is necessary and when patient compliance with a treatment regimen is crucial. Compounds in transdermal delivery systems are frequently attached to a skin-adhesive solid support. The compound of interest can also be combined with a penetration enhancer, e.g., Azone (1-dodecylazacycloheptan-2-one). Sustained release delivery systems are inserted subcutaneously into to the subdermal layer by surgery or injection. The subdermal implants encapsulate the compound in a lipid soluble membrane, e.g., silicone rubber, or a biodegradable polymer, e.g., polyactic acid.

Suitable formulations along with pharmaceutical carriers, diluents and excipients are described in Remington: The Science and Practice of Pharmacy 1995, edited by E. W. Martin, Mack Publishing Company, 19th edition, Easton, Pa. A skilled formulation scientist may modify the formulations within the teachings of the specification to provide numerous formulations for a particular route of administration without rendering the compositions of the present invention unstable or compromising their therapeutic activity.

The modification of the present compounds to render them more soluble in water or other vehicle, for example, may be easily accomplished by minor modifications (salt formulation, esterification, etc.), which are well within the ordinary skill in the art. It is also well within the ordinary skill of the art to modify the route of administration and dosage regimen of a particular compound in order to manage the pharmacokinetics of the present compounds for maximum beneficial effect in patients.

The term “therapeutically effective amount” as used herein means an amount required to reduce symptoms of the disease in an individual. The dose will be adjusted to the individual requirements in each particular case. That dosage can vary within wide limits depending upon numerous factors such as the severity of the disease to be treated, the age and general health condition of the patient, other medicaments with which the patient is being treated, the route and form of administration and the preferences and experience of the medical practitioner involved. For oral administration, a daily dosage of between about 0.01 and about 1000 mg/kg body weight per day should be appropriate in monotherapy and/or in combination therapy. A preferred daily dosage is between about 0.1 and about 500 mg/kg body weight, more preferred 0.1 and about 100 mg/kg body weight and most preferred 1.0 and about 10 mg/kg body weight per day. Thus, for administration to a 70 kg person, the dosage range would be about 7 mg to 0.7 g per day. The daily dosage can be administered as a single dosage or in divided dosages, typically between 1 and 5 dosages per day. Generally, treatment is initiated with smaller dosages which are less than the optimum dose of the compound. Thereafter, the dosage is increased by small increments until the optimum effect for the individual patient is reached. One of ordinary skill in treating diseases described herein will be able, without undue experimentation and in reliance on personal knowledge, experience and the disclosures of this application, to ascertain a therapeutically effective amount of the compounds of the present invention for a given disease and patient.

The pharmaceutical preparations are preferably in unit dosage forms. In such form, the preparation is subdivided into unit doses containing appropriate quantities of the active component. The unit dosage form can be a packaged preparation, the package containing discrete quantities of preparation, such as packeted tablets, capsules, and powders in vials or ampoules. Also, the unit dosage form can be a capsule, tablet, cachet, or lozenge itself, or it can be the appropriate number of any of these in packaged form.

Indications and Method of Treatment

The application provides a method for treating an inflammatory or autoimmune condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides the above method, further comprising administering an additional therapeutic agent selected from a chemotherapeutic or anti-proliferative agent, an anti-inflammatory agent, an immunomodulatory or immunosuppressive agent, a neurotrophic factor, an agent for treating cardiovascular disease, an agent for treating diabetes, or an agent for treating immunodeficiency disorders.

The application provides a method for treating rheumatoid arthritis comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating asthma comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an inflammatory condition comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for inhibiting T-cell proliferative disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for inhibiting T-cell proliferative disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I

The application provides the above method, wherein the proliferative disorder is cancer.

The application provides a method for treating a B-cell proliferative disorder comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for treating an immune disorder including lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes, complications from organ transplants, xeno transplantation, diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, and Leukemia, comprising administering to a patient in need thereof a therapeutically effective amount of the compound of Formula I.

The application provides a method for preventing or treating all forms of organ rejection, including acute allograft or xenograft rejection and chronic allograft or xenograft rejection, of vascularized or non-vascularized transplants, comprising administering to a patient in need thereof the compound of Formula I.

The application provides a method for inhibiting JAK3 activity comprising administering the compound of Formula I, wherein the compound exhibits an IC 50 of 50 micromolar or less in an in vitro biochemical assay of JAK3 activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 100 nanomolar or less in an in vitro biochemical assay of JAK3 activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 10 nanomolar or less in an in vitro biochemical assay of JAK3 activity.

A method for inhibiting SYK activity comprising administering the compound of Formula I, wherein the compound exhibits an IC 50 of 50 micromolar or less in an in vitro biochemical assay of SYK activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 100 nanomolar or less in an in vitro biochemical assay of SYK activity.

The application provides the above method, wherein the compound exhibits an IC 50 of 10 nanomolar or less in an in vitro biochemical assay of SYK activity.

The application provides a method for treating an inflammatory condition comprising co-administering to a patient in need thereof a therapeutically effective amount of an anti-inflammatory compound in combination with the compound of Formula I.

The application provides a method for treating an immune disorder comprising co-administering to a patient in need thereof a therapeutically effective amount of an immunosuppressant compound in combination with the compound of Formula I.

The following examples illustrate the preparation and biological evaluation of compounds within the scope of the invention. In general, the nomenclature used in this section is based on AUTONOM™ v.4.0, as noted above, or, alternatively, based on ChemDraw. These examples and preparations which follow are provided to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

Commonly used abbreviations include: acetyl (Ac), azo-bis-isobutyrylnitrile (AIBN), atmospheres (Atm), 9-borabicyclo[3.3.1]nonane (9-BBN or BBN), tert-butoxycarbonyl (Boc), di-tert-butyl pyrocarbonate or boc anhydride (BOC 2 O), benzyl (Bn), butyl (Bu), Chemical Abstracts Registration Number (CASRN), benzyloxycarbonyl (CBZ or Z), carbonyl diimidazole (CDI), 1,4-diazabicyclo[2.2.2]octane (DABCO), diethylaminosulfur trifluoride (DAST), dibenzylideneacetone (dba), 1,5-diazabicyclo[4.3.0]non-5-ene (DBN), 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), N,N′-dicyclohexylcarbodiimide (DCC), 1,2-dichloroethane (DCE), dichloromethane (DCM), diethyl azodicarboxylate (DEAD), di-iso-propylazodicarboxylate (DIAD), di-iso-butylaluminumhydride (DIBAL or DIBAL-H), di-iso-propylethylamine (DIPEA), N,N-dimethyl acetamide (DMA), 4-N,N-dimethylaminopyridine (DMAP), N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), 1,1′-bis-(diphenylphosphino)ethane (dppe), 1,1′-bis-(diphenylphosphino)ferrocene (dppf), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI), ethyl (Et), ethyl acetate (EtOAc), ethanol (EtOH), 2-ethoxy-2H-quinoline-1-carboxylic acid ethyl ester (EEDQ), diethyl ether (Et 2 O), O-(7-azabenzotriazole-1-yl)-N,N,N′N′-tetramethyluronium hexafluorophosphate acetic acid (HATU), acetic acid (HOAc), 1-N-hydroxybenzotriazole (HOBt), high pressure liquid chromatography (HPLC), iso-propanol (IPA), lithium hexamethyl disilazane (LiHMDS), methanol (MeOH), melting point (mp or MP), MeSO 2 — (mesyl or Ms), methyl (Me), acetonitrile (MeCN), m-chloroperbenzoic acid (MCPBA), mass spectrum (ms or MS), methyl t-butyl ether (MTBE), N-bromosuccinimide (NBS), N-carboxyanhydride (NCA), N-chlorosuccinimide (NCS), N-methylmorpholine (NMM), N-methylpyrrolidone (NMP), pyridinium chlorochromate (PCC), pyridinium dichromate (PDC), phenyl (Ph), propyl (Pr), iso-propyl (i-Pr), pounds per square inch (psi), pyridine (pyr), room temperature (rt or RT), 2-(trimethylsilyl)ethoxymethyl chloride (SEMC1), tert-butyldimethylsilyl or t-BuMe 2 Si (TBDMS), triethylamine (TEA or Et 3 N), 2,2,6,6-tetramethylpiperidine 1-oxyl (TEMPO), triflate or CF 3 SO 2 — (Tf), trifluoroacetic acid (TFA), 1,1′-bis-2,2,6,6-tetramethylheptane-2,6-dione (TMHD), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (TBTU), thin layer chromatography (TLC), tetrahydrofuran (THF), trimethylsilyl or Me 3 Si (TMS), p-toluenesulfonic acid monohydrate (TsOH or pTsOH), 4-Me-C 6 H 4 SO 2 — or tosyl (Ts), N-urethane-N-carboxyanhydride (UNCA). Conventional nomenclature including the prefixes normal (n), iso (i-), secondary (sec-), tertiary (tert-) and neo have their customary meaning when used with an alkyl moiety. (J. Rigaudy and D. P. Klesney, Nomenclature in Organic Chemistry , IUPAC 1979 Pergamon Press, Oxford.).

2-(1-Methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

3-Iodo-1H-indazole

In a 50 mL round-bottomed flask, indazole (0.80 g, 6.8 mmol) was dissolved in DMF (14 mL). Iodine (3.4 g, 13.5 mmol) was added followed by potassium hydroxide (1.47 g, 26.2 mmol). The dark reaction mixture was stirred at room temperature for 1.25 h then was quenched with 10% aq NaHSO 3 and extracted with diethyl ether (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to give 1.65 g (95%) of 3-iodo-1H-indazole as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.56 (br. s, 1H), 7.47-7.57 (m, 3H), 7.23-7.30 (m, 1H).

3-Iodo-1-methyl-1H-indazole

In a 50 ml round-bottomed flask, 3-iodo-1H-indazole (1.0 g, 3.9 mmol) was dissolved in THF (12 ml) and the solution was cooled to 0° C. Potassium tert-butoxide (612 mg, 5.45 mmol) was added and the reaction mixture was stirred at 0° C. for 1.25 h. Methyl iodide (0.29 ml, 4.64 mmol) was added dropwise then the ice bath was removed and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with EtOAc/Hexanes (gradient 0-10% EtOAc) to afford 863 mg (86%) of 3-iodo-1-methyl-1H-indazole as a yellow oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.42-7.53 (m, 2H), 7.33-7.40 (m, 1H), 7.22 (ddd, J=8.0, 6.9, 0.9 Hz, 1H), 4.11 (s, 3H).

1-Methyl-3-tributylstannanyl-1H-indazole

3-Iodo-1-methyl-1H-indazole (0.15 g, 0.58 mmol) was dissolved in THF (3 ml) and the solution was cooled to −16° C. using a NaCl/ice bath. Isopropylmagnesium chloride (2.0M in THF, 0.32 ml, 0.64 mmol) was added dropwise and the reaction mixture was stirred at −16° C. for 15 min. Tributylchlorostannane (0.18 ml, 0.66 mmol) was slowly added and the reaction mixture was allowed to warm to room temperature over 1.5 h. The reaction mixture was quenched with saturated NH 4 Cl solution and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with EtOAc/Hexanes (0.5% triethylamine, gradient 0-5% EtOAc) to give 224 mg (92%) of 1-methyl-3-tributylstannanyl-1H-indazole as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.70 (d, J=8.3 Hz, 1H), 7.32-7.45 (m, 2H), 7.11 (ddd, J=8.0, 6.3, 1.5 Hz, 1H), 1.52-1.69 (m, 6H), 1.19-1.44 (m, 12H), 0.83-0.95 (m, 9H).

[(R)-2-(4-Cyanopiperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

In a round-bottomed flask, Boc-D-cyclopropylglycine (1.80 g, 8.36 mmol) and piperidine-4-carbonitrile (1.2 g, 10.9 mmol) were dissolved in DMF (30 ml). HATU (3.5 g, 9.2 mmol) and N,N-diisopropylethylamine (2.3 ml, 13.2 mmol) were added and the yellow solution was stirred at room temperature overnight. The reaction mixture was quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to afford 2.72 g (95%) of [(R)-2-(4-cyanopiperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-carbamic acid tert-butyl ester as a light yellow oil which was used without further purification.

1-((R)-2-Amino-2-cyclopropyl-acetyl)-piperidine-4-carbonitrile trifluoroacetate

In a round-bottomed flask, [(R)-2-(4-cyanopiperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (2.71 g, 7.93 mmol) was dissolved in dichloromethane (50 ml). The solution was cooled to 0° C. and trifluoroacetic acid (18 ml, 234 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated to provide 1-((R)-2-amino-2-cyclopropyl-acetyl)-piperidine-4-carbonitrile trifluoroacetate as a yellow oil which was used without further purification.

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 1-((R)-2-amino-2-cyclopropyl-acetyl)-piperidine-4-carbonitrile trifluoroacetate (5.19 g, 7.27 mmol) was dissolved in DMF (25 ml) and N,N-diisopropylethylamine (8.5 ml, 48.7 mmol) was added. Then 2-bromo-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (2.20 g, 5.91 mmol) (approx 2:1 Br:Cl) and HATU (2.47 g, 6.5 mmol) were added and the reaction mixture was stirred at room temperature overnight. The reaction was quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with EtOAc/Hexanes (gradient 0-80% EtOAc) to afford 3.0 g of an off-white foam. SFC chromatography (Chiralpak IA-H 2×25 column, 40% MeOH) afforded 1.71 g (52%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a white foam and 779 mg (26%) 2-chloro-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as an off-white foam.

2-(1-Methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

In a dry round-bottomed flask 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (0.12 g, 0.21 mmol) and 1-methyl-3-tributylstannanyl-1H-indazole (117 mg, 0.28 mmol) were dissolved in DMF (2 ml). The reaction mixture was evacuated and backfilled with Argon then tetrakis(triphenylphosphine)palladium(0) (13 mg, 0.011 mmol) and copper(I) iodide (9 mg, 0.047 mmol) were added. The reaction mixture was stirred at 80° C. for 1.5 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with MeOH/CH 2 Cl 2 (0.5% NH 4 OH) (gradient 0-3% MeOH) to afford 161 mg of 2-(1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a yellow oil.

2-(1-Methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (0.158 g, 0.193 mmol) was dissolved in dichloromethane (1 ml) and trifluoroacetic acid (0.6 ml, 7.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was redissolved in dichloromethane (1 ml) and ethylenediamine (0.8 ml, 11.7 mmol) was added. The solution was stirred at room temperature for 1 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with MeOH/CH 2 Cl 2 (0.5% NH 4 OH) (gradient 0-4% MeOH) followed by trituration with ethyl acetate to afford 31 mg (32%) of 2-(1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a light yellow powder. MS: (M+H) + =483; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.89 (br. s., 1H), 9.17 (s, 1H), 8.79 (d, J=7.9 Hz, 1H), 8.65 (d, J=8.3 Hz, 1H), 8.45 (d, J=9.4 Hz, 1H), 7.75 (d, J=8.3 Hz, 1H), 7.50 (t, J=7.6 Hz, 1H), 7.13-7.33 (m, 1H), 4.88 (t, J=7.9 Hz, 1H), 4.19 (s, 3H), 3.68-4.05 (m, 2H), 3.34-3.66 (m, 2H), 3.14 (br. s., 1H), 1.47-2.07 (m, 4H), 1.34 (br. s., 1H), 0.37-0.65 (m, 4H).

6-Chloro-3-iodo-1H-indazole

In a round-bottomed flask, 6-chloro-1H-indazole (90 mg, 0.59 mmol) was dissolved in DMF (1.4 mL). Iodine (300 mg, 1.18 mmol) was added followed by potassium hydroxide (128 mg, 2.28 mmol). The dark reaction mixture was stirred at room temperature for 3 h then was quenched with 10% aq NaHSO 3 and extracted with diethyl ether (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to give 169 mg (98%) of 6-chloro-3-iodo-1H-indazole as an orange solid.

6-Chloro-3-iodo-1-methyl-1H-indazole

In a round-bottomed flask, 6-chloro-3-iodo-1H-indazole (167 mg, 0.57 mmol) was dissolved in THF (2 ml) and the solution was cooled to 0° C. Potassium tert-butoxide (90 mg, 0.80 mmol) was added and the reaction mixture was stirred at 0° C. for 1.25 h. Methyl iodide (0.045 ml, 0.72 mmol) was added dropwise then the ice bath was removed and the reaction mixture was stirred at room temperature for 2 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with EtOAc/Hexanes (gradient 0-5% EtOAc) to afford 110 mg (63%) of 6-chloro-3-iodo-1-methyl-1H-indazole as a yellow solid.

6-Chloro-1-methyl-3-tributylstannanyl-1H-indazole

6-Chloro-3-iodo-1-methyl-1H-indazole (108 mg, 0.35 mmol) was dissolved in THF (2 ml) and the solution was cooled to −16° C. using a NaCl/ice bath. Isopropylmagnesium chloride (2.0M in THF, 0.20 ml, 0.40 mmol) was added dropwise and the reaction mixture was stirred at −16° C. for 15 min. Tributylchlorostannane (0.11 ml, 0.40 mmol) was slowly added and the reaction mixture was allowed to warm to room temperature over 1.5 h. The reaction mixture was quenched with saturated NH 4 Cl solution and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to afford 6-chloro-1-methyl-3-tributylstannanyl-1H-indazole as a brown oil which was used without further purification.

[(R)-2-(3-Cyanoazetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

In a round-bottomed flask were combined Boc-D-alanine (500 mg, 2.64 mmol), azetidine-3-carbonitrile hydrochloride (376 mg, 3.17 mmol), HOBT (445 mg, 2.91 mmol) and HATU (1.11 g, 2.91 mmol). Then added DMF (5 mL) followed by N,N-diisopropylethylamine (1.38 mL, 7.93 mmol). The yellow reaction mixture was stirred at room temperature for 3 h then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×) dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (50% to 100% EtOAc/hexanes) to afford 493 mg (74%) of [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester as a white solid.

1-((R)-2-Amino-propionyl)-azetidine-3-carbonitrile trifluoroacetate

To a solution of [(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (860 mg, 3.4 mmol) in CH 2 Cl 2 (20 mL) was added trifluoroacetic acid (4.0 mL). The reaction mixture was stirred at room temperature for 2 h then concentrated to afford 1-((R)-2-amino-propionyl)-azetidine-3-carbonitrile trifluoroacetate as a pale yellow oil which was used without further purification.

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask were combined 2-bromo-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1.05 g, 2.82 mmol) (approx 3:1 Br:Cl), 1-((R)-2-amino-propionyl)-azetidine-3-carbonitrile trifluoroacetate (900 mg, 3.37 mmol), and HATU (1.18 g, 3.1 mmol). Then added DMF (10 mL) followed by N,N-diisopropylethylamine (1.48 mL, 8.46 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×), dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (30% to 100% EtOAc/hexanes) to afford 1.19 g (83%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white foamy solid (approx 3:1 mixture of Br and Cl compounds).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (0.135 g, 0.27 mmol) and 6-chloro-1-methyl-3-tributylstannyl-1H-indazole (crude from step 3, 342 mg, 0.38 mmol) were dissolved in DMF (2.4 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (16 mg, 0.014 mmol) and copper(I) iodide (11 mg, 0.058 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 3 h. The reaction mixture was cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and purified by chromatography with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2.5% MeOH) to afford 157 mg (90%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (154 mg, 0.23 mmol) was dissolved in dichloromethane (1.2 ml) and trifluoroacetic acid (0.72 ml, 9.35 mmol) was added. The orange reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was redissolved in dichloromethane (1.2 ml) and ethylenediamine (1.0 ml, 14.8 mmol) was added. The solution was stirred at room temperature for 1.5 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washing with water (hot), ethyl acetate and dichloromethane then dried under high vacuum to afford 37 mg (33%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white powder. MS: (M+H) + =463; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.70 (br. s., 1H), 9.15 (s, 1H), 8.73 (d, J=8.7 Hz, 1H), 8.47 (t, J=7.4 Hz, 2H), 7.98 (s, 1H), 7.27 (d, J=8.7 Hz, 1H), 4.47-4.84 (m, 3H), 4.18 (s, 3H), 4.02-4.32 (m, 2H), 3.86 (br. s., 1H), 1.42 (d, J=4.5 Hz, 3H).

[(R)-1-(4-Cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester

A round-bottomed flask was charged with Boc-D-tert-leucine (2.5 g, 10.8 mmol), HOBT (4.2 g, 24.9 mmol), EDC (4.77 g, 24.9 mmol) and piperidine-4-carbonitrile (2.98 g, 27.0 mmol). Then added DMF (50 mL) followed by N,N-diisopropylethylamine (10.7 ml, 61.6 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with 10% citric acid and extracted with EtOAc (2×). The combined organic layers were washed twice with 10% citric acid, twice with sat'd LiCl and once with brine then dried over MgSO 4 , filtered and concentrated to give 3.4 g (97%) of [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as a beige foamy solid.

1-((R)-2-Amino-3,3-dimethyl-butyryl)-piperidine-4-carbonitrile trifluoroacetate

To a solution of [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester (3.4 g, 10.5 mmol) in CH 2 Cl 2 (60 mL) was added trifluoroacetic acid (20 mL). The reaction mixture was stirred at room temperature overnight then concentrated to afford 1-((R)-2-amino-3,3-dimethyl-butyryl)-piperidine-4-carbonitrile trifluoroacetate as a light brown oil which was used without further purification.

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide

In a flask were combined 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1.6 g, 4.3 mmol), 1-((R)-2-amino-3,3-dimethyl-butyryl)-piperidine-4-carbonitrile trifluoroacetate (crude from step 2), EDC (1.89 g, 9.9 mmol) and HOBt (1.67 g, 9.9 mmol). DMF (40 mL) was added followed by i-Pr 2 NEt (5.2 mL, 30.1 mmol). The reaction mixture was stirred at room temperature for overnight and then concentrated. The residue was taken up in EtOAc and 10% citric acid and the organic layer washed with 10% citric acid, sat. NaHCO 3 , sat LiCl and brine, dried over MgSO 4 , and concentrated. The residue was purified by silica gel chromatography (40%-100% EtOAc/hexanes) to give 1.46 g (59%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide as a beige foamy solid.

2-(5-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide

In a round-bottomed flask 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide (150 mg, 0.26 mmol) and 5-chloro-1-methyl-3-tributylstannanyl-1H-indazole (372 mg, 0.45 mmol) were dissolved in DMF (2.4 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.013 mmol) and copper(I) iodide (10 mg, 0.053 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 3.5 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2% MeOH) to isolate 137 mg (80%) of 2-(5-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide as a yellow oil.

2-(5-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide

In a round-bottomed flask, 2-(5-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide (0.158 g, 0.193 mmol) was dissolved in dichloromethane (1 ml) and trifluoroacetic acid (0.6 ml, 7.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was redissolved in dichloromethane (1 ml) and ethylenediamine (0.8 ml, 11.7 mmol) was added. The solution was stirred at room temperature for 1 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with EtOAc/hexanes (gradient 0-100% EtOAc) to afford 26 mg (24%) of 2-(5-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyano-piperidine-1-carbonyl)-2,2-dimethyl-propyl]-amide as an off-white solid. MS: (M+H) + =533; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.09 (s, 1H), 8.73 (d, J=6.8 Hz, 1H), 8.61 (t, J=8.1 Hz, 1H), 8.46 (d, J=9.1 Hz, 1H), 7.80 (d, J=9.1 Hz, 1H), 7.50 (d, J=9.1 Hz, 1H), 5.20 (d, J=9.4 Hz, 1H), 4.19 (s, 3H), 3.97-4.12 (m, 1H), 3.35-3.91 (m, 2H), 3.01-3.23 (m, 2H), 1.39-2.07 (m, 4H), 1.04 (d, J=6.4 Hz, 9H).

2-(6-Cyclopropyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

6-Bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole

In a round-bottomed flask 6-bromo-1H-indazole (0.70 g, 3.55 mmol) was dissolved in DMF (7.5 ml). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 172 mg, 4.3 mmol) was added). The reaction mixture was warmed to room temperature and stirred for 30 min then cooled back to 0° C. and SEM-Cl (0.76 ml, 4.28 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction mixture was warmed to room temperature. After 1.5 h the reaction was quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/Hexanes (gradient 0-10% EtOAc) to give 802 mg (69%) of 6-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole as a light yellow oil.

6-Cyclopropyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole

A round-bottomed flask was charged with 6-bromo-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole (0.80 g, 2.44 mmol), cyclopropylboronic acid (377 mg, 4.39 mmol), palladium(II) acetate (28 mg, 0.125 mmol), potassium phosphate tribasic (1.04 g, 4.88 mmol), toluene (9 ml) and water (0.9 ml). The reaction mixture was stirred at 100° C. in an oil bath overnight then cooled to room temperature, quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/Hexanes (gradient 0-5% EtOAc) to afford 670 mg (90%) of 6-cyclopropyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole as a light yellow oil.

6-Cyclopropyl-1H-indazole

In a round-bottomed flask, 6-cyclopropyl-1-(2-trimethylsilanyl-ethoxymethyl)-1H-indazole (668 mg, 2.2 mmol) was dissolved in dichloromethane (12 ml) and trifluoroacetic acid (6.5 ml, 84.4 mmol) was added. The yellow reaction mixture was stirred at room temperature for 2.25 h then concentrated. The residue was redissolved in dichloromethane (12 ml) and ethylenediamine (9.0 ml, 133 mmol) was added. The solution was stirred at room temperature for 1 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/Hexanes (gradient 0-25% EtOAc) to provide 317 mg (91%) of 6-cyclopropyl-1H-indazole as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.99-8.08 (m, 1H), 7.59-7.70 (m, 1H), 7.16-7.25 (m, 1H), 6.88-7.01 (m, 1H), 1.94-2.14 (m, 1H), 0.96-1.11 (m, 2H), 0.71-0.84 (m, 2H).

2-(6-Cyclopropyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 1, substituting 6-cyclopropyl-1H-indazole for indazole in step 1. MS: (M+H) + =523; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.88 (br. s., 1H), 9.15 (s, 1H), 8.63 (t, J=8.7 Hz, 2H), 8.44 (d, J=9.4 Hz, 1H), 7.37 (s, 1H), 7.04 (br. s., 1H), 4.74-4.95 (m, 1H), 4.14 (s, 3H), 3.35-4.06 (m, 4H), 3.17 (br. s., 1H), 2.13 (br. s., 1H), 1.51-2.05 (m, 4H), 1.35 (br. s., 1H), 1.04 (d, J=6.8 Hz, 2H), 0.83 (d, J=3.4 Hz, 2H), 0.34-0.65 (m, 4H).

2-(1-Methyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 1, substituting 4,5,6,7-tetrahydro-1H-indazole for indazole in step 1. MS: (M+H) + =487; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.76 (s, 1H), 8.93 (s, 1H), 8.58 (d, J=8.1 Hz, 1H), 8.36 (d, J=15.2 Hz, 1H), 4.66 (t, J=8.1 Hz, 1H), 3.78 (s, 3H), 3.34-4.04 (m, 4H), 2.84-3.18 (m, 3H), 2.60-2.70 (m, 2H), 1.44-1.97 (m, 8H), 1.17-1.31 (m, 1H), 0.29-0.66 (m, 4H).

2-(5-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

A round-bottomed flask was charged with 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (150 mg, 0.40 mmol), HOBT (68 mg, 0.44 mmol) and EDC (85 mg, 0.44 mmol). DMF (1.8 ml) was added followed by (S)-3,3-dimethylbutan-2-amine (0.10 ml, 0.73 mmol) and N,N-diisopropylethylamine (0.11 ml, 0.63 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-20% EtOAc) to afford 97 mg (50%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide as a light brown oil.

2-(5-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide (94 mg, 0.21 mmol) and 5-chloro-1-methyl-3-tributylstannyl-1H-indazole (367 mg, 0.40 mmol) were dissolved in DMF (1.9 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (12 mg, 0.010 mmol) and copper(I) iodide (8 mg, 0.042 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 3.5 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-40% EtOAc) to afford 92 mg (82%) of 2-(5-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide as an off-white solid.

2-(5-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

In a round-bottomed flask, 2-(5-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide (90 mg, 0.17 mmol) was dissolved in dichloromethane (0.8 ml) and trifluoroacetic acid (0.5 ml, 6.6 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was redissolved in dichloromethane (0.8 ml) and ethylenediamine (0.7 ml, 9.9 mmol) was added. The solution was stirred at room temperature for 1.5 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, rinsed with hot water and ethyl acetate then dried under high vacuum to provide 60 mg (83%) of 2-(5-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide as a light yellow powder. MS: (M+H) + =411; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.43 (br. s., 1H), 9.08 (s, 1H), 8.45 (s, 1H), 8.33 (s, 1H), 8.00 (d, J=10.2 Hz, 1H), 7.85 (d, J=8.9 Hz, 1H), 7.55 (dd, J=8.9, 1.5 Hz, 1H), 4.20 (s, 3H), 4.06-4.28 (m, 1H), 1.33 (d, J=6.8 Hz, 3H), 0.92 (s, 9H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide

((R)-2-Hydroxy-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester

To a solution of Boc-D-alanine methyl ester (5.00 g, 24.6 mmol) in THF (100 mL) at 0° C. was slowly added methyl magnesium bromide (3.0 M in Et 2 O, 28.7 mL, 86.1 mmol). The resultant white slurry was stirred at 0° C. for 1 h then at room temperature for 2 h. The reaction mixture was quenched with saturated aqueous NH 4 Cl, diluted with H 2 O and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO 4 and concentrated to give 4.93 g (99%) ((R)-2-hydroxy-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester as a colorless viscous oil.

(R)-3-Amino-2-methyl-butan-2-ol hydrochloride

((R)-2-Hydroxy-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester (4.93 g, 24.2 mmol) was dissolved in 1.0 M HCl (150 mL) and stirred at 50° C. for 4 h. Concentration gave 4.01 g of (R)-3-amino-2-methyl-butan-2-ol hydrochloride as a pale brown solid which was used without further purification.

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide

In a flask were combined 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3.25 g, 8.74 mmol), (R)-3-amino-2-methyl-butan-2-ol hydrochloride (3.05 g, 21.9 mmol), EDC (3.85 g, 20.1 mmol) and HOBt (2.72 g, 20.1 mmol). Then added DMF (50 mL) followed by i-Pr 2 NEt (4.87 mL, 28.0 mmol). The mixture was stirred at room temperature overnight then concentrated under reduced pressure. The residue purified by SiO 2 chromatography (20-100% EtOAc/hexane) to afford 2.40 g (60%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide as a yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide (120 mg, 0.26 mmol) and 6-chloro-1-methyl-3-tributylstannyl-1H-indazole (319 mg, 0.42 mmol) were dissolved in DMF (2.5 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (16 mg, 0.014 mmol) and copper(I) iodide (10 mg, 0.053 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath overnight then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2% MeOH) to afford 122 mg (86%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide as an off-white solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide (121 mg, 0.22 mmol) was dissolved in dichloromethane (1 ml) and trifluoroacetic acid (0.7 ml, 9.0 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was redissolved in dichloromethane (1 ml) and ethylenediamine (0.9 ml, 13.3 mmol) was added. The solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, rinsed with hot water and ethyl acetate then dried under high vacuum to provide 53 mg (58%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-hydroxy-1,2-dimethyl-propyl)-amide as an off-white powder. MS: (M+H) + =413; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.83 (br. s., 1H), 9.14 (s, 1H), 8.75 (d, J=8.7 Hz, 1H), 8.42 (s, 1H), 8.16 (d, J=9.4 Hz, 1H), 7.95 (d, J=1.1 Hz, 1H), 7.36 (dd, J=8.7, 1.1 Hz, 1H), 4.78 (s, 1H), 4.17 (s, 3H), 4.03-4.16 (m, 1H), 1.22-1.28 (m, 6H), 1.16 (s, 3H).

2-(1,5,5-Trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-[1-Hydroxy-meth-(Z)-ylidene]-4,4-dimethyl-cyclohexanone

A dry round-bottomed flask was charged with sodium hydride (60% dispersion in mineral oil, 475 mg, 11.9 mmol) and diethyl ether (24 ml). The reaction was cooled to 0° C. and ethanol (0.06 ml, 1.03 mmol) was added dropwise. The suspension was stirred for at 0° C. for 20 min then a solution of 4,4-dimethylcyclohexanone (1.50 g, 11.9 mmol) and ethyl formate (1.45 ml, 17.8 mmol) in diethyl ether (3 ml) was added dropwise over 15 min. The yellow solution was stirred at 0° C. for 3 h then slowly allowed to warm to room temperature overnight. Ethanol (0.24 ml) was added and the mixture was stirred at room temperature for 1 h then quenched with water and extracted with diethyl ether. The aqueous layer was acidified with 6M HCl until pH=2 then extracted with diethyl ether (2×). The combined organic layers were washed with brine then dried over sodium sulfate, filtered and concentrated to give 1.30 g (71%) of 2-[1-hydroxy-meth-(Z)-ylidene]-4,4-dimethyl-cyclohexanone as a pale brown oil which was used without further purification. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 14.40 (br. s., 1H), 8.58 (s, 1H), 2.39 (t, J=6.8 Hz, 2H), 2.13 (s, 2H), 1.48 (t, J=6.8 Hz, 2H), 1.00 (s, 6H).

5,5-Dimethyl-4,5,6,7-tetrahydro-1H-indazole

In a 100 ml round-bottomed flask, 2-[1-hydroxy-meth-(Z)-ylidene]-4,4-dimethyl-cyclohexanone (1.30 g, 8.43 mmol) was dissolved in methanol (8.5 ml). Hydrazine (0.27 ml, 8.43 mmol) was added very slowly which resulted in an exothermic reaction. The reaction mixture was stirred at room temperature for 50 min then concentrated. The residue was triturated with petroleum ether to afford 1.05 g (83%) of 5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazole as a light brown solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.28 (s, 1H), 2.67 (t, J=6.6 Hz, 2H), 2.32 (s, 2H), 1.60 (t, J=6.6 Hz, 2H), 0.99 (s, 6H).

3-Iodo-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazole

In a round-bottomed flask, 5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazole (0.50 g, 3.33 mmol) was dissolved in DMF (7 mL). Iodine (1.69 g, 6.66 mmol) was added followed by potassium hydroxide (723 mg, 12.9 mmol). The dark reaction mixture was stirred at room temperature for 1.25 h. Additional iodine (1.69 g, 6.66 mmol) and potassium hydroxide (723 mg, 12.9 mmol) were added and the dark brown reaction mixture was stirred at room temperature for 1.5 h. The reaction was quenched with 10% aqueous NaHSO 3 solution and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/Hexanes (gradient 0-20% EtOAc) to give 645 mg (70%) of 3-iodo-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazole as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 2.66 (t, J=6.6 Hz, 2H), 2.14 (s, 2H), 1.59 (t, J=6.4 Hz, 2H), 1.01 (s, 6H).

3-Iodo-1,5,5-trimethyl-4,5,6,7-tetrahydro-1H-indazole

In a round-bottomed flask, 3-iodo-5,5-dimethyl-4,5,6,7-tetrahydro-1H-indazole (642 mg, 2.33 mmol) was dissolved in THF (8.5 ml). The solution was cooled to 0° C. and potassium tert-butoxide (365 mg, 3.26 mmol) was added. The reaction mixture was stirred at 0° C. for 40 min then methyl iodide (0.18 ml, 2.88 mmol) was added dropwise. The reaction mixture was warmed to room temperature and stirred for 1.5 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/Hexanes (gradient 0-15% EtOAc) to provide 497 mg (74%) of 3-iodo-1,5,5-trimethyl-4,5,6,7-tetrahydro-1H-indazole as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 3.76 (s, 3H), 2.53 (t, J=6.4 Hz, 2H), 2.11 (s, 2H), 1.58 (t, J=6.6 Hz, 2H), 0.99 (s, 6H).

1,5,5-Trimethyl-3-tributylstannanyl-4,5,6,7-tetrahydro-1H-indazole

In a round-bottomed flask, 3-iodo-1,5,5-trimethyl-4,5,6,7-tetrahydro-1H-indazole (140 mg, 0.48 mmol) was dissolved in THF (3 ml). The colorless solution was cooled to −16° C. (NaCl/ice bath) and isopropylmagnesium chloride (2.0M in THF, 0.27 ml, 0.54 mmol) was added dropwise. The reaction mixture was stirred at −16° C. for 20 min then tributylchlorostannane (0.15 ml, 0.55 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature over 1.5 h then quenched with saturated NH 4 Cl, diluted with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to afford 1,5,5-trimethyl-3-tributylstannanyl-4,5,6,7-tetrahydro-1H-indazole as a colorless oil which was used without further purification.

5-(2-Trimethylsilanyl-ethoxymethyl)-2-(1,5,5-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (130 mg, 0.26 mmol) and 1,5,5-trimethyl-3-(tributylstannyl)-4,5,6,7-tetrahydro-1H-indazole (375 mg, 0.41 mmol) were dissolved in DMF (2.4 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (15 mg, 0.013 mmol) and copper(I) iodide (10 mg, 0.053 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 2.5 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-5% MeOH) to afford 113 mg (75%) of 5-(2-trimethylsilanyl-ethoxymethyl)-2-(1,5,5-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow foam.

2-(1,5,5-Trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 5-(2-trimethylsilanyl-ethoxymethyl)-2-(1,5,5-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (112 mg, 0.19 mmol) was dissolved in dichloromethane (0.9 ml) and trifluoroacetic acid (0.6 ml, 7.5 mmol) was added. The yellow solution was stirred at room temperature for 2.5 h then concentrated. The residue was redissolved in dichloromethane (0.9 ml) and ethylenediamine (0.8 ml, 11.4 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 47 mg (51%) of 2-(1,5,5-Trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white powder. MS: (M+H) + =461; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.61 (br. s., 1H), 8.94 (s, 1H), 8.27-8.41 (m, 2H), 4.43-4.80 (m, 3H), 3.94-4.24 (m, 2H), 3.80 (s, 3H), 3.72-3.91 (m, 1H), 2.89 (d, J=15.9 Hz, 1H), 2.59-2.71 (m, 3H), 1.59 (t, J=6.2 Hz, 2H), 1.40 (dd, J=6.8, 3.0 Hz, 3H), 1.00 (s, 6H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (400 mg, 1.12 mmol) and 6-chloro-1-methyl-3-tributylstannyl-1H-indazole (1.11 g, 1.7 mmol) were dissolved in DMF (10 mL). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (65 mg, 0.056 mmol) and copper(I) iodide (43 mg, 0.23 mmol) were added. The reaction mixture was stirred at 80° C. in an oil bath overnight then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-30% EtOAc) to provide 416 mg (84%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (412 mg, 0.93 mmol) was suspended in 1,4-dioxane (15 ml) and water (3 ml). The suspension was cooled to 0° C. and sulfamic acid (543 mg, 5.59 mmol) was added. Then, a solution of sodium chlorite (80%, 137 mg, 1.21 mmol) and potassium dihydrogen phosphate (1.52 g, 11.2 mmol) in water (9 ml) was added via dropping funnel over ˜20 min. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 3 h. THF (15 ml) was added and the reaction mixture was stirred at room temperature for an additional 3 h. The reaction mixture was diluted with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was triturated with ethyl acetate/hexanes to afford 358 mg (84%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid as a light yellow powder.

[(R)-2-(3,3-Difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

A round-bottomed flask was charged with Boc-D-alanine (400 mg, 2.11 mmol), 3,3-difluoroazetidine hydrochloride (383 mg, 2.96 mmol), HOBT (356 mg, 2.33 mmol) and EDC (446 mg, 2.33 mmol). DMF (9 ml) was added followed by N,N-diisopropylethylamine (1.0 ml, 5.73 mmol). The reaction mixture was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to give 509 mg (91%) of [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 5.14 (d, J=7.2 Hz, 1H), 4.59-4.80 (m, 1H), 4.17-4.55 (m, 4H), 1.45 (s, 9H), 1.32 (d, J=7.2 Hz, 3H).

(R)-2-Amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one

A 5 ml microwave vial was charged with [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (170 mg, 0.64 mmol) and 2,2,2-trifluoroethanol (2.4 ml, 32.9 mmol). The vial was flushed with argon, sealed and heated at 150° C. under microwave irradiation for 3 h. The reaction mixture was concentrated to afford 102 mg (97%) of (R)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one as a brown oil which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

A round-bottomed flask was charged with 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (110 mg, 0.24 mmol), (R)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one (98 mg, 0.60 mmol), HOBT (41 mg, 0.27 mmol) and EDC (51 mg, 0.27 mmol). DMF (1.1 ml) was added followed by N,N-diisopropylethylamine (0.10 ml, 0.57 mmol). The reaction mixture was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/Hexanes (gradient 0-50% EtOAc) to afford 89 mg (61%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (88 mg, 0.146 mmol) was dissolved in dichloromethane (0.7 ml) and trifluoroacetic acid (0.45 ml, 5.84 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was dissolved in dichloromethane (0.7 ml) and ethylenediamine (0.6 ml, 8.74 mmol) was added. The solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 45 mg (62%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3,3-difluoro-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow powder. MS: (M+H) + =474; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 10.55-11.71 (b. s, 1H), 9.13 (s, 1H), 8.71 (d, J=8.7 Hz, 1H), 8.40-8.54 (m, 2H), 7.97 (d, J=1.5 Hz, 1H), 7.26 (dd, J=8.7, 1.5 Hz, 1H), 4.67-4.99 (m, 3H), 4.38 (t, J=12.7 Hz, 2H), 4.17 (s, 3H), 1.44 (d, J=6.8 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methanesulfonyl-piperidin-3-yl)-amide

(R)-3-{[2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-piperidine-1-carboxylic acid tert-butyl ester

A round-bottomed flask was charged with 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.26 mmol), (R)-tert-butyl 3-aminopiperidine-1-carboxylate (80 mg, 0.40 mmol), HOBT (45 mg, 0.29 mmol) and EDC (56 mg, 0.29 mmol). DMF (1.2 ml) was added followed by N,N-diisopropylethylamine (0.10 ml, 0.57 mmol). The reaction mixture was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-50% EtOAc) to provide 139 mg (83%) of (R)-3-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-piperidine-1-carboxylic acid tert-butyl ester as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (R)-piperidin-3-ylamide

In a round-bottomed flask, (R)-3-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-piperidine-1-carboxylic acid tert-butyl ester (138 mg, 0.22 mmol) was suspended in methanol (2 ml). The reaction was cooled to 0° C. and acetyl chloride (0.30 ml, 4.22 mmol) was added dropwise over 10 min. The resultant bright yellow suspension was stirred at room temperature for 50 min. THF (1 ml) and methanol (1 ml) were added and stirred was continued for 1 h at room temperature then the solvent was evaporated at room temperature. The residue was suspended in dichloromethane and washed with saturated Na 2 CO 3 -solution. The aqueous layer was extracted with dichloromethane. The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford 105 mg (90%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (R)-piperidin-3-ylamide as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methanesulfonyl-piperidin-3-yl)-amide

To a solution of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (R)-piperidin-3-ylamide (104 mg, 0.19 mmol) in dichloromethane (1.5 ml) at 0° C. was added triethylamine (0.04 ml, 0.29 mmol) followed by methanesulfonyl chloride (0.02 ml, 0.26 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-4% MeOH) then triturated with ethyl acetate to afford 106 mg (89%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methanesulfonyl-piperidin-3-yl)-amide as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methanesulfonyl-piperidin-3-yl)-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methanesulfonyl-piperidin-3-yl)-amide (103 mg, 0.167 mmol) was dissolved in dichloromethane (0.8 ml) and trifluoroacetic acid (0.5 ml, 6.6 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was dissolved in dichloromethane (0.8 ml) and ethylenediamine (0.67 ml, 9.92 mmol) was added. The resultant light yellow suspension was stirred at room temperature for 45 min then quenched with water and diluted with ethyl acetate. The suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 54 mg (63%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methanesulfonyl-piperidin-3-yl)-amide as a light yellow powder. MS: (M+H) + =488; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.06 (s, 1H), 8.47 (s, 1H), 8.41 (d, J=8.7 Hz, 1H), 8.13 (d, J=7.6 Hz, 1H), 8.00 (s, 1H), 7.36 (d, J=8.7 Hz, 1H), 4.17 (s, 3H), 4.06-4.15 (m, 1H), 3.66-3.75 (m, 1H), 3.34-3.41 (m, 1H), 2.89-2.99 (m, 1H), 2.86 (s, 3H), 2.80 (d, J=10.6 Hz, 1H), 2.11 (br. s., 1H), 1.87 (br. s., 1H), 1.51-1.74 (m, 2H)

[(R)-1-(3-Cyano-azetidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester

In a round-bottomed flask Boc-D-2-aminobutyric acid (400 mg, 1.97 mmol) and azetidine-3-carbonitrile hydrochloride (373 mg, 3.15 mmol) were dissolved in DMF (9 ml). N,N-Diisopropylethylamine (1.0 ml, 5.73 mmol) was added followed by HATU (823 mg, 2.16 mmol). The reaction mixture was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to provide 410 mg (70%) of [(R)-1-(3-cyano-azetidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester as an off-white solid.

1-((R)-2-Amino-butyryl)-azetidine-3-carbonitrile trifluoroacetate

To a solution of [(R)-1-(3-cyano-azetidine-1-carbonyl)-propyl]-carbamic acid tert-butyl ester (200 mg, 0.67 mmol) in dichloromethane (4 ml) was added trifluoroacetic acid (1.8 ml, 23.4 mmol). The reaction mixture was stirred at room temperature for 2 h then concentrated to afford 1-((R)-2-amino-butyryl)-azetidine-3-carbonitrile trifluoroacetate as a light yellow oil which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-cyano-azetidine-1-carbonyl)-propyl]-amide

Prepared according to the procedure outlined in Example 14, Steps 5-6, substituting 1-((R)-2-amino-butyryl)-azetidine-3-carbonitrile trifluoroacetate for (R)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one in Step 5. MS: (M+H) + =477; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.73 (s, 1H), 9.15 (s, 1H), 8.73 (d, J=8.7 Hz, 1H), 8.40-8.55 (m, 2H), 7.99 (s, 1H), 7.24 (d, J=8.3 Hz, 1H), 4.48-4.79 (m, 3H), 4.18 (s, 3H), 3.99-4.33 (m, 2H), 3.75-3.96 (m, 1H), 1.62-1.97 (m, 2H), 0.83-1.02 (m, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

[(R)-2-(3-Cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

In a round-bottomed flask Boc-D-cyclopropylglycine (500 mg, 2.32 mmol) and azetidine-3-carbonitrile hydrochloride (441 mg, 3.72 mmol) were dissolved in DMF (10 ml). N,N-Diisopropylethylamine (1.2 ml, 6.87 mmol) was added followed by HATU (972 mg, 2.56 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was triturated with petroleum ether to afford 384 mg (59%) of [(R)-2-(3-cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-carbamic acid tert-butyl ester as an off-white solid.

1-((R)-2-Amino-2-cyclopropyl-acetyl)-azetidine-3-carbonitrile trifluoroacetate

To a solution of [(R)-2-(3-cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (190 mg, 0.69 mmol) in dichloromethane (4 ml) was added trifluoroacetic acid (1.8 ml, 23.4 mmol). The reaction mixture was stirred at room temperature for 2.5 h then concentrated to afford 1-((R)-2-amino-2-cyclopropyl-acetyl)-azetidine-3-carbonitrile trifluoroacetate as a light yellow oil which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 14, Steps 5-6, substituting 1-((R)-2-amino-2-cyclopropyl-acetyl)-azetidine-3-carbonitrile trifluoroacetate for (R)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one in Step 5. MS: (M+H) + =489; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.92 (br. s., 1H), 9.15 (s, 1H), 8.72 (dd, J=8.6, 3.5 Hz, 1H), 8.43-8.56 (m, 2H), 7.98 (s, 1H), 7.24 (t, J=7.1 Hz, 1H), 4.44-4.76 (m, 2H), 4.17 (s, 3H), 4.01-4.36 (m, 3H), 3.81-3.93 (m, 1H), 1.24-1.38 (m, 1H), 0.36-0.65 (m, 4H).

2-(6-Cyano-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 4, substituting 6-cyano-1H-indazole for 6-chloro-1H-indazole in step 1. MS: (M+H) + =454; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.93 (br. s., 1H), 9.15 (s, 1H), 8.89 (d, J=8.1 Hz, 1H), 8.39-8.55 (m, 3H), 7.49-7.59 (m, 1H), 4.50-4.83 (m, 3H), 4.25 (s, 3H), 4.20-4.28 (m, 1H), 4.07-4.18 (m, 1H), 3.79-3.93 (m, 1H), 1.41 (t, J=6.8 Hz, 3H).

2-(6-Chloro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

6-Chloro-3-tributylstannanyl-1H-indazole

In a round-bottomed flask, 6-chloro-3-iodo-1H-indazole (250 mg, 0.85 mmol) was dissolved in THF (5 ml) and sodium hydride (60% dispersion in mineral oil, 41 mg, 1.03 mmol) was added. The reaction mixture was stirred at room temperature for 10 min then cooled to −16° C. (NaCl/ice bath) and isopropylmagnesium chloride (2.0 M in THF, 0.52 ml, 1.04 mmol) was added dropwise. The reaction mixture was stirred at −16° C. for 30 min then additional isopropylmagnesium chloride (2.0 M in THF (0.14 ml, 0.28 mmol) was added. The reaction mixture was stirred at −16° C. for 10 min then tributylchlorostannane (0.28 ml, 1.03 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature over 2.5 h then quenched with saturated NH 4 Cl-solution and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered, concentrated to give 6-chloro-3-tributylstannanyl-1H-indazole as a yellow oil which was used without further purification.

2-(6-Chloro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (190 mg, 0.37 mmol) and 6-chloro-3-tributylstannyl-1H-indazole (crude form step 1, 619 mg, 0.70 mmol) were dissolved in DMF (3.4 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium(0) (22 mg, 0.019 mmol) and copper(I) iodide (15 mg, 0.079 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 3 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then concentrated. The residue was absorbed on silica gel and chromatographed with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-3% MeOH) then triturated with diethyl ether/ethyl acetate to afford 159 mg (73%) of 2-(6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light brown powder.

2-(6-Chloro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (65 mg, 0.112 mmol) was dissolved in dichloromethane (0.6 ml) and trifluoroacetic acid (0.35 ml, 4.5 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was redissolved in dichloromethane (0.6 ml) and ethylenediamine (0.46 ml, 6.8 mmol) was added. The solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 30 mg (59%) of 2-(6-chloro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow powder. MS: (M+H) + =449.

1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 13.35-13.88 (m, 1H), 12.77 (s, 1H), 9.20 (s, 1H), 8.73 (dd, J=8.7, 2.9 Hz, 1H), 8.48 (d, J=8.0 Hz, 2H), 7.74 (d, J=1.5 Hz, 1H), 7.22-7.28 (m, 1H), 4.71-4.78 (m, 1H), 4.64-4.70 (m, 1H), 4.60 (d, J=7.8 Hz, 1H), 4.51-4.57 (m, 1H), 4.23 (td, J=9.5, 3.4 Hz, 1H), 4.06-4.15 (m, 1H), 3.80-3.93 (m, 1H), 1.41 (t, J=6.5 Hz, 3H).

2-[6-Chloro-1-(2-methoxy-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-[6-Chloro-1-(2-methoxy-ethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (90 mg, 0.155 mmol) was dissolved in DMF (1 ml). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 8 mg, 0.20 mmol) was added. The reaction mixture was stirred at 0° C. for 30 min then 1-bromo-2-methoxyethane (22 μl, 0.23 mmol) was added. The reaction mixture was stirred at 0° C. for 3 h and then at room temperature overnight. The reaction mixture was quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-3% MeOH) to afford 51 mg (52%) of 2-[6-chloro-1-(2-methoxy-ethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow foam.

2-[6-Chloro-1-(2-methoxy-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-[6-chloro-1-(2-methoxy-ethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (50 mg, 0.079 mmol) was dissolved in dichloromethane (0.5 ml) and trifluoroacetic acid (0.25 ml, 3.24 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.5 ml) and ethylenediamine (0.32 ml, 4.74 mmol) was added. The reaction was stirred at room temperature for 1.5 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 19 mg (48%) of 2-[6-chloro-1-(2-methoxy-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow powder. MS: (M+H) + =507; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.88 (br. s., 1H), 9.16 (s, 1H), 8.72 (dd, J=8.6, 3.0 Hz, 1H), 8.49 (dd, J=8.6, 4.8 Hz, 2H), 8.00 (s, 1H), 7.23-7.30 (m, 1H), 4.52-4.79 (m, 5H), 4.19-4.28 (m, 1H), 4.08-4.16 (m, 1H), 3.85 (t, J=5.3 Hz, 3H), 3.24 (s, 3H), 1.41 (t, J=6.6 Hz, 3H).

2-(6-Chloro-1H-indol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

A vial was charged with 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (158 mg, 0.31 mmol), tert-butyl 6-chloro-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indole-1-carboxylate (176 mg, 0.47 mmol) and tetrakis(triphenylphosphine)palladium(0) (18.0 mg, 0.016 mmol). The vial was evacuated and backfilled with argon then 1,2-dimethoxyethane (1.8 ml) and aqueous 2 M sodium carbonate (0.47 ml, 0.940 mmol) were added. The vial was sealed and the reaction was stirred at 90° C. in an oil bath overnight. The reaction mixture was cooled to room temperature, quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-3% MeOH) to isolate 93 mg (52%) 2-(6-chloro-1H-indol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light green foam. A minor amount of impure 6-chloro-3-[7-[(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethylcarbamoyl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-2-yl]-indole-1-carboxylic acid tert-butyl ester was also insolated as a light brown solid.

2-(6-Chloro-1-methyl-1H-indol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1H-indol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (90 mg, 0.156 mmol) was dissolved in DMF (1 ml). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 8 mg, 0.20 mmol) was added. The reaction mixture was stirred at 0° C. for 30 min then methyl iodide (10 μl, 0.16 mmol) was added. The reaction mixture was stirred at 0° C. for 1.5 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2% MeOH) to afford 56 mg (61%) of 2-(6-chloro-1-methyl-1H-indol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow foam.

2-(6-Chloro-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (54 mg, 0.091 mmol) was dissolved in dichloromethane (0.5 ml) and trifluoroacetic acid (0.28 ml, 3.63 mmol) was added. The dark red solution was stirred at room temperature for 2 h then concentrated. The residue was redissolved in dichloromethane (0.5 ml) and ethylenediamine (0.37 ml, 5.48 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 28 mg (63%) of 2-(6-chloro-1-methyl-1H-indol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow powder.

MS: (M+H) + =462; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.62 (br. s., 1H), 8.88 (s, 1H), 8.61 (d, J=7.6 Hz, 1H), 8.55 (d, J=8.7 Hz, 1H), 8.27-8.39 (m, 2H), 7.70 (d, J=1.5 Hz, 1H), 7.17 (dd, J=8.5, 2.5 Hz, 1H), 4.46-4.77 (m, 3H), 4.14-4.27 (m, 1H), 4.01-4.12 (m, 1H), 3.88 (s, 3H), 3.83 (br. s., 1H), 1.40 (dd, J=6.8, 4.2 Hz, 3H).

2-(6-Chloro-5-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 4, substituting 6-chloro-5-fluoro-1H-indazole for 6-chloro-1H-indazole in step 1. MS: (M+H) + =481; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.87 (br. s., 1H), 9.13 (s, 1H), 8.49 (d, J=7.9 Hz, 2H), 8.44 (d, J=7.6 Hz, 1H), 8.21 (d, J=6.0 Hz, 1H), 4.48-4.77 (m, 3H), 4.20 (s, 3H), 4.13-4.28 (m, 1H), 4.07 (dt, J=9.7, 5.1 Hz, 1H), 3.79-3.93 (m, 1H), 1.45 (t, J=6.2 Hz, 3H).

2-(6-Methyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

(5-Methyl-pyridin-2-yl)-methylamine

In a dry round-bottomed flask 5-methyl-pyridine-2-carbonitrile (1.0 g, 8.46 mmol) was dissolved in THF (45 ml). The solution was cooled to 0° C. and lithium aluminum hydride (1.0 M in THF, 25 ml, 25.0 mmol) was added dropwise over 20 min. The reaction mixture was stirred at 0° C. for 30 min then sodium sulfate decahydrate was carefully added. When gas evolution had ceased, the ice bath was removed, sodium sulfate was added and the mixture was stirred vigorously for 30 min at room temperature. The suspension was filtered over Celite and rinsed with ethyl acetate, dichloromethane, and methanol. The filtrate was concentrated to afford (5-methyl-pyridin-2-yl)-methylamine as a brown solid which was used without further purification.

N-(5-Methyl-pyridin-2-ylmethyl)-formamide

In a round-bottomed flask, (5-methyl-pyridin-2-yl)-methylamine (crude from step 1) was dissolved in 88% formic acid (6.0 ml, 156 mmol). The dark brown solution was stirred at reflux in an oil bath overnight. The reaction mixture was cooled to 0° C. and adjusted carefully to pH=8 by addition of 25% aqueous ammonium hydroxide. The mixture was diluted with water and the aqueous layer was extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to give N-(5-methyl-pyridin-2-ylmethyl)-formamide as a dark brown oil and used without further purification.

6-Methyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, N-(5-methyl-pyridin-2-ylmethyl)-formamide (crude from step 2) was dissolved in toluene (30 ml) and phosphorus oxychloride (1.2 ml, 12.9 mmol) was added. The reaction mixture was stirred at 100° C. in an oil bath overnight then cooled to 0° C. and carefully quenched with ice. Aqueous 25% ammonium hydroxide was added until pH=˜9. The mixture was diluted with water and extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-80% EtOAc) to give 386 mg (41%, 3 steps) of 6-methyl-imidazo[1,5-a]pyridine as a light brown solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.09 (s, 1H), 7.74 (s, 1H), 7.32-7.43 (m, 2H), 6.60 (dd, J=9.4, 1.1 Hz, 1H), 2.25 (d, J=1.1 Hz, 3H).

1-Iodo-6-methyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, sodium bicarbonate (215 mg, 2.56 mmol) was suspended in water (0.6 ml) and ethanol (1.2 ml). 6-methyl-imidazo[1,5-a]pyridine (90 mg, 0.68 mmol) was added followed by iodine (242 mg, 0.95 mmol). The dark brown suspension was stirred at room temperature overnight then quenched with 10% Na 2 S 2 O 3 -solution and extracted with EtOAc (2×). The organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to provide 99 mg (56%) of 1-iodo-6-methyl-imidazo[1,5-a]pyridine as a light brown solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.11 (s, 1H), 7.73 (s, 1H), 7.24 (d, J=9.4 Hz, 1H), 6.67 (d, J=9.1 Hz, 1H), 2.27 (s, 3H).

6-Methyl-1-tributylstannanyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, 1-iodo-6-methyl-imidazo[1,5-a]pyridine (97 mg, 0.38 mmol) was dissolved in THF (3 ml). The solution was cooled to −16° C. (NaCl/ice bath) and isopropylmagnesium chloride (2.0M solution in THF, 0.23 ml, 0.46 mmol) was added dropwise. The reaction mixture was stirred at −16° C. for 20 min then tributylchlorostannane (0.12 ml, 0.44 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature and stirred for 2 h then quenched with saturated aqueous NH 4 Cl and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to provide 6-methyl-1-tributylstannanyl-imidazo[1,5-a]pyridine as a brown oil which was used without further purification.

2-(6-Methyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (100 mg, 0.20 mmol) and 6-methyl-1-tributylstannyl-imidazo[1,5-a]pyridine (crude from step 5, 307 mg, 0.36 mmol) were dissolved in DMF (1.8 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (12 mg, 0.010 mmol) and copper (I) iodide (8 mg, 0.042 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath overnight then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-3% MeOH) to afford 98 mg (89%) of 2-(6-methyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow oil.

2-(6-Methyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-methyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (92 mg, 0.165 mmol) was dissolved in dichloromethane (0.8 ml) and trifluoroacetic acid (0.5 ml, 6.6 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.8 ml) and ethylenediamine (0.67 ml, 9.9 mmol) was added. The reaction was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 48 mg (65%) of 2-(6-methyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow powder. MS: (M+H) + =429; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.40 (br. s, 1H), 9.11 (s, 1H), 8.39-8.61 (m, 3H), 8.34 (d, J=7.2 Hz, 1H), 8.28 (s, 1H), 6.79-7.05 (m, 1H), 4.41-4.86 (m, 3H), 4.15-4.33 (m, 1H), 3.99-4.15 (m, 1H), 3.71-3.94 (m, 1H), 2.26 (s, 3H), 1.40 (d, J=4.9 Hz, 3H).

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

(5-Fluoro-pyridin-2-yl)-methylamine

In a Parr pressure bottle, 2-cyano-5-fluoropyridine (2.0 g, 16.4 mmol) was dissolved in ethanol (60 ml). Palladium on carbon, 10% Pd (wet) (574 mg, 5.39 mmol) was added followed by conc. HCl (4.6 ml, 56.0 mmol). The bottle was placed on a Parr hydrogenator and shaken for 3.5 h under a 45 psi hydrogen atmosphere. The reaction mixture was filtered over Celite and rinsed with methanol. The filtrate was concentrated to a light yellow solid. The solid was taken up in dichloromethane, cooled to 0° C., and basified with saturated aqueous NaHCO 3 . The aqueous layer was extracted with dichloromethane (3×) and the combined organics were dried over sodium sulfate, filtered and concentrated to give 558 mg (27%) of (5-fluoro-pyridin-2-yl)-methylamine as a yellow oil which was used without further purification.

N-(5-Fluoro-pyridin-2-ylmethyl)-formamide

In a round-bottomed flask, (5-fluoro-pyridin-2-yl)methylamine (557 mg, 4.42 mmol) was dissolved in 88% formic acid (3.6 ml, 82.6 mmol). The brown solution was stirred at reflux in an oil bath overnight. The reaction mixture was cooled to 0° C. and adjusted carefully to pH=9 by addition of 25% aqueous ammonium hydroxide. The mixture was diluted with water and the aqueous layer was extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to give 614 mg (90%) of N-(5-fluoro-pyridin-2-ylmethyl)-formamide as a brown oil which was used without further purification.

6-Fluoro-imidazo[1,5-a]pyridine

In a round-bottomed flask, N-(5-fluoro-pyridin-2-ylmethyl)-formamide (612 mg, 3.97 mmol) was dissolved in toluene (16 ml) and phosphorus oxychloride (0.68 ml, 7.3 mmol) was added. The reaction mixture was stirred at 100° C. in an oil bath for 4 h then cooled to 0° C. and carefully quenched with ice. Aqueous 25% ammonium hydroxide was added until pH=˜9. The mixture was diluted with water and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to give 517 mg (96%) of 6-fluoro-imidazo[1,5-a]pyridine as a light brown oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.16 (s, 1H), 7.84-7.94 (m, 1H), 7.50 (s, 1H), 7.46 (dd, J=9.8, 5.3 Hz, 1H), 6.69 (ddd, J=9.8, 7.7, 2.1 Hz, 1H).

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 31, Steps 4-7, substituting 6-fluoro-imidazo[1,5-a]pyridine for 6-methyl-imidazo[1,5-a]pyridine in Step 4. MS: (M+H) + =433; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.76 (br. s., 1H), 9.14 (s, 1H), 8.62-8.80 (m, 2H), 8.53 (s, 1H), 8.31-8.47 (m, 2H), 7.00-7.15 (m, 1H), 4.44-4.83 (m, 3H), 4.25 (q, J=9.2 Hz, 1H), 4.05-4.18 (m, 1H), 3.77-3.94 (m, 1H), 1.40 (t, J=5.7 Hz, 3H).

2-(6,8-Difluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

(3,5-Difluoro-pyridin-2-yl)-methylamine

In a Parr pressure bottle, 2-cyano-3,5-difluoropyridine (1.0 g, 7.14 mmol) was dissolved in ethanol (30 ml). Palladium on carbon, 10% Pd (wet) (250 mg, 2.35 mmol) was added followed by conc. HCl (2.0 ml, 24.4 mmol). The bottle was placed on a Parr hydrogenator and shaken for 3.5 h under a 45 psi hydrogen atmosphere. The reaction mixture was filtered over Celite and rinsed with methanol. The filtrate was concentrated to a light yellow solid. The solid was taken up in dichloromethane, cooled to 0° C., and basified with saturated aqueous NaHCO 3 . The aqueous layer was extracted with dichloromethane (3×) and the combined organics were dried over sodium sulfate, filtered and concentrated to give 662 mg (64%) of (3,5-difluoro-pyridin-2-yl)-methylamine as a light yellow oil which was used without further purification.

N-(3,5-Difluoro-pyridin-2-ylmethyl)-formamide

In a round-bottomed flask, (3,5-difluoro-pyridin-2-yl)methylamine (660 mg, 4.58 mmol) was dissolved in 88% formic acid (3.6 ml, 82.6 mmol). The brown solution was stirred at reflux in an oil bath overnight. The reaction mixture was cooled to 0° C. and adjusted carefully to pH=8 by addition of 25% aqueous ammonium hydroxide. The mixture was diluted with water and the aqueous layer was extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. NMR showed an approximate 50% ratio of starting material to product. This mixture was resubjected to identical reaction conditions. After workup, isolated 657 mg of a brown oil which was determined by NMR to be an approximate 3:1 ratio of N-(3,5-difluoro-pyridin-2-ylmethyl)-formamide to starting material. This product was used without further purification.

6,8-Difluoro-imidazo[1,5-a]pyridine

In a round-bottomed flask, N-(3,5-difluoro-pyridin-2-ylmethyl)-formamide (crude from Step 2) was dissolved in toluene (14 ml) and phosphorus oxychloride (0.65 ml, 7.0 mmol) was added. The reaction mixture was stirred at 100° C. in an oil bath for 3.5 h then cooled to 0° C. and carefully quenched with ice. Aqueous 25% ammonium hydroxide was added until pH=˜9. The mixture was diluted with water and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-60% EtOAc) to give 319 mg (45%, 2 steps) of 6,8-difluoro-imidazo[1,5-a]pyridine as a yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.36 (d, J=3.0 Hz, 1H), 7.84 (d, J=3.4 Hz, 1H), 7.65 (s, 1H), 6.39-6.57 (m, 1H).

2-(6,8-Difluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 31, Steps 4-7, substituting 6,8-difluoro-imidazo[1,5-a]pyridine for 6-methyl-imidazo[1,5-a]pyridine in Step 4. MS: (M+H) + =451; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.39 (br. s., 1H), 9.03 (s, 1H), 8.70 (d, J=2.3 Hz, 1H), 8.63 (dd, J=4.2, 1.5 Hz, 1H), 8.54 (d, J=7.2 Hz, 1H), 8.41 (d, J=11.0 Hz, 1H), 7.21 (t, J=10.2 Hz, 1H), 4.40-4.74 (m, 3H), 4.08-4.24 (m, 1H), 3.95-4.07 (m, 1H), 3.74-3.90 (m, 1H), 1.31-1.44 (m, 3H).

2-(6-Fluoro-3-methyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

(5-Fluoro-pyridin-2-yl)-methylamine dihydrochloride

In a Parr pressure bottle, 2-cyano-5-fluoropyridine (1.0 g, 8.2 mmol) was dissolved in ethanol (30 ml). Palladium on carbon, 10% Pd (wet) (290 mg, 2.73 mmol) was added followed by conc. HCl (2.3 ml, 28.0 mmol). The bottle was placed on a Parr hydrogenator and shaken for 4 h under a 45 psi hydrogen atmosphere. The reaction mixture was filtered over Celite and rinsed with methanol. The filtrate was concentrated to give 1.61 g (99%) of (5-fluoro-pyridin-2-yl)-methylamine dihydrochloride as a light yellow solid which was used without further purification.

N-(5-Fluoro-pyridin-2-ylmethyl)-acetamide

In a round-bottomed flask, (5-fluoropyridin-2-yl)methylamine dihydrochloride (800 mg, 4.0 mmol) was suspended in THF (15 ml). The suspension was cooled to 0° C. and triethylamine (1.75 ml, 12.6 mmol) was added followed by dropwise addition of acetyl chloride (0.30 ml, 4.22 mmol). After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 2 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to give 654 mg (97%) of N-(5-fluoro-pyridin-2-ylmethyl)-acetamide as a light brown oil which was used without further purification.

6-Fluoro-3-methyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, N-(5-fluoro-pyridin-2-ylmethyl)-acetamide (653 mg, 3.88 mmol) was dissolved in toluene (19 ml) and phosphorus oxychloride (0.66 ml, 7.1 mmol) was added. The reaction mixture was stirred at 100° C. in an oil bath overnight then cooled to 0° C. and carefully quenched with ice. Aqueous 25% ammonium hydroxide was added until pH=˜9. The mixture was diluted with water and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-70% EtOAc) to give 255 mg (44%) of 6-fluoro-3-methyl-imidazo[1,5-a]pyridine as a yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.61 (d, J=5.3 Hz, 1H), 7.38-7.50 (m, 2H), 6.67 (ddd, J=9.7, 7.6, 1.9 Hz, 1H), 2.66 (s, 3H).

2-(6-Fluoro-3-methyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 31, Steps 4-7, substituting 6-fluoro-3-methyl-imidazo[1,5-a]pyridine for 6-methyl-imidazo[1,5-a]pyridine in Step 4. MS: (M+H) + =447; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.53 (br. s., 1H), 9.09 (s, 1H), 8.61-8.76 (m, 1H), 8.28-8.54 (m, 3H), 7.01 (br. s., 1H), 4.45-4.81 (m, 3H), 4.19-4.32 (m, 1H), 4.14 (br. s., 1H), 3.87 (br. s., 1H), 2.67 (s, 3H), 1.39 (br. s., 3H).

2-(6-Fluoro-3-hydroxymethyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

N-(5-Fluoro-pyridin-2-ylmethyl)-oxalamic acid methyl ester

In a round-bottomed flask, (5-fluoropyridin-2-yl)methylamine dihydrochloride (800 mg, 4.0 mmol) was suspended in THF (15 ml). The suspension was cooled to 0° C. and triethylamine (1.75 ml, 12.6 mmol) was added followed by dropwise addition of methyl oxalyl chloride (0.40 ml, 4.18 mmol). After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 2.5 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to give N-(5-fluoro-pyridin-2-ylmethyl)-oxalamic acid methyl ester as a light brown oil which was used without further purification.

6-Fluoro-imidazo[1,5-a]pyridine-3-carboxylic acid methyl ester

In a round-bottomed flask, N-(5-fluoro-pyridin-2-ylmethyl)-oxalamic acid methyl ester (crude from Step 1) was dissolved in toluene (8 ml) and phosphorus oxychloride (1.5 ml, 16.1 mmol) was added. The reaction mixture was stirred at 105° C. in an oil bath overnight then cooled to 0° C. and carefully quenched with ice. Aqueous 25% ammonium hydroxide was added until pH=˜9. The mixture was diluted with water and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-50% EtOAc) to give 230 mg (31%, 2 steps) of 6-fluoro-imidazo[1,5-a]pyridine-3-carboxylic acid methyl ester as a light brown solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 9.33 (dd, J=5.1, 1.3 Hz, 1H), 7.75 (s, 1H), 7.69 (dd, J=9.8, 5.3 Hz, 1H), 7.09 (ddd, J=9.7, 7.5, 2.1 Hz, 1H), 4.06 (s, 3H).

(6-Fluoro-imidazo[1,5-a]pyridin-3-yl)-methanol

In a round-bottomed flask, 6-fluoro-imidazo[1,5-a]pyridine-3-carboxylic acid methyl ester (223 mg, 1.15 mmol) was dissolved in THF (7 ml). The solution was cooled to 0° C. and lithium aluminum hydride (1.0 M in THF, 1.4 ml, 1.4 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 1.5 h then sodium sulfate decahydrate was carefully added. When gas evolution had ceased, the ice bath was removed, sodium sulfate was added and the mixture was stirred vigorously for 30 min at room temperature. The suspension was filtered over Celite and rinsed with ethyl acetate and methanol. The filtrate was concentrated to give 225 mg of (6-fluoro-imidazo[1,5-a]pyridin-3-yl)-methanol as a brown solid which was used without further purification.

(6-Fluoro-1-iodo-imidazo[1,5-a]pyridin-3-yl)-methanol

In a round-bottomed flask, (6-fluoro-imidazo[1,5-a]pyridin-3-yl)-methanol (225 mg, 1.15 mmol) was dissolved in ethanol (2 ml) and water (1 ml). Sodium bicarbonate (341 mg, 4.06 mmol) was added followed by iodine (383 mg, 1.51 mmol). The dark brown suspension was stirred at room temperature for 3 h then quenched with 10% Na 2 S 2 O 3 -solution and extracted with EtOAc (2×). The organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-40% EtOAc) to provide 157 mg (50%, 2 steps) of (6-fluoro-1-iodo-imidazo[1,5-a]pyridin-3-yl)-methanol as a light yellow solid.

(6-Fluoro-1-tributylstannanyl-imidazo[1,5-a]pyridin-3-yl)-methanol

In a round-bottomed flask, (6-fluoro-1-iodo-imidazo[1,5-a]pyridin-3-yl)-methanol (156 mg, 0.53 mmol) was dissolved in THF (4 ml). Sodium hydride (60% dispersion in mineral oil, 26 mg, 0.65 mmol) was added and the reaction mixture was stirred at room temperature for 10 min. The reaction mixture was cooled to −16° C. (NaCl/ice bath) and isopropylmagnesium chloride (2.0 M in THF, 0.32 ml, 0.64 mmol) was added dropwise. The reaction was stirred at −16° C. for 25 min then tributylchlorostannane (0.17 ml, 0.63 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature and stirred for 1.5 h then quenched with saturated aqueous NH 4 Cl and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to afford (6-Fluoro-1-tributylstannanyl-imidazo[1,5-a]pyridin-3-yl)-methanol as a brown semisolid which was used without further purification.

2-(6-Fluoro-3-hydroxymethyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (100 mg, 0.20 mmol) and (6-Fluoro-1-tributylstannanyl-imidazo[1,5-a]pyridin-3-yl)-methanol (crude from Step 5) were dissolved in DMF (2 ml The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (12 mg, 0.010 mmol) and copper (I) iodide (8 mg, 0.042 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 3 h then cooled to room temperature, quenched with water and extracted with dichloromethane (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-3% MeOH) to afford 83 mg (71%) of 2-(6-fluoro-3-hydroxymethyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light brown solid.

2-(6-Fluoro-3-hydroxymethyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-3-hydroxymethyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (82 mg, 0.138 mmol) was dissolved in dichloromethane (0.7 ml) and trifluoroacetic acid (0.43 ml, 5.6 mmol) was added. The reaction was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.7 ml) and ethylenediamine (0.56 ml, 8.3 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with dichloromethane. The resulting precipitate was filtered, washing with water and dichloromethane then dried under high vacuum to provide 46 mg (68%) of 2-(6-fluoro-3-hydroxymethyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow powder. MS: (M+H) + =463; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.30 (br. s, 1H), 9.12 (s, 1H), 8.79 (dd, J=9.6, 3.2 Hz, 1H), 8.55 (d, J=4.9 Hz, 1H), 8.44 (d, J=7.9 Hz, 1H), 8.40 (d, J=5.7 Hz, 1H), 7.07-7.17 (m, 1H), 5.61 (t, J=5.7 Hz, 1H), 4.94 (d, J=5.3 Hz, 2H), 4.50-4.81 (m, 3H), 4.20-4.32 (m, 1H), 4.14 (dt, J=10.3, 5.2 Hz, 1H), 3.81-3.93 (m, 1H), 1.40 (t, J=6.0 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((1R,3R)-3-cyano-cyclopentyl)-amide

((1R,3R)-3-Carbamoyl-cyclopentyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, (1R,3R)—N-Boc-1-aminocyclopentane-3-carboxylic acid (300 mg, 1.31 mmol) and ammonium chloride (210 mg, 3.93 mmol) were suspended in DMF (6 ml). HATU (547 mg, 1.44 mmol) and N,N-diisopropylethylamine (0.80 ml, 4.58 mmol) were added and the yellow suspension was stirred at room temperature for 72 h. The reaction mixture was quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to afford 97 mg (33%) of ((1R,3R)-3-carbamoyl-cyclopentyl)-carbamic acid tert-butyl ester as a white solid.

((1R,3R)-3-Cyano-cyclopentyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, ((1R,3R)-3-carbamoyl-cyclopentyl)-carbamic acid tert-butyl ester (96 mg, 0.42 mmol) was suspended in THF (2.5 ml). The reaction mixture was cooled to 0° C. and triethylamine (0.28 ml, 2.01 mmol) followed by trifluoroacetic anhydride (0.095 ml, 0.67 mmol) were added. The homogeneous reaction mixture was stirred at 0° C. for 1.5 h then quenched with water and extracted with dichloromethane (2×). The combined organic layers were dried over sodium sulfate, filtered and concentrated to afford ((1R,3R)-3-cyanocyclopentyl)-carbamic acid tert-butyl ester as an off-white waxy solid which contained some triethylamine trifluoroacetate as a major impurity. This material was used without further purification.

(1R,3R)-3-Amino-cyclopentanecarbonitrile trifluoroacetate

In a round-bottomed flask, ((1R,3R)-3-cyano-cyclopentyl)-carbamic acid tert-butyl ester (crude from Step 2) was dissolved in dichloromethane (2.5 ml). The solution was cooled to 0° C. and trifluoroacetic acid (1.1 ml, 14.3 mmol) was slowly added. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 2 h then concentrated to give (1R,3R)-3-amino-cyclopentanecarbonitrile trifluoroacetate as a light brown oil which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((1R,3R)-3-cyano-cyclopentyl)-amide

Prepared according to the procedure outlined in Example 14, Steps 5-6, substituting (1R,3R)-3-amino-cyclopentanecarbonitrile trifluoroacetate for (R)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one in Step 5. MS: (M+H) + =420; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.48 (br. s, 1H), 9.08 (s, 1H), 8.44 (s, 1H), 8.42 (d, J=8.7 Hz, 1H), 8.13 (d, J=6.8 Hz, 1H), 8.00 (s, 1H), 7.35 (dd, J=8.7, 1.5 Hz, 1H), 4.44-4.58 (m, 1H), 4.17 (s, 3H), 3.22-3.29 (m, 1H), 2.19-2.39 (m, 3H), 1.99-2.12 (m, 1H), 1.81-1.97 (m, 1H), 1.62-1.76 (m, 1H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-aminocyclopentyl)-amide

(3-{[2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-cyclopentyl)-carbamic acid tert-butyl ester

A round-bottomed flask was charged with 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (300 mg, 0.66 mmol) and (3-aminocyclopentyl)-carbamic acid tert-butylester hydrochloride (233 mg, 0.98 mmol). DMF (3 ml) was added followed by HATU (274 mg, 0.72 mmol) and N,N-diisopropylethylamine (0.30 ml, 1.72 mmol). The reaction mixture was stirred at room temperature for 30 min. Additional DMF (2 ml) was added and the light yellow suspension was stirred at room temperature overnight. Water was added and the resulting suspension was filtered, washed with water and petroleum ether and dried under high vacuum to afford 413 mg (99%) of (3-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-cyclopentyl)-carbamic acid tert-butyl ester as an off-white powder. The isolated product was determined to be a single diastereomer of unknown relative stereochemistry by NMR analysis.

2-(6-Chloro-1-methyl-1H-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-aminocyclopentyl)-amide

In a round-bottomed flask, (3-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-cyclopentyl)-carbamic acid tert-butyl ester (80 mg, 0.125 mmol) was dissolved in dichloromethane (0.7 ml) and trifluoroacetic acid (0.4 ml, 5.0 mmol) was added. The reaction mixture was stirred at room temperature for 3.5 h then concentrated. The residue was dissolved in dichloromethane (0.7 ml) and ethylenediamine (0.5 ml, 7.5 mmol) was added. The solution was stirred at room temperature for 2 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 40 mg (74%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-amino-cyclopentyl)-amide as an off-white powder. MS: (M+H) + =410; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.07 (s, 1H), 8.55 (d, J=8.7 Hz, 1H), 8.40 (s, 1H), 8.24 (d, J=7.6 Hz, 1H), 7.99 (s, 1H), 7.40 (d, J=9.1 Hz, 1H), 5.54 (br. s, 2H), 4.34-4.45 (m, 1H), 4.17 (s, 3H), 3.36-3.44 (m, 1H), 2.25-2.37 (m, 1H), 2.03-2.16 (m, 1H), 1.71-1.88 (m, 2H), 1.51-1.62 (m, 1H), 1.32-1.43 (m, 1H). The isolated product was determined to be a single diastereomer of unknown relative stereochemistry by NMR analysis.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-methanesulfonylamino-cyclopentyl)-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-amino-cyclopentyl)-amide hydrochloride

In a round-bottomed flask, (3-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-cyclopentyl)-carbamic acid tert-butyl ester (150 mg, 0.23 mmol) was suspended in methanol (2 ml). The reaction mixture was cooled to 0° C. and acetyl chloride (0.33 ml, 4.64 mmol) was added dropwise. The ice bath was removed and the reaction mixture was stirred at room temperature for 1.5 h. The solvent was evaporated at room temperature and the residue was dried under high vacuum to afford 147 mg (98%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-amino-cyclopentyl)-amide hydrochloride as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-methanesulfonylamino-cyclopentyl)-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-amino-cyclopentyl)-amide hydrochloride (145 mg, 0.23 mmol) was suspended in dichloromethane (2.5 ml). The suspension was cooled to 0° C. and triethylamine (0.10 ml, 0.72 mmol) was added followed by methanesulfonyl chloride (0.02 ml, 0.26 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with dichloromethane (2×). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-5% MeOH) to afford 111 mg (79%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-methanesulfonylamino-cyclopentyl)-amide as a light yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-methanesulfonylamino-cyclopentyl)-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-methanesulfonylamino-cyclopentyl)-amide (109 mg, 0.176 mmol) was dissolved in dichloromethane (0.9 ml) and trifluoroacetic acid (0.54 ml, 7.0 mmol) was added. The orange solution was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.9 ml) and ethylenediamine (0.7 ml, 10.5 mmol) was added. The yellow solution was stirred at room temperature for 1.5 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 76 mg (88%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-methanesulfonylamino-cyclopentyl)-amide as an off-white powder. MS: (M+H) + =488; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.30 (br. s, 1H), 9.11 (s, 1H), 8.42-8.52 (m, 2H), 8.17 (d, J=7.2 Hz, 1H), 8.02 (s, 1H), 7.41 (dd, J=8.7, 1.5 Hz, 1H), 7.31 (d, J=7.2 Hz, 1H), 4.27-4.40 (m, 1H), 4.18 (s, 3H), 3.67-3.82 (m, 1H), 2.92 (s, 3H), 2.53-2.63 (m, 1H), 1.97-2.20 (m, 2H), 1.65-1.81 (m, 2H), 1.55 (dt, J=12.3, 9.0 Hz, 1H).

2-(3-Chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a round-bottomed flask, 6-fluoro-1-tributylstannyl-imidazo[1,5-a]pyridine (577 mg, 0.81 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (210 mg, 0.59 mmol) were dissolved in DMF (5 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (33 mg, 0.029 mmol) and copper (I) iodide (22 mg, 0.12 mmol) were added. The reaction mixture was stirred at 80° C. in an oil bath for 4 h then cooled to room temperature. Water was added and the resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 256 mg (95%) of 2-(6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a yellow powder.

2-(3-Chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

In a round-bottomed flask, 2-(6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (254 mg, 0.55 mmol) was suspended in THF (10 ml) and water (2 ml). The suspension was cooled to 0° C. and sulfamic acid (324 mg, 3.33 mmol) was added. Then, a solution of sodium chlorite (80%, 88 mg, 0.78 mmol) and potassium dihydrogen phosphate (907 mg, 6.67 mmol) in water (6 ml) was added dropwise over 10 min. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 4 h. The reaction mixture was diluted with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was triturated with hexanes to afford 184 mg of 2-(3-chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid as a light green powder which was used without further purification.

2-(3-Chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

A round-bottomed flask was charged with 2-(3-chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (90 mg, 0.16 mmol) and (S)-1-methoxypropan-2-amine hydrochloride (40 mg, 0.32 mmol). DMF (1 ml) was added followed by N,N-diisopropylethylamine (0.1 ml, 0.57 mmol) and HATU (71 mg, 0.19 mmol). The reaction mixture was stirred at room temperature overnight then water was added. The resulting suspension was filtered, washing with water and petroleum ether. The brown powder was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2% MeOH) to afford 37 mg (44%) of 2-(3-chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide as a yellow solid.

2-(3-Chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

In a round-bottomed flask, 2-(3-chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide (36 mg, 0.068 mmol) was dissolved in dichloromethane (0.4 ml) and trifluoroacetic acid (0.22 ml, 2.86 mmol) was added. The reaction was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.4 ml) and ethylenediamine (0.3 ml, 4.3 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 21 mg (77%) of 2-(3-chloro-6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide as a yellow powder. MS: (M+H) + =403; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.01 (br. s, 1H), 9.03 (s, 1H), 8.58 (d, J=3.8 Hz, 1H), 8.49 (dd, J=10.0, 5.5 Hz, 1H), 8.40 (s, 1H), 8.10 (d, J=8.3 Hz, 1H), 7.18-7.29 (m, 1H), 4.39 (d, J=7.9 Hz, 1H), 3.50 (qd, J=9.9, 4.3 Hz, 2H), 3.30 (s, 3H), 1.31 (d, J=6.8 Hz, 3H).

2-(6,8-Difluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

In a round-bottomed flask were combined 2-bromo-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.32 mmol) and (S)-1-methoxypropan-2-amine hydrochloride (61 mg, 0.49 mmol). DMF (1.5 mL) was added followed by N,N-diisopropylethylamine (0.15 mL, 0.86 mmol) and HATU (135 mg, 0.36 mmol). The yellow reaction mixture was stirred at room temperature overnight then water was added. The resulting suspension was filtered and the filter cake was washed with water and petroleum ether then dried under high vacuum to provide 129 mg (90%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide as an off-white powder.

2-(6,8-Difluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide (125 mg, 0.28 mmol) and 6,8-difluoro-1-tributylstannyl-imidazo[1,5-a]pyridine (458 mg, 0.62 mmol) were dissolved in DMF (2.5 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (17 mg, 0.015 mmol) and copper (I) iodide (11 mg, 0.058 mmol) were added. The reaction mixture was stirred at 90° C. in an oil bath for 1.5 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed twice over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-3% MeOH) to afford 136 mg (89%) of 2-(6,8-difluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide as a yellow solid.

2-(6,8-Difluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

In a round-bottomed flask, 2-(6,8-difluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide (134 mg, 0.25 mmol) was dissolved in dichloromethane (1.2 ml) and trifluoroacetic acid (0.75 ml, 9.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1.2 ml) and ethylenediamine (1.0 ml, 14.8 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 74 mg (78%) of 2-(6,8-difluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide as a yellow powder. MS: (M+H) + =387; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.14 (br. s., 1H), 9.03 (s, 1H), 8.70 (d, J=1.9 Hz, 1H), 8.63 (dd, J=4.2, 1.9 Hz, 1H), 8.37 (s, 1H), 8.29 (d, J=8.3 Hz, 1H), 7.24-7.36 (m, 1H), 4.32 (dt, J=13.2, 6.6 Hz, 1H), 3.42-3.51 (m, 1H), 3.35-3.41 (m, 1H), 3.25 (s, 3H), 1.24 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

Prepared according to the procedure outlined in Example 40, Steps 2-3, substituting 6-fluoro-1-tributylstannyl-imidazo[1,5-a]pyridine for 6,8-difluoro-1-tributylstannyl-imidazo[1,5-a]pyridine in Step 2. MS: (M+H) + =369; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.15 (br. s., 1H), 9.11 (s, 1H), 8.68-8.75 (m, 1H), 8.54 (s, 1H), 8.44 (dd, J=9.8, 5.7 Hz, 1H), 8.35 (s, 1H), 8.16 (d, J=8.7 Hz, 1H), 7.08-7.18 (m, 1H), 4.39 (d, J=7.2 Hz, 1H), 3.49 (qd, J=9.8, 4.5 Hz, 2H), 3.30 (s, 3H), 1.31 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-3-methanesulfonyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

6-Fluoro-2H-imidazo[1,5-a]pyridine-3-thione

In a round-bottomed flask, (5-fluoropyridin-2-yl)methylamine dihydrochloride (600 mg, 3.0 mmol) was suspended in methanol (16 ml). Triethylamine (1.4 ml, 10.0 mmol) was added followed by carbon disulfide (1.4 ml, 23.2 mmol). The reaction mixture was stirred at reflux (oil bath temperature=75° C.) overnight then cooled to room temperature and then concentrated. The residue was partitioned between dichloromethane and water. The aqueous layer was extracted with dichloromethane then the organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-60% EtOAc) to afford 169 mg (33%) of 6-fluoro-2H-imidazo[1,5-a]pyridine-3-thione as an orange solid. 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.47 (br. s., 1H), 8.04 (dd, J=4.9, 1.1 Hz, 1H), 7.43-7.56 (m, 2H), 6.88 (ddd, J=10.0, 7.9, 2.1 Hz, 1H).

6-Fluoro-3-methylsulfanyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, 6-fluoro-2H-imidazo[1,5-a]pyridine-3-thione (158 mg, 0.94 mmol) was suspended in methanol (1 ml) and sodium methoxide (0.5 M in MeOH, 2.0 ml, 1.0 mmol) was added dropwise. The reaction was stirred at room temperature for 10 min then methyl iodide (0.07 ml, 1.12 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was partitioned between dichloromethane and water. The aqueous layer was extracted with dichloromethane then the organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford 179 mg of 6-fluoro-3-methylsulfanyl-imidazo[1,5-a]pyridine as a brown oil which was used without further purification. 1 H NMR (CDCl 3 , 400 MHz): δ (ppm) 7.98-8.05 (m, 1H), 7.58 (s, 1H), 7.45 (dd, J=9.3, 4.8 Hz, 1H), 6.73 (ddd, J=9.6, 7.6, 2.0 Hz, 1H), 2.56 (s, 3H).

6-Fluoro-1-iodo-3-methylsulfanyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, 6-fluoro-3-methylsulfanyl-imidazo[1,5-a]pyridine (178 mg, 0.88 mmol) was dissolved in ethanol (1.6 ml). Water (0.8 ml), sodium bicarbonate (278 mg, 3.31 mmol) and iodine (312 mg, 1.23 mmol) were added. The dark brown suspension was stirred at room temperature overnight then quenched with 10% aqueous Na 2 S 2 O 3 and extracted with EtOAc (2×). The combined organic layers were washed with 10% aqueous Na 2 S 2 O 3 , water, and brine then dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with EtOAc/hexanes (gradient 0-10% EtOAc) to afford 110 mg (41%) of 6-fluoro-1-iodo-3-methylsulfanyl-imidazo[1,5-a]pyridine as a brown solid.

6-Fluoro-3-methylsulfanyl-1-tributylstannanyl-imidazo[1,5-a]pyridine

In a round-bottomed flask, 6-fluoro-1-iodo-3-methylsulfanyl-imidazo[1,5-a]pyridine (109 mg, 0.35 mmol) was dissolved in THF (3 ml). The light brown solution was cooled to −16° C. (NaCl/ice bath) and isopropylmagnesium chloride (2.0 M in THF, 0.21 ml, 0.42 mmol) was added dropwise. The reaction mixture was stirred at −16° C. for 20 min then tributylchlorostannane (0.11 ml, 0.40 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature and stirred for 2 h then quenched with saturated aqueous NH 4 Cl and extracted with ethyl acetate (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to give 6-fluoro-3-methylsulfanyl-1-tributylstannanyl-imidazo[1,5-a]pyridine as a brown oil which was used without further purification.

2-(6-Fluoro-3-methylsulfanyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (100 mg, 0.20 mmol) and 6-fluoro-3-methylsulfanyl-1-tributylstannanyl-imidazo[1,5-a]pyridine (crude from Step 4) were dissolved in DMF (2 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (12 mg, 0.010 mmol) and copper (I) iodide (8 mg, 0.042 mmol) were added. The reaction mixture was stirred at 80° C. in an oil bath overnight then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2.5% MeOH) to afford 109 mg (82%) of 2-(6-fluoro-3-methylsulfanyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a brown oil.

2-(6-Fluoro-3-methanesulfonyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-3-methylsulfanyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (105 mg, 0.155 mmol) was dissolved in dichloromethane (4 ml). The solution was cooled to 0° C. and m-CPBA (75%, 79 mg, 0.343 mmol) was added. The ice bath was removed and the reaction mixture was stirred at room temperature overnight. Additional m-CPBA (75%, 36 mg, 0.155 mmol) was added and the reaction mixture was stirred at room temperature for 30 min. A solution of 10% aqueous Na 2 S 2 O 3 (3 ml) was added and the biphasic mixture was stirred at room temperature for 1 h. The reaction mixture was diluted with water and extracted with dichloromethane. The organic layer was washed with saturated aqueous NaHCO 3 . The aqueous layer was extracted dichloromethane (2×). The combined organic layers were dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2.5% MeOH) to afford 25 mg (25%) of 2-(6-fluoro-3-methanesulfonyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light brown oil.

2-(6-Fluoro-3-methanesulfonyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-3-methanesulfonyl-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (0.024 g, 37.5 μmol, Eq: 1.00) was dissolved in dichloromethane (0.3 ml) and trifluoroacetic acid (0.12 ml, 1.6 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was redissolved in dichloromethane/methanol/ammonium hydroxide (60:10:1) (3.5 ml). The solution was stirred at room temperature overnight then concentrated. The residue was absorbed on silica gel and chromatographed with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-7% MeOH) to afford 6 mg (30%) of 2-(6-fluoro-3-methanesulfonyl-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow solid. MS: (M+H) + =511; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.17 (s, 1H), 9.01-9.10 (m, 1H), 8.95 (d, J=3.0 Hz, 1H), 8.47-8.53 (m, 1H), 8.42 (d, J=7.6 Hz, 1H), 7.43-7.53 (m, 1H), 4.51-4.80 (m, 3H), 4.27 (q, J=9.6 Hz, 1H), 4.11-4.21 (m, 1H), 3.81-3.94 (m, 1H), 3.57 (s, 3H), 1.40 (t, J=6.4 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-cyano-azetidine-1-carbonyl)-2,2-dimethyl-propyl]-amide

[(R)-1-(3-Cyano-azetidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester

A round-bottomed flask was charged with Boc-D-tert-leucine (300 mg, 1.3 mmol) and azetidine-3-carbonitrile hydrochloride (231 mg, 1.95 mmol). DMF (6 ml) was added followed by N,N-diisopropylethylamine (0.68 ml, 3.9 mmol) and HATU (543 mg, 1.43 mmol). The light yellow solution was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to afford 458 mg of [(R)-1-(3-cyano-azetidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester as a light yellow oil.

1-((R)-2-Amino-3,3-dimethyl-butyryl)-azetidine-3-carbonitrile trifluoroacetate

To a solution [(R)-1-(3-cyano-azetidine-1-carbonyl)-2,2-dimethyl-propyl]-carbamic acid tert-butyl ester (180 mg, 0.49 mmol) in dichloromethane (3 ml) at 0° C. was added trifluoroacetic acid (1.2 ml, 15.6 mmol). The reaction mixture was stirred at room temperature for 2 h then concentrated to afford 1-((R)-2-amino-3,3-dimethyl-butyryl)-azetidine-3-carbonitrile trifluoroacetate as a light yellow oil which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-cyano-azetidine-1-carbonyl)-2,2-dimethyl-propyl]-amide

Prepared according to the procedure outlined in Example 14, Steps 5-6, substituting 1-((R)-2-amino-3,3-dimethyl-butyryl)-azetidine-3-carbonitrile trifluoroacetate for (R)-2-amino-1-(3,3-difluoro-azetidin-1-yl)-propan-1-one in Step 5. MS: (M+H) + =505; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.15 (s, 1H), 8.90 (dd, J=8.5, 5.9 Hz, 1H), 8.54 (d, J=9.8 Hz, 1H), 8.49 (d, J=7.6 Hz, 1H), 7.94 (s, 1H), 7.21 (d, J=8.7 Hz, 1H), 4.57-4.70 (m, 2H), 4.52 (m, 1H), 4.17 (s, 3H), 4.07-4.31 (m, 2H), 3.76-3.95 (m, 1H), 1.01 (d, J=4.2 Hz, 9H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-fluoro-1,2-dimethyl-propyl)-amide

((R)-2-Hydroxy-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester

To a solution of Boc-D-alanine methyl ester (5.00 g, 24.6 mmol) in THF (100 mL) at 0° C. was slowly added methyl magnesium bromide (3.0 M in Et 2 O, 28.7 mL, 86.1 mmol). The resultant white slurry was stirred at 0° C. for 1 h then at room temperature for 2 h. The reaction mixture was quenched with saturated aqueous NH 4 Cl, diluted with H 2 O and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO 4 and concentrated to give 4.93 g (99%) ((R)-2-hydroxy-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester as a colorless viscous oil.

((R)-2-Fluoro-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester

In a dry round-bottomed flask, ((R)-2-hydroxy-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester (534 mg, 2.36 mmol) was dissolved in dichloromethane (22 ml). The solution was cooled to −76° C. and DAST (0.34 ml, 2.57 mmol) was added dropwise. The reaction mixture was stirred at −76° C. for 1.5 h then quenched with saturated aqueous NaHCO 3 (5 mL), warmed to room temperature and extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford 534 mg of ((R)-2-fluoro-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester as a yellow oil which was used without further purification.

(R)-2-Fluoro-1,2-dimethyl-propylamine hydrochloride

((R)-2-Fluoro-1,2-dimethyl-propyl)-carbamic acid tert-butyl ester (140 mg, 0.61 mmol) was dissolved in 1.0 M HCl solution in MeOH (10 mL). The reaction mixture was stirred at room temperature overnight then concentrated to provide (R)-2-fluoro-1,2-dimethyl-propylamine hydrochloride as a light brown oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-fluoro-1,2-dimethyl-propyl)-amide

A 10 ml round-bottomed flask was charged with 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.27 mmol) and (R)-2-fluoro-1,2-dimethyl-propylamine hydrochloride (crude from Step 3, 155 mg, 0.55 mmol). DMF (1.2 ml) was added followed by N,N-diisopropylethylamine (0.20 ml, 1.15 mmol) and HATU (114 mg, 0.30 mmol). The reaction mixture was stirred at room temperature for 5 h. Water was added and the resultant suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 95 mg (66%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-fluoro-1,2-dimethyl-propyl)-amide as a light brown powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-fluoro-1,2-dimethyl-propyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-fluoro-1,2-dimethyl-propyl)amide (93 mg, 0.176 mmol) was dissolved in dichloromethane (0.9 ml) and trifluoroacetic acid (0.54 ml, 7.0 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.9 ml) and ethylenediamine (0.7 ml, 10.5 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was absorbed on silica gel and chromatographed with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-6% MeOH) then triturated with ethyl acetate to afford 34 mg (46%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-fluoro-1,2-dimethyl-propyl)-amide as a light yellow powder. MS: (M+H) + =399; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.90 (br. s., 1H), 9.12 (s, 1H), 8.45-8.54 (m, 2H), 8.25 (d, J=9.8 Hz, 1H), 7.68 (dd, J=9.8, 2.3 Hz, 1H), 7.09 (td, J=9.1, 2.3 Hz, 1H), 4.30-4.48 (m, 1H), 4.15 (s, 3H), 1.29-1.52 (m, 9H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

In a round-bottomed flask 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.27 mmol) was dissolved in DMF (1.2 ml). (S)-3,3-Dimethylbutan-2-amine (0.25 ml, 1.84 mmol) was added followed by HATU (114 mg, 0.30 mmol) and the yellow solution was stirred at room temperature overnight. Water was added and the resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 104 mg (73%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide as a light yellow powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide (102 mg, 0.194 mmol) was dissolved in dichloromethane (0.9 ml) and trifluoroacetic acid (0.6 ml, 7.8 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.9 ml) and ethylenediamine (0.8 ml, 11.7 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 52 mg (64%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1,2,2-trimethyl-propyl)-amide as a light yellow powder. MS: (M+H) + =395; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.38 (br. s., 1H), 9.08 (s, 1H), 8.44 (s, 1H), 8.40 (dd, J=9.1, 5.3 Hz, 1H), 8.03 (d, J=9.8 Hz, 1H), 7.69 (dd, J=9.8, 1.9 Hz, 1H), 7.20 (td, J=9.1, 2.3 Hz, 1H), 4.15 (s, 3H), 4.09-4.19 (m, 1H), 1.26 (d, J=6.8 Hz, 3H), 0.93 (s, 9H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-hydroxy-cyclopentyl)-amide

(cis-3-Hydroxy-cyclopentyl)-carbamic acid tert-butyl ester and (trans-3-Hydroxy-cyclopentyl)-carbamic acid tert-butyl ester

In a dry round-bottomed flask, N-1-Boc-amino-3-cyclopentene (1.0 g, 5.46 mmol) was dissolved in THF (7 ml). The solution was cooled to 0° C. and borane tetrahydrofuran complex (1.0M in THF, 6.0 ml, 6.0 mmol) was added dropwise. The reaction was stirred at 0° C. for 1 h then warmed to room temperature overnight. The mixture was cooled back to 0° C. and water (2 ml) was added. Then 10% aqueous sodium hydroxide (8 ml, 20.0 mmol) was added dropwise followed by dropwise addition of hydrogen peroxide (30% solution in water, 5.0 ml, 49 mmol). After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 5 h. The reaction mixture was extracted with ethyl acetate (2×). The combined organic layers were washed with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-60% EtOAc) to afford 330 mg (30%) of (cis-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 5.12 (br. s., 1H), 4.39 (m, 1H), 4.03 (br. s., 1H), 1.95-2.17 (m, 2H), 1.78 (d, J=2.6 Hz, 3H), 1.64 (d, J=12.5 Hz, 1H), 1.44 (s, 9H). Also isolated 99 mg (9%) of (trans-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 4.35-4.51 (m, 2H), 4.15 (br. s, 1H), 2.15-2.30 (m, 1H), 1.98-2.10 (m, 2H), 1.45 (s, 9H), 1.34-1.72 (m, 3H).

cis-3-Amino-cyclopentanol trifluoroacetate

In a round-bottomed flask, (cis-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester (320 mg, 1.59 mmol) was dissolved in dichloromethane (10 ml) and trifluoroacetic acid (3.6 ml, 46.7 mmol) was slowly added. The reaction mixture was stirred at room temperature for 2 h then concentrated to afford cis-3-amino-cyclopentanol trifluoroacetate as a light yellow oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-hydroxy-cyclopentyl)-amide

In a round-bottomed flask, cis-3-amino-cyclopentanol trifluoroacetate (crude from Step 2) was dissolved in DMF (1.2 ml) and N,N-diisopropylethylamine (0.40 ml, 2.3 mmol) was added. Then 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.27 mmol) and HATU (114 mg, 0.30 mmol) were added. The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then concentrated. The residue was absorbed on silica gel and chromatographed with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-4% MeOH) to afford 50 mg (35%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-hydroxy-cyclopentyl)-amide as a light yellow solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-hydroxy-cyclopentyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-hydroxy-cyclopentyl)-amide (49 mg, 0.093 mmol) was dissolved in dichloromethane (0.5 ml) and trifluoroacetic acid (0.3 ml, 3.8 mmol) was added. The orange reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.5 ml) and ethylenediamine (0.4 ml, 5.7 mmol) was added. The light yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting precipitate was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 29 mg (75%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-hydroxy-cyclopentyl)-amide as an off-white powder. MS: (M+H) + =395; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.42 (br. s., 1H), 9.11 (s, 1H), 8.59 (dd, J=9.1, 5.3 Hz, 1H), 8.42 (s, 1H), 8.20 (d, J=8.3 Hz, 1H), 7.68 (dd, J=9.6, 2.1 Hz, 1H), 7.24 (td, J=9.2, 2.1 Hz, 1H), 4.78 (br. s., 1H), 4.36-4.52 (m, 1H), 4.22 (br. s., 1H), 4.15 (s, 3H), 2.30 (ddd, J=13.7, 8.2, 5.7 Hz, 1H), 2.04-2.19 (m, 1H), 1.67-1.86 (m, 3H), 1.49-1.63 (m, 1H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (trans-3-hydroxy-cyclopentyl)-amide

Prepared according to the procedure outlined in Example 46, but substituting (trans-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester for (cis-3-hydroxy-cyclopentyl)-carbamic acid tert-butyl ester in Step 2. MS: (M+H) + =395. 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.26 (br. s., 1H), 9.06 (s, 1H), 8.36-8.47 (m, 2H), 8.09 (d, J=7.6 Hz, 1H), 7.69 (d, J=9.8 Hz, 1H), 7.06-7.22 (m, 1H), 4.49-4.71 (m, 2H), 4.30 (br. s., 1H), 4.13 (s, 3H), 2.17-2.32 (m, 1H), 1.92-2.10 (m, 2H), 1.65-1.77 (m, 1H), 1.43-1.62 (m, 2H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

2-Methyl-propane-2-sulfinic acid 1-oxazol-2-yl-meth-(E)-ylideneamide

In a round-bottomed flask, oxazole-2-carbaldehyde (300 mg, 3.09 mmol) was dissolved in THF (7 ml) and 2-methylpropane-2-sulfinamide (450 mg, 3.71 mmol) and titanium(IV) ethoxide (1.3 ml, 6.18 mmol) were added. The reaction mixture was stirred at room temperature overnight then slowly quenched by dropwise addition of brine (2 ml) which resulted in the formation of a thick yellow precipitate. The reaction mixture was diluted with ethyl acetate and stirred vigorously at room temperature for 10 min. The suspension was filtered over Celite and rinsed with ethyl acetate. The filtrate was concentrated and the residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to afford 419 mg (68%) of 2-methyl-propane-2-sulfinic acid 1-oxazol-2-yl-meth-(E)-ylideneamide as a light yellow solid.

2-Methyl-propane-2-sulfinic acid (1-oxazol-2-yl-ethyl)-amide

In a round-bottomed flask, 2-methyl-propane-2-sulfinic acid 1-oxazol-2-yl-meth-(E)-ylideneamide (414 mg, 2.07 mmol) was dissolved in dichloromethane (7 ml). The reaction mixture was cooled to 0° C. and methylmagnesium bromide (3.0 M in diethyl ether, 0.76 ml, 2.28 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 1 h then quenched with saturated aqueous NH 4 Cl and extracted with ethyl acetate (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to afford 453 mg (96%) of 2-methyl-propane-2-sulfinic acid (1-oxazol-2-yl-ethyl)-amide as a yellow oil.

1-Oxazol-2-yl-ethylamine dihydrochloride

In a round-bottomed flask, 2-methyl-propane-2-sulfinic acid (1-oxazol-2-yl-ethyl)-amide (449 mg, 1.97 mmol) was dissolved in methanol (3.5 ml) and hydrogen chloride (4.0 M in 1,4-dioxane, 1.0 ml, 4.0 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 15 min then concentrated to give 417 mg of 1-oxazol-2-yl-ethylamine dihydrochloride as an orange waxy solid which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

A round-bottomed flask was charged with 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.22 mmol) and 1-oxazol-2-yl-ethylamine dihydrochloride (91 mg, 0.39 mmol). DMF (1 ml) was added followed by N,N-diisopropylethylamine (0.25 ml, 1.43 mmol) and HATU (92 mg, 0.24 mmol). The light yellow solution was stirred at room temperature for 48 h. Water was added and the resulting suspension was filtered. The solid was washed with water and petroleum ether then dried under high vacuum to afford 108 mg (90%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide as an off-white powder.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

In a round-bottomed flask, 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide (106 mg, 0.192 mmol) was dissolved in dichloromethane (0.9 ml) and trifluoroacetic acid (0.6 ml, 7.7 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.9 ml) and ethylenediamine (0.8 ml, 11.7 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 66 mg (82%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide as an off-white powder. MS: (M+H) + =422; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.91 (br. s., 1H), 9.13 (s, 1H), 8.66 (d, J=8.3 Hz, 1H), 8.51 (s, 1H), 8.46 (d, J=8.3 Hz, 1H), 8.11 (s, 1H), 8.00 (s, 1H), 7.23 (s, 1H), 7.15-7.21 (m, 1H), 5.47-5.61 (m, 1H), 4.18 (s, 3H), 1.66 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

A round-bottomed flask was charged with 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (210 mg, 0.48 mmol) and 1-oxazol-2-yl-ethylamine dihydrochloride (198 mg, 0.86 mmol). DMF (2.2 ml) was added followed by N,N-diisopropylethylamine (0.55 ml, 3.15 mmol) and HATU (199 mg, 0.52 mmol). The light yellow solution was stirred at room temperature overnight. Water was added and the resulting suspension was filtered. The solid was washed with water and petroleum ether then dried under high vacuum to afford 248 mg (97%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide as a light yellow powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide (64 mg, 0.12 mmol) was dissolved in dichloromethane (0.6 ml) and trifluoroacetic acid (0.4 ml, 5.0 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was dissolved in dichloromethane (0.6 ml) and ethylenediamine (0.5 ml, 7.3 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 33 mg (65%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide as a light yellow powder. MS: (M+H) + =406; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.93 (br. s., 1H), 9.13 (s, 1H), 8.66 (d, J=8.7 Hz, 1H), 8.51 (s, 1H), 8.47 (dd, J=8.9, 5.5 Hz, 1H), 8.11 (s, 1H), 7.69 (dd, J=9.8, 2.3 Hz, 1H), 7.25 (s, 1H), 7.07 (td, J=9.2, 2.1 Hz, 1H), 5.48-5.61 (m, 1H), 4.15 (s, 3H), 1.67 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide and 2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-oxazol-2-yl-ethyl)-amide

A racemic sample of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide (182 mg, 0.34 mmol) was subjected to chiral SFC chromatography. Separation of the enantiomers was achieved with a WHELK-O1 R,R column using 30% EtOH/CO 2 as the eluent. Obtained 76 mg (42%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide as a light yellow solid and 72 mg (40%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-oxazol-2-yl-ethyl)-amide as a light yellow solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide (75 mg, 0.14 mmol) was dissolved in dichloromethane (0.7 ml) and trifluoroacetic acid (0.45 ml, 5.6 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was dissolved in dichloromethane (0.7 ml) and ethylenediamine (0.6 ml, 8.4 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 23 mg (39%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide as a light yellow powder. MS: (M+H) + =406; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.95 (br. s., 1H), 9.13 (s, 1H), 8.66 (d, J=8.7 Hz, 1H), 8.51 (s, 1H), 8.47 (dd, J=9.1, 5.3 Hz, 1H), 8.11 (s, 1H), 7.69 (dd, J=9.6, 2.1 Hz, 1H), 7.24 (s, 1H), 7.02-7.11 (m, 1H), 5.48-5.60 (m, 1H), 4.15 (s, 3H), 1.66 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-oxazol-2-yl-ethyl)-amide

Prepared according to Example 50, substituting 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-oxazol-2-yl-ethyl)-amide for 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide in Step 2. MS: (M+H) + =406; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.93 (br. s., 1H), 9.12 (s, 1H), 8.64 (d, J=8.7 Hz, 1H), 8.50 (s, 1H), 8.46 (dd, J=9.1, 5.3 Hz, 1H), 8.10 (s, 1H), 7.68 (dd, J=9.8, 2.3 Hz, 1H), 7.23 (s, 1H), 7.05 (td, J=9.1, 2.3 Hz, 1H), 5.53 (quin, J=7.5 Hz, 1H), 4.14 (s, 3H), 1.65 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-4-yl-ethyl)-amide

2-Methyl-propane-2-sulfinic acid 1-oxazol-4-yl-meth-(E)-ylideneamide

In a round-bottomed flask, oxazole-4-carbaldehyde (300 mg, 3.09 mmol) was dissolved in THF (7 ml) and 2-methylpropane-2-sulfinamide (450 mg, 3.71 mmol) and titanium(IV) ethoxide (1.3 ml, 6.18 mmol) were added. The reaction mixture was stirred at room temperature overnight then slowly quenched by dropwise addition of brine (2 ml) which resulted in the formation of a thick light yellow precipitate. The reaction mixture was diluted with ethyl acetate and stirred vigorously at room temperature for 30 min. The suspension was filtered over Celite and rinsed with ethyl acetate. The filtrate was concentrated and the residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-40% EtOAc) to afford 552 mg (89%) of 2-methyl-propane-2-sulfinic acid 1-oxazol-4-yl-meth-(E)-ylideneamide as a white solid.

2-Methyl-propane-2-sulfinic acid (1-oxazol-4-yl-ethyl)-amide

In a round-bottomed flask, 2-methyl-propane-2-sulfinic acid 1-oxazol-4-yl-meth-(E)-ylideneamide (548 mg, 2.74 mmol) was dissolved in dichloromethane (9 ml). The reaction mixture was cooled to 0° C. and methylmagnesium bromide (3.0 M in diethyl ether, 1.0 ml, 3.0 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 1 h then quenched with saturated aqueous NH 4 Cl and extracted with ethyl acetate (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to afford 588 mg of 2-methyl-propane-2-sulfinic acid (1-oxazol-4-yl-ethyl)-amide as a light yellow oil.

1-Oxazol-4-yl-ethylamine dihydrochloride

In a round-bottomed flask, 2-methyl-propane-2-sulfinic acid (1-oxazol-4-yl-ethyl)-amide (585 mg, 2.57 mmol) was dissolved in methanol (4.5 ml) and hydrogen chloride (4.0 M in 1,4-dioxane, 1.3 ml, 5.2 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 15 min then concentrated to give 1-oxazol-4-yl-ethylamine dihydrochloride as a viscous orange oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-4-yl-ethyl)-amide

A round-bottomed flask was charged with 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.23 mmol) and 1-oxazol-2-yl-ethylamine dihydrochloride (crude from Step 3, 90 mg, 0.41 mmol). DMF (1.1 ml) was added followed by N,N-diisopropylethylamine (0.26 ml, 1.49 mmol) and HATU (95 mg, 0.25 mmol). The light yellow solution was stirred at room temperature for 48 h. Water was added and the resulting suspension was filtered. The solid was washed with water and petroleum ether then dried under high vacuum to afford 113 mg (93%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-4-yl-ethyl)-amide as an off-white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-4-yl-ethyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-4-yl-ethyl)-amide (110 mg, 0.205 mmol) was dissolved in dichloromethane (1 ml) and trifluoroacetic acid (0.63 ml, 8.2 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1 ml) and ethylenediamine (0.83 ml, 12.3 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 58 mg (70%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-4-yl-ethyl)-amide as a light yellow powder. MS: (M+H) + =406; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.83 (br. s., 1H), 9.12 (s, 1H), 8.42-8.51 (m, 2H), 8.32-8.42 (m, 2H), 8.20 (s, 1H), 7.68 (dd, J=9.8, 1.9 Hz, 1H), 7.04 (td, J=9.3, 1.9 Hz, 1H), 5.28-5.46 (m, 1H), 4.14 (s, 3H), 1.58 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-3-yl-ethyl)-amide

2-Methyl-propane-2-sulfinic acid 1-isoxazol-3-yl-meth-(E)-ylideneamide

In a round-bottomed flask, isoxazole-3-carbaldehyde (300 mg, 3.09 mmol) was dissolved in THF (7 ml) and 2-methylpropane-2-sulfinamide (450 mg, 3.71 mmol) and titanium(IV) ethoxide (1.3 ml, 6.18 mmol) were added. The reaction mixture was stirred at room temperature overnight then slowly quenched by dropwise addition of brine (2 ml) which resulted in the formation of a thick yellow precipitate. The reaction mixture was diluted with ethyl acetate and stirred vigorously at room temperature for 10 min. The suspension was filtered over Celite and rinsed with ethyl acetate. The filtrate was concentrated and the residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-20% EtOAc) to afford 585 mg (95%) of 2-methyl-propane-2-sulfinic acid 1-isoxazol-3-yl-meth-(E)-ylideneamide as a colorless oil.

2-Methyl-propane-2-sulfinic acid (1-isoxazol-3-yl-ethyl)-amide

In a round-bottomed flask, 2-methyl-propane-2-sulfinic acid 1-isoxazol-3-yl-meth-(E)-ylideneamide (584 mg, 2.92 mmol) was dissolved in dichloromethane (10 ml). The reaction mixture was cooled to 0° C. and methylmagnesium bromide (3.0 M in diethyl ether, 1.1 ml, 3.3 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 2 h then quenched with saturated aqueous NH 4 Cl and extracted with ethyl acetate (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to afford 655 mg of 2-methyl-propane-2-sulfinic acid (1-isoxazol-3-yl-ethyl)-amide as a colorless oil.

1-Isoxazol-3-yl-ethylamine hydrochloride

In a round-bottomed flask, 2-methyl-propane-2-sulfinic acid (1-isoxazol-3-yl-ethyl)-amide (652 mg, 2.71 mmol) was dissolved in methanol (5 ml) and hydrogen chloride (4.0 M in 1,4-dioxane, 1.4 ml, 5.6 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 15 min then concentrated to give 1-isoxazol-3-yl-ethylamine hydrochloride as an off-white solid which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-3-yl-ethyl)-amide

A round-bottomed flask was charged with 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.23 mmol) and 1-isoxazol-3-yl-ethylamine hydrochloride (crude from Step 3, 81 mg, 0.41 mmol). DMF (1.1 ml) was added followed by N,N-diisopropylethylamine (0.26 ml, 1.49 mmol) and HATU (95 mg, 0.25 mmol). The yellow solution was stirred at room temperature for 48 h. Water was added and the resulting suspension was filtered. The solid was washed with water and petroleum ether then dried under high vacuum to afford 115 mg (95%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-3-yl-ethyl)-amide as an off-white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-3-yl-ethyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-3-yl-ethyl)-amide (113 mg, 0.211 mmol) was dissolved in dichloromethane (1.1 ml) and trifluoroacetic acid (0.65 ml, 8.4 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1.1 ml) and ethylenediamine (0.86 ml, 12.7 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 46 mg (54%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-3-yl-ethyl)-amide as a light yellow powder. MS: (M+H) + =406; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.89 (br. s., 1H), 9.12 (s, 1H), 8.91 (d, J=1.5 Hz, 1H), 8.58 (d, J=8.7 Hz, 1H), 8.50 (s, 1H), 8.44 (dd, J=8.9, 5.5 Hz, 1H), 7.68 (dd, J=9.6, 2.1 Hz, 1H), 7.02 (td, J=9.1, 1.9 Hz, 1H), 6.68 (d, J=1.5 Hz, 1H), 5.53 (quin, J=7.2 Hz, 1H), 4.15 (s, 3H), 1.65 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [145-methyl-isoxazol-3-yl)-ethyl]-amide

Prepared according to the procedure outlined in Example 53, substituting 5-methylisoxazole-3-carbaldehyde for isoxazole-3-carbaldehyde in Step 1. MS: (M+H) + =420.

1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.86 (br. s., 1H), 9.12 (s, 1H), 8.55 (d, J=8.3 Hz, 1H), 8.50 (s, 1H), 8.45 (dd, J=8.9, 5.5 Hz, 1H), 7.68 (dd, J=9.8, 2.3 Hz, 1H), 7.04 (td, J=9.2, 2.1 Hz, 1H), 6.31 (s, 1H), 5.38-5.50 (m, 1H), 4.15 (s, 3H), 2.37 (s, 3H), 1.62 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-5-yl-ethyl)-amide

Isoxazol-5-yl-methanol

In a round-bottomed flask, isoxazole-5-carboxylic acid (1.0 g, 8.84 mmol) was dissolved in THF (35 ml). The solution was cooled to 0° C. and triethylamine (1.4 ml, 10.0 mmol) was added followed by ethyl chloroformate (0.94 ml, 9.8 mmol). A thick precipitate was formed upon the addition of the latter. The suspension was stirred at 0° C. for 15 min then a solution of sodium borohydride (1.00 g, 26.5 mmol) in water (14 ml) was added portionwise via pipet. Vigorous gas evolution was observed. The reaction mixture was stirred at 0° C. for 1 h then diluted with water and saturated aqueous NH 4 Cl and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-50% EtOAc) to afford 513 mg (59%) of isoxazol-5-yl-methanol as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.23 (d, J=1.9 Hz, 1H), 6.26-6.30 (m, 1H), 4.82 (s, 2H), 2.13 (br. s., 1H).

Isoxazole-5-carbaldehyde

In a round-bottomed flask, isoxazol-5-yl-methanol (511 mg, 5.16 mmol) was dissolved in dichloromethane (30 ml). Dess-Martin periodinane (2.3 g, 5.41 mmol) was added and the reaction mixture was stirred at room temperature for 1.5 h. The reaction was quenched with 50 ml of a 1:1 solution of 10% aqueous Na 2 S 2 O 3 and saturated aqueous NaHCO 3 and then extracted with dichloromethane (2×). The organic layers were washed with saturated aqueous NaHCO 3 , water and brine. The aqueous layers were back extracted with dichloromethane. The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-40% EtOAc) to afford 226 mg (45%) of isoxazole-5-carbaldehyde as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.05 (s, 1H), 8.44 (d, J=1.9 Hz, 1H), 7.02 (d, J=1.9 Hz, 1H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-isoxazol-5-yl-ethyl)-amide

Prepared according to the procedure outlined in Example 53, substituting isoxazole-5-carbaldehyde for isoxazole-3-carbaldehyde in Step 1. MS: (M+H) + =406.

1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.94 (br. s., 1H), 9.12 (s, 1H), 8.49-8.62 (m, 3H), 8.34 (dd, J=8.9, 5.5 Hz, 1H), 7.69 (dd, J=9.8, 1.9 Hz, 1H), 7.12 (td, J=9.2, 2.1 Hz, 1H), 6.56 (d, J=1.9 Hz, 1H), 5.62 (quin, J=7.5 Hz, 1H), 4.15 (s, 3H), 1.67 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-propyl)-amide

[(R)-1-(Methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester

A round-bottomed flask was charged with Boc-D-alanine (1.0 g, 5.29 mmol) and N,O-dimethylhydroxylamine hydrochloride (670 mg, 6.87 mmol). DMF (12 ml) was added followed by N,N-diisopropylethylamine (2.4 ml, 13.7 mmol) and HATU (2.21 g, 5.81 mmol). The yellow suspension was stirred at room temperature for 48 h. The reaction mixture was quenched with water and petroleum ether was added. The resulting suspension was filtered, washed with water and petroleum ether and dried under high vacuum to afford 1.05 g (85%) of [(R)-1-(methoxymethyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester as a white powder.

((R)-1-Methyl-2-oxo-propyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, [(R)-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester (3.00 g, 12.9 mmol) was dissolved in THF (100 ml). The solution was cooled to −16° C. (NaCl/ice bath) and methylmagnesium bromide (3.0 M in diethyl ether, 12.0 ml, 36.0 mmol) was added dropwise over 20 min. After the addition, the reaction mixture was allowed to warm slowly to room temperature overnight. The reaction mixture was cooled to 0° C., quenched with saturated aqueous NH 4 Cl and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-20% EtOAc) to afford 2.21 g (91%) of ((R)-1-methyl-2-oxo-propyl)-carbamic acid tert-butyl ester as a white solid.

((R)-2,2-Difluoro-1-methyl-propyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, ((R)-1-methyl-2-oxo-propyl)-carbamic acid tert-butyl ester (300 mg, 1.6 mmol) was dissolved in dichloromethane (15 ml). DAST (0.64 ml, 4.84 mmol) was added dropwise at room temperature and the reaction mixture was stirred at room temperature overnight then at reflux for 7 h. The reaction was cooled to room temperature, quenched with 15 ml of saturated aqueous NaHCO 3 and then extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-5% EtOAc) to afford 152 mg (45%) of ((R)-2,2-difluoro-1-methyl-propyl)-carbamic acid tert-butyl ester as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 4.59 (br. s., 1H), 3.90-4.08 (m, 1H), 1.62 (t, J=18.9 Hz, 3H), 1.46 (s, 9H), 1.23 (d, J=6.8 Hz, 3H).

(R)-2,2-Difluoro-1-methyl-propylamine trifluoroacetate

In a round-bottomed flask, ((R)-2,2-difluoro-1-methyl-propyl)-carbamic acid tert-butyl ester (148 mg, 0.71 mmol) was dissolved in dichloromethane (3 ml) and trifluoroacetic acid (1.6 ml, 20.8 mmol) was slowly added. The reaction mixture was stirred at room temperature for 1.5 h then concentrated to give (R)-2,2-difluoro-1-methyl-propylamine trifluoroacetate as a light brown oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-propyl)-amide

In a round-bottomed flask, (R)-2,2-difluoro-1-methyl-propylamine trifluoroacetate (crude from Step 4) was dissolved in DMF (1.2 ml) and N,N-diisopropylethylamine (0.5 ml, 2.86 mmol) was added. Then 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (110 mg, 0.25 mmol) was added followed by HATU (104 mg, 0.27 mmol). The yellow solution was stirred at room temperature overnight. Water was added and the suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 108 mg (81%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-propyl)-amide as an off-white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-propyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-propyl)-amide (105 mg, 197 mmol) was dissolved in dichloromethane (1 ml) and trifluoroacetic acid (0.6 ml, 7.9 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1 ml) and ethylenediamine (0.8 ml, 11.8 mmol) was added. The reaction was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 48 mg (61%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-propyl)-amide as an off-white powder. MS: (M+H) + =403; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.85 (br. s., 1H), 9.12 (s, 1H), 8.51 (s, 1H), 8.45 (dd, J=8.9, 5.5 Hz, 1H), 8.32 (d, J=9.8 Hz, 1H), 7.69 (dd, J=9.8, 2.3 Hz, 1H), 7.10 (td, J=9.1, 1.9 Hz, 1H), 4.56-4.80 (m, 1H), 4.15 (s, 3H), 1.72 (t, J=19.3 Hz, 3H), 1.37 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-cyanomethyl-cyclopentyl)-amide

3-Oxo-2-aza-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid tert-butyl ester

In a round-bottomed flask, 2-azabicyclo[2.2.1]hept-5-en-3-one (1.0 g, 9.16 mmol) was suspended in THF (10 ml) and triethylamine (1.9 ml, 13.6 mmol) di-tert-butyl dicarbonate (2.4 g, 11.0 mmol) and 4-dimethylaminopyridine (112 mg, 0.92 mmol were added. The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with ethyl acetate (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to afford 1.79 g (93%) of 3-oxo-2-aza-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid tert-butyl ester as a light yellow solid.

3-Oxo-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester

In a Parr pressure bottle, 3-oxo-2-aza-bicyclo[2.2.1]hept-5-ene-2-carboxylic acid tert-butyl ester (1.77 g, 8.46 mmol) was dissolved in methanol (12 ml) and 10% palladium on carbon (wet, 170 mg, 0.16 mmol) was carefully added. The bottle was placed on a Parr hydrogenator and shaken under 40 psi hydrogen pressure for 2 h. The reaction mixture was filtered over Celite and rinsed with methanol/ethyl acetate. The filtrate was concentrated to give 1.88 g of 3-oxo-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester as a light grey oil which was used without further purification.

(cis-3-Hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, 3-oxo-2-aza-bicyclo[2.2.1]heptane-2-carboxylic acid tert-butyl ester (crude from Step 2, 1.87 g) was dissolved in THF (20 ml) and water (2 ml). The reaction mixture was cooled to 0° C. and sodium borohydride (301 mg, 7.97 mmol) was added. The reaction was stirred at 0° C. for 30 min then a second portion of sodium borohydride (301 mg, 7.97 mmol) was added. The reaction mixture was stirred at 0° C. for 7.5 h then a third portion of sodium borohydride (602 mg, 15.94 mmol) was added. The reaction mixture was stirred at room temperature overnight then a fourth portion of sodium borohydride (602 mg, 15.94 mmol) was added. The reaction mixture was stirred at room temperature overnight then cooled to 0° C. and carefully quenched with 1M HCl. When gas evolution had ceased (pH=˜6) the mixture was extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-60% EtOAc) to afford 1.73 g (95%, 2 steps) of (cis-3-hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester as an off-white solid.

Methanesulfonic acid (cis)-3-tert-butoxycarbonylamino-cyclopentylmethyl ester

In a round-bottomed flask, (cis-3-hydroxymethyl-cyclopentyl)-carbamic acid tert-butyl ester (500 mg, 2.21 mmol) was dissolved in dichloromethane (5 ml). The solution was cooled to 0° C. and triethylamine (0.40 ml, 2.87 mmol) was added followed by methanesulfonyl chloride (0.20 ml, 2.57 mmol). The reaction mixture was stirred at 0° C. for 45 min then quenched with water and extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to give 780 mg of methanesulfonic acid (cis)-3-tert-butoxycarbonylamino-cyclopentylmethyl ester as a pale yellow oil which was used without further purification.

(cis-3-Cyanomethyl-cyclopentyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, methanesulfonic acid (cis)-3-tert-butoxycarbonylamino-cyclopentylmethyl ester (crude from Step 4, 779 mg) was dissolved in DMF (5 ml). Potassium cyanide (277 mg, 4.25 mmol) was added and the reaction mixture was stirred at 80° C. overnight. Sodium cyanide (104 mg, 2.12 mmol) was added and the reaction mixture was stirred at 80° C. for 48 h. The reaction was cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to afford 190 mg (38%, 2 steps) of (cis-3-cyanomethyl-cyclopentyl)-carbamic acid tert-butyl ester as a light yellow oil.

(cis-3-Amino-cyclopentyl)-acetonitrile trifluoroacetate

In a round-bottomed flask, (cis-3-cyanomethyl-cyclopentyl)-carbamic acid tert-butyl ester (188 mg, 0.84 mmol) was dissolved in dichloromethane (5 ml) and trifluoroacetic acid (2.0 ml, 26.0 mmol) was slowly added. The reaction mixture was stirred at room temperature for 2 h then concentrated to afford (cis-3-amino-cyclopentyl)-acetonitrile trifluoroacetate as a yellow oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-cyanomethyl-cyclopentyl)-amide

In a round-bottomed flask, (cis-3-amino-cyclopentyl)-acetonitrile trifluoroacetate (crude from Step 6) was dissolved in DMF (1.3 ml) and N,N-diisopropylethylamine (0.65 ml, 3.72 mmol) was added. Then, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (110 mg, 0.25 mmol) and HATU (104 mg, 0.27 mmol) were added. The yellow solution was stirred at room temperature for 48 h. Water and petroleum ether were added and the resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 128 mg (94%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-cyanomethyl-cyclopentyl)-amide as an off-white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-cyanomethyl-cyclopentyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-cyanomethyl-cyclopentyl)-amide (126 mg, 0.23 mmol) was dissolved in dichloromethane (1.2 ml) and trifluoroacetic acid (0.7 ml, 9.2 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1.2 ml) and ethylenediamine (0.93 ml, 13.8 mmol) was added. The yellow solution was stirred at room temperature for 1.25 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 75 mg (74%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (cis-3-cyanomethyl-cyclopentyl)-amide as a light yellow powder. MS: (M+H) + =418; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.61 (br. s., 1H), 9.09 (s, 1H), 8.40-8.49 (m, 2H), 8.18 (d, J=7.2 Hz, 1H), 7.69 (dd, J=9.8, 2.3 Hz, 1H), 7.24 (td, J=9.2, 2.1 Hz, 1H), 4.29-4.45 (m, 1H), 4.15 (s, 3H), 2.66 (d, J=6.4 Hz, 2H), 2.34-2.43 (m, 1H), 2.23-2.34 (m, 1H), 2.11-2.23 (m, 1H), 1.85-2.00 (m, 1H), 1.46-1.74 (m, 2H), 1.28-1.41 (m, 1H).

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide

A round-bottomed flask was charged with 2-bromo-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (300 mg, 0.81 mmol) and 1-oxazol-2-yl-ethylamine dihydrochloride (244 mg, 1.0 mmol). DMF (4 ml) was added followed by N,N-diisopropylethylamine (0.9 ml, 5.15 mmol) and HATU (337 mg, 0.89 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and diluted with petroleum ether. The resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 268 mg (71%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide as an off-white powder.

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide and 2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-oxazol-2-yl-ethyl)-amide

A racemic sample of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-oxazol-2-yl-ethyl)-amide (268 mg) was subjected to SFC chromatography. Separation of the enantiomers was achieved with a DAICEL OD 3×25 column using 20% MeOH/CO 2 as the eluent. Obtained 152 mg (57%) of 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide as an off-white powder and 85 mg (32%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-1-oxazol-2-yl-ethyl)-amide as an off-white powder.

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide (148 mg, 0.32 mmol) and 6-Fluoro-1-tributylstannyl-imidazo[1,5-a]pyridine (380 mg, 0.45 mmol) were dissolved in DMF (3 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (19 mg, 0.016 mmol) and copper (I) iodide (13 mg, 0.068 mmol) were added. The reaction mixture was stirred at 80° C. in an oil bath overnight then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica sel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2% MeOH) to afford 109 mg (66%) of 2-(6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide as a yellow solid.

2-(6-Fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide

In a round-bottomed flask, 2-(6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide (107 mg, 0.205 mmol) was dissolved in dichloromethane (1.1 ml) and trifluoroacetic acid (0.64 ml, 8.3 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1.1 ml) and ethylenediamine (0.84 ml, 12.4 mmol) was added. The yellow reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 76 mg (90%) of 2-(6-fluoro-imidazo[1,5-a]pyridin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-oxazol-2-yl-ethyl)-amide as a yellow powder. MS: (M+Na) + =414; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.76 (br. s., 1H), 9.12 (s, 1H), 8.70 (dd, J=4.7, 2.1 Hz, 1H), 8.60 (d, J=8.7 Hz, 1H), 8.54 (s, 1H), 8.36-8.46 (m, 2H), 8.11 (s, 1H), 7.25 (s, 1H), 7.04 (ddd, J=9.9, 7.8, 1.9 Hz, 1H), 5.45-5.60 (m, 1H), 1.65 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-amide

[(R)-1-(3-Fluoro-azetidine-1-carbonyl)-butyl]-carbamic acid tert-butyl ester

A round-bottomed flask was charged with Boc-D-norvaline (300 mg, 1.38 mmol) and 3-fluoroazetidine hydrochloride (216 mg, 1.93 mmol). DMF (6 ml) was added followed by N,N-diisopropylethylamine (0.65 ml, 3.72 mmol) and HATU (578 mg, 1.52 mmol). The yellow reaction mixture was stirred at room temperature for 48 h the quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to give 417 mg of [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-carbamic acid tert-butyl ester as a light yellow solid.

(R)-2-Amino-1-(3-fluoro-azetidin-1-yl)-pentan-1-one trifluoroacetate

In a round-bottomed flask, [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-carbamic acid tert-butyl ester (200 mg, 0.66 mmol) was dissolved in dichloromethane (4 ml) and trifluoroacetic acid (1.6 ml, 20.8 mmol) was slowly added. The reaction mixture was stirred at room temperature for 2 h then concentrated to provide (R)-2-amino-1-(3-fluoro-azetidin-1-yl)-pentan-1-one trifluoroacetate as a pale brown oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-amide

In a round-bottomed flask, (R)-2-amino-1-(3-fluoro-azetidin-1-yl)-pentan-1-one trifluoroacetate (crude from Step 2) was dissolved in DMF (1.5 ml) and N,N-diisopropylethylamine (0.60 ml, 3.44 mmol) was added. Then 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (110 mg, 0.25 mmol) and HATU (104 mg, 0.27 mmol) were added. The yellow reaction mixture was stirred at room temperature overnight then quenched with water and diluted with petroleum ether. The resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 128 mg (86%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-amide as an off-white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-amide (126 mg, 0.21 mmol) was dissolved in dichloromethane (1.1 ml) and trifluoroacetic acid (0.65 ml, 8.4 mmol) was added. The reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was dissolved in dichloromethane (1.1 ml) and ethylenediamine (0.85 ml, 12.7 mmol) was added. The reaction was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 49 mg (50%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(3-fluoro-azetidine-1-carbonyl)-butyl]-amide as an off-white powder. MS: (M+H) + =468; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.84 (br. s, 1H), 9.15 (s, 1H), 8.74 (dt, J=9.3, 4.6 Hz, 1H), 8.41-8.52 (m, 2H), 7.68 (d, J=7.9 Hz, 1H), 7.02-7.17 (m, 1H), 5.29-5.61 (m, 1H), 4.18-4.84 (m, 4H), 4.16 (s, 3H), 3.87-4.09 (m, 1H), 1.62-1.91 (m, 2H), 1.41 (d, J=7.2 Hz, 2H), 0.82-0.97 (m, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4,5-dihydro-oxazol-2-yl)-ethyl]-amide

[(R)-1-(2-Hydroxy-ethylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester

In a round-bottomed flask, Boc-D-alanine (1.0 g, 5.29 mmol was dissolved in THF (40 ml) and 1,1′-carbonyldiimidazole (1.03 g, 6.34 mmol) was added. The reaction mixture was stirred at 60° C. for 45 min then cooled to room temperature and ethanolamine (3.2 ml, 52.9 mmol) was added. The reaction mixture was stirred at room temperature overnight then quenched with 1 M aqueous HCl (15 ml) and extracted with dichloromethane. The organic layer was washed with 1 M aqueous HCl, water and brine. The aqueous layers were back-extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford 1.11 g (90%) of [(R)-1-(2-hydroxy-ethylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester as a colorless oil.

(R)-2-Amino-N-(2-hydroxy-ethyl)-propionamide trifluoroacetate

In a round-bottomed flask, [(R)-1-(2-hydroxy-ethylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester (180 mg, 0.78 mmol) was dissolved in dichloromethane (5 ml) and trifluoroacetic acid (1.8 ml, 23.4 mmol) was slowly added. The pale yellow reaction mixture was stirred at room temperature for 2 h then concentrated to afford (R)-2-amino-N-(2-hydroxy-ethyl)-propionamide trifluoroacetate as a light yellow oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(2-hydroxy-ethylcarbamoyl)-ethyl]-amide

In a round-bottomed flask, (R)-2-amino-N-(2-hydroxy-ethyl)-propionamide trifluoroacetate (crude from Step 2) was dissolved in DMF (2 ml) and N,N-diisopropylethylamine (0.70 ml, 4.0 mmol) was added. Then 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (170 mg, 0.39 mmol) was added followed by HATU (161 mg, 0.42 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with water and diluted with petroleum ether. The resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-100% EtOAc) and MeOH/EtOAc (gradient 0-10% MeOH) to give 127 mg (59%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(2-hydroxy-ethylcarbamoyl)-ethyl]-amide as an off-white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4,5-dihydro-oxazol-2-yl)-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(2-hydroxy-ethylcarbamoyl)-ethyl]-amide (126 mg, 0.23 mmol) was dissolved in dichloromethane (2.2 ml). The solution was cooled to −76° C. and DAST (45 μl, 0.34 mmol) was added. The pale yellow reaction mixture was stirred at −76° C. for 6 h then anhydrous potassium carbonate (64 mg, 0.46 mmol) was added in one portion. The reaction mixture was allowed to warm to room temperature, quenched with saturated aqueous NaHCO 3 and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-90% EtOAc) to afford 86 mg (71%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4,5-dihydro-oxazol-2-yl)-ethyl]-amide as a light yellow solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4,5-dihydro-oxazol-2-yl)-ethyl]-amide

In a small vial, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4,5-dihydro-oxazol-2-yl)-ethyl]-amide (85 mg, 0.16 mmol) was dissolved in tetrabutylammonium fluoride (1.0 M in THF, 1.6 ml, 1.6 mmol). The yellow reaction mixture was stirred at 60° C. overnight then cooled to room temperature, quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-5% MeOH) to afford 27 mg (40%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4,5-dihydro-oxazol-2-yl)-ethyl]-amide as an off-white solid. MS: (M+Na) + =430; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.93 (br. s., 1H), 9.14 (s, 1H), 8.69 (dd, J=9.1, 5.3 Hz, 1H), 8.57 (d, J=8.3 Hz, 1H), 8.49 (s, 1H), 7.69 (dd, J=9.8, 1.9 Hz, 1H), 7.14 (td, J=9.1, 2.3 Hz, 1H), 4.97 (quin, J=7.5 Hz, 1H), 4.27-4.39 (m, 2H), 4.16 (s, 3H), 3.79 (td, J=9.3, 4.3 Hz, 2H), 1.50 (d, J=7.2 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-amide

((R)-1-Methyl-2-oxo-3-phenyl-propyl)-carbamic acid tert-butyl ester

In a round-bottomed flask, [(R)-1-(methoxy-methyl-carbamoyl)-ethyl]-carbamic acid tert-butyl ester (300 mg, 1.29 mmol) was dissolved in THF (8 ml). The solution was cooled to −16° C. (NaCl/ice bath) and benzylmagnesium chloride (1.0 M in diethyl ether, 3.8 ml, 3.8 mmol) was added dropwise. After the addition, the reaction mixture was allowed to warm slowly to room temperature and stirred for 5.5 h. The reaction mixture was quenched with saturated aqueous NH 4 Cl and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-20% EtOAc) to afford 353 mg (99%) of ((R)-1-methyl-2-oxo-3-phenyl-propyl)-carbamic acid tert-butyl ester as a colorless oil.

((R)-2,2-Difluoro-1-methyl-3-phenyl-propyl)-carbamic acid tert-butyl ester

In a dry round-bottomed flask, ((R)-1-methyl-2-oxo-3-phenyl-propyl)-carbamic acid tert-butyl ester (171 mg, 0.65 mmol) was dissolved in dichloromethane (0.3 ml). DAST (0.26 ml, 1.97 mmol) was added dropwise at room temperature and the reaction mixture was stirred at room temperature overnight. The reaction mixture was diluted with dichloromethane and slowly quenched with 5 ml of saturated aqueous NaHCO 3 . The aqueous layer was extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-5% EtOAc) to afford 95 mg (51%) of ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-carbamic acid tert-butyl ester as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.23-7.39 (m, 5H), 4.57-4.72 (m, 1H), 3.93-4.14 (m, 1H), 3.12-3.28 (m, 2H), 1.47 (s, 9H), 1.24 (dd, J=6.8, 1.1 Hz, 3H).

(R)-2,2-Difluoro-1-methyl-3-phenyl-propylamine trifluoroacetate

In a round-bottomed flask, ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-carbamic acid tert-butyl ester (92 mg, 0.32 mmol) was dissolved in dichloromethane (2 ml) and trifluoroacetic acid (0.75 ml, 9.73 mmol) was slowly added. The reaction was stirred at room temperature for 2 h then concentrated to give (R)-2,2-difluoro-1-methyl-3-phenyl-propylamine trifluoroacetate as a light brown oil which was used without further purification

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-amide

In a round-bottomed flask, (R)-2,2-difluoro-1-methyl-3-phenyl-propylamine trifluoroacetate (crude from Step 3) was dissolved in DMF (1.1 ml) and N,N-diisopropylethylamine (0.25 ml, 1.43 mmol) was added. Then 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 23 mmol) was added followed by HATU (95 mg, 0.25 mmol). The yellow reaction was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was triturated with petroleum ether to afford 136 mg (94%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-amide as an off-white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-amide (133 mg, 0.21 mmol was dissolved in dichloromethane (1.1 ml) and trifluoroacetic acid (0.64 ml, 8.3 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1.1 ml) and ethylenediamine (0.84 ml, 12.4 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was triturated with 5% EtOAc/diethyl ether to afford 73 mg (70%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2,2-difluoro-1-methyl-3-phenyl-propyl)-amide as a light yellow powder. MS: (M+Na) + =501; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.94 (br. s., 1H), 9.12 (s, 1H), 8.52 (s, 1H), 8.47 (dd, J=8.9, 5.4 Hz, 1H), 8.36 (d, J=9.8 Hz, 1H), 7.68 (dd, J=9.8, 2.0 Hz, 1H), 7.23-7.35 (m, 5H), 7.02 (td, J=9.0, 2.3 Hz, 1H), 4.60-4.78 (m, 1H), 4.15 (s, 3H), 3.33-3.45 (m, 2H), 1.41 (d, J=7.0 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanomethyl-oxazol-2-yl)-ethyl]-amide

2-((R)-2-tert-Butoxycarbonylamino-propionylamino)-3-hydroxy-propionic acid methyl ester

A round-bottomed flask was charged with Boc-D-alanine (600 mg, 3.17 mmol) and DL-serine methyl ester hydrochloride (691 mg, 4.44 mmol). DMF (12 ml) was added followed by N,N-diisopropylethylamine (1.5 ml, 8.6 mmol) and HATU (1.33 g, 3.49 mmol). The yellow reaction mixture was stirred at room temperature for 48 h then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated to afford 422 mg (41%) of 2-((R)-2-tert-butoxycarbonylamino-propionylamino)-3-hydroxy-propionic acid methyl ester as a colorless oil.

2-((R)-1-tert-Butoxycarbonylamino-ethyl)-4,5-dihydro-oxazole-4-carboxylic acid methyl ester

In a round-bottomed flask, 2-((R)-2-tert-butoxycarbonylamino-propionylamino)-3-hydroxy-propionic acid methyl ester (419 mg, 1.3 mmol) was dissolved in dichloromethane (11 ml). The solution was cooled to −76° C. and DAST (0.20 ml, 1.51 mmol) was added dropwise. The light yellow solution was stirred at −76° C. for 2 h then anhydrous potassium carbonate (269 mg, 1.95 mmol) was added in one portion. The reaction mixture was allowed to warm to room temperature, quenched with 10 ml of saturated aqueous NaHCO 3 and extracted with dichloromethane (3×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford 339 mg (91%) of 2-((R)-1-tert-butoxycarbonylamino-ethyl)-4,5-dihydro-oxazole-4-carboxylic acid methyl ester as a brown oil.

2-((R)-1-tert-Butoxycarbonylamino-ethyl)-oxazole-4-carboxylic acid methyl ester

In a round-bottomed flask, 2-((R)-1-tert-butoxycarbonylamino-ethyl)-4,5-dihydro-oxazole-4-carboxylic acid methyl ester (337 mg, 1.18 mmol) was dissolved in dichloromethane (11 ml). The solution was cooled to −16° C. (NaCl/ice bath) and DBU (0.35 ml, 2.32 mmol) was added. After 5 min, bromotrichloromethane (0.13 ml, 1.33 mmol) was added and the reaction mixture was allowed slowly to warm to room temperature and stirred for 4 days. The reaction was quenched with 0.1 M aqueous HCl and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to afford 152 mg (48%) of 2-((R)-1-tert-butoxycarbonylamino-ethyl)-oxazole-4-carboxylic acid methyl ester as an off-white solid.

[(R)-1-(4-Hydroxymethyl-oxazol-2-yl)-ethyl]-carbamic acid tert-butyl ester

In a round-bottomed flask, 2-((R)-1-tert-butoxycarbonylamino-ethyl)-oxazole-4-carboxylic acid methyl ester (151 mg, 0.56 mmol) was dissolved in THF (4 ml). The pale yellow solution was cooled to 0° C. and lithium aluminum hydride (1.0 M in THF, 0.60 ml, 0.60 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 1.5 h then sodium sulfate decahydrate was carefully added. When gas evolution had ceased, the ice bath was removed, sodium sulfate was added and the mixture was stirred vigorously for 30 min at room temperature. The suspension was filtered over Celite and rinsed with ethyl acetate/methanol. The filtrate was concentrated to give 140 mg (93%) of [(R)-1-(4-hydroxymethyl-oxazol-2-yl)-ethyl]-carbamic acid tert-butyl ester as yellow oil which was used without further purification.

[2-((R)-1-Amino-ethyl)-oxazol-4-yl]-methanol trifluoroacetate

In a round-bottomed flask, [(R)-1-(4-hydroxymethyl-oxazol-2-yl)-ethyl]-carbamic acid tert-butyl ester (137 mg, 0.51 mmol) was dissolved in dichloromethane (3 ml) and trifluoroacetic acid (1.2 ml, 15.6 mmol) was slowly added. The reaction was stirred at room temperature for 1.5 h then concentrated to afford [2-((R)-1-amino-ethyl)-oxazol-4-yl]-methanol trifluoroacetate as a brown oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxymethyl-oxazol-2-yl)-ethyl]-amide

In a round-bottomed flask, [2-((R)-1-amino-ethyl)-oxazol-4-yl]-methanol trifluoroacetate (crude from Step 5) was dissolved in DMF (1.5 ml) and N,N-diisopropylethylamine (0.70 ml, 4.0 mmol) was added. Then 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (140 mg, 0.32 mmol was added followed by HATU (133 mg, 0.35 mmol). The reaction was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-100% EtOAc) to afford 118 mg (66%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxymethyl-oxazol-2-yl)-ethyl]-amide as a light brown foam.

Methanesulfonic acid 2-((R)-1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-oxazol-4-ylmethyl ester

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-hydroxymethyl-oxazol-2-yl)-ethyl]-amide (115 mg, 0.20 mmol) was dissolved in dichloromethane (1 ml). The solution was cooled to 0° C. and triethylamine (0.04 ml, 0.29 mmol) and methanesulfonyl chloride (19 μl, 0.24 mmol) were added. The reaction mixture was stirred at 0° C. for 2 h then quenched with water and extracted with dichloromethane (2×). The organic layers were combined, dried over sodium sulfate, filtered and concentrated to afford 147 mg of methanesulfonic acid 2-((R)-1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-oxazol-4-ylmethyl ester as a yellow foam which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanomethyl-oxazol-2-yl)-ethyl]-amide

In a round-bottomed flask, methanesulfonic acid 2-((R)-1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-oxazol-4-ylmethyl ester (146 mg, 0.18 mmol) was dissolved in DMF (0.5 ml). Sodium cyanide (27 mg, 0.55 mmol) was added and the reaction mixture was stirred at 80° C. overnight. The reaction was cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-60% EtOAc) to isolate 37 mg (36%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanomethyl-oxazol-2-yl)-ethyl]-amide as a yellow solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanomethyl-oxazol-2-yl)-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanomethyl-oxazol-2-yl)-ethyl]-amide (36 mg, 0.063 mmol) was dissolved in dichloromethane (0.4 ml) and trifluoroacetic acid (0.20 ml, 2.6 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.4 ml) and ethylenediamine (0.26 ml, 3.8 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resultant suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 18 mg (65%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-cyanomethyl-oxazol-2-yl)-ethyl]-amide as an off-white powder. MS: (M+Na) + =467; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.93 (br. s., 1H), 9.12 (s, 1H), 8.66 (d, J=8.3 Hz, 1H), 8.50 (s, 1H), 8.46 (dd, J=8.9, 5.4 Hz, 1H), 8.06 (t, J=1.0 Hz, 1H), 7.69 (dd, J=9.7, 2.1 Hz, 1H), 7.12 (td, J=9.0, 2.3 Hz, 1H), 5.44-5.56 (m, 1H), 4.15 (s, 3H), 3.92 (d, J=1.3 Hz, 2H), 1.68 (d, J=7.0 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide

(S)-2-Methyl-propane-2-sulfinic acid 1-furan-2-yl-meth-(E)-ylideneamide

In a round-bottomed flask, furan-2-carbaldehyde (800 mg, 8.33 mmol) was dissolved in THF (20 ml) and (S)-2-methylpropane-2-sulfinamide (1.21 g, 10.0 mmol) and titanium(IV) ethoxide (3.5 ml, 16.7 mmol) were added. The reaction mixture was stirred at room temperature for 5 h then slowly quenched by dropwise addition of brine (5 ml) which resulted in the formation of a thick precipitate. The reaction mixture was diluted with ethyl acetate and stirred vigorously at room temperature for 15 min. The suspension was filtered over Celite and rinsed with ethyl acetate. The filtrate was concentrated and the residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-25% EtOAc) to give 1.48 g (89%) of (S)-2-methyl-propane-2-sulfinic acid 1-furan-2-yl-meth-(E)-ylideneamide as a light yellow oil.

(S)-2-Methyl-propane-2-sulfinic acid ((R)-1-furan-2-yl-ethyl)-amide

In a round-bottomed flask, (S)-2-methyl-propane-2-sulfinic acid 1-furan-2-yl-meth-(E)-ylideneamide (500 mg, 2.51 mmol) was dissolved in dichloromethane (10 ml). The solution was cooled to −76° C. and methylmagnesium bromide (3.0 M in diethyl ether, 1.0 ml, 3.00 mmol) was added dropwise. The reaction mixture was stirred at −76° C. for 1.5 h and then allowed to warm to room temperature over 1.5 h. The reaction mixture was recooled to −76° C. and a second portion of methylmagnesium bromide (3.0 M in diethyl ether, 1.0 ml, 3.00 mmol) was added dropwise. The reaction mixture was stirred at −76° C. for 1 h and then allowed to warm to room temperature over 3 h. The reaction mixture was recooled to −76° C. and a third portion of methylmagnesium bromide (3.0 M in diethyl ether, 0.5 ml, 1.5 mmol) was added dropwise. The reaction mixture was allowed to warm slowly to room temperature overnight then quenched with saturated aqueous NH 4 Cl and extracted with ethyl acetate (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to give 515 mg (91%) of a yellow solid. NMR analysis indicated a 9:1 mixture (80% de) of diastereomers with the major diastereomer assigned as (S)-2-methyl-propane-2-sulfinic acid ((R)-1-furan-2-yl-ethyl)-amide based on literature correlation.

(R)-1-Furan-2-yl-ethylamine hydrochloride

In a round-bottomed flask, (S)-2-methyl-propane-2-sulfinic acid ((R)-1-furan-2-yl-ethyl)-amide (514 mg, 2.27 mmol) was dissolved in methanol 4 ml) and hydrogen chloride (4.0 M in 1,4-dioxane, 1.2 ml, 4.8 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 15 min then concentrated to give 416 mg of (R)-1-furan-2-yl-ethylamine hydrochloride as a dark brown waxy solid which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-furan-2-yl-ethyl)-amide

A round-bottomed flask was charged with 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (300 mg, 0.68 mmol) and (R)-1-furan-2-yl-ethylamine hydrochloride (416 mg, 1.55 mmol). DMF (3.5 ml) was added followed by N,N-diisopropylethylamine (0.85 ml, 4.87 mmol) and HATU (284 mg, 0.75 mmol). The reaction was stirred at room temperature overnight then water and petroleum ether were added. The resulting suspension was filtered. The filter cake was washed with water and petroleum ether then dried under high vacuum to afford 338 mg (88%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-furan-2-yl-ethyl)-amide as a light brown powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-furan-2-yl-ethyl)-amide (370 mg, 0.66 mmol) was dissolved in methanol (6 ml) and ethyl acetate (2 ml). The flask was flushed with argon then 20% palladium hydroxide on carbon (50% water, 100 mg, 0.71 mmol) was added. The reaction mixture was stirred under hydrogen atmosphere (balloon) at room temperature for 48 h then filtered over Celite and rinsed with dichloromethane/ethyl acetate. The filtrate was concentrated and the residue was chromatographed over silica gel with MeOH/CH 2 Cl 2 /0.5% NH 4 OH (gradient 0-2.5% MeOH) to afford 300 mg (86%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide as a light yellow solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide and 2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide

A sample of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide (300 mg, 0.56 mmol) was subjected to chiral SFC chromatography. Separation of the diastereomers was achieved with WHELK-O1 R,R 3×25 column using 45% MeOH/CO 2 (with 0.2% triethylamine added) as the eluent. Obtained 163 mg (54%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide as an off-white solid and 38 mg (13%) 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide as an off white powder.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide

In a round-bottomed flask, 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide (152 mg, 0.28 mmol) was dissolved in dichloromethane (1.4 ml) and trifluoroacetic acid (0.87 ml, 11.3 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (1.4 ml) and ethylenediamine (1.2 ml, 17.8 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered, washed with hot water and ethyl acetate and dried under high vacuum to provide 46 mg (40%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide as an off-white powder. MS: (M+Na) + =431; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.09 (br. s., 1H), 9.13 (s, 1H), 8.64 (dd, J=8.7, 5.3 Hz, 1H), 8.44 (s, 1H), 8.22 (d, J=9.4 Hz, 1H), 7.67 (d, J=8.3 Hz, 1H), 7.10 (t, J=8.1 Hz, 1H), 4.32 (br. s., 1H), 4.15 (s, 3H), 3.96 (d, J=3.0 Hz, 1H), 3.52-3.68 (m, 2H), 1.86-2.00 (m, 1H), 1.52-1.84 (m, 3H), 1.33 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide

Prepared according to Example 63, Step 7, substituting 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(R)-1-(tetrahydro-furan-2-yl)-ethyl]-amide for 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)—(S)-1-(tetrahydro-furan-2-yl)-ethyl]-amide. MS: (M+Na) + =431; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.12 (s, 1H), 8.56 (dd, J=8.7, 5.3 Hz, 1H), 8.44 (s, 1H), 8.24 (d, J=9.1 Hz, 1H), 7.69 (dd, J=9.8, 2.3 Hz, 1H), 7.14 (td, J=9.1, 2.3 Hz, 1H), 4.26 (dd, J=13.4, 7.0 Hz, 1H), 4.15 (s, 3H), 3.79-4.00 (m, 2H), 3.69 (q, J=7.3 Hz, 1H), 1.65-2.02 (m, 4H), 1.26 (d, J=6.4 Hz, 3H).

2-(5-Hydroxy-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

5-(tert-Butyl-dimethyl-silanyloxy)-1H-indazole

In a round-bottomed flask, 5-hydroxy-1H-indazole (700 mg, 5.22 mmol) was dissolved in DMF (15 ml) and TBDMS-Cl (865 mg, 5.74 mmol) and imidazole (426 mg, 6.26 mmol) were added. The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to afford 1.21 g (93%) of 5-(tert-butyl-dimethyl-silanyloxy)-1H-indazole as an off-white solid.

5-(tert-Butyl-dimethyl-silanyloxy)-3-iodo-1H-indazole

In a round-bottomed flask, 5-(tert-butyl-dimethyl-silanyloxy)-1H-indazole (1.20 g, 4.83 mmol) was dissolved in DMF (12 ml). Iodine (2.45 g, 9.66 mmol) was added followed by potassium carbonate (2.58 g, 18.7 mmol). The dark suspension was stirred at room temperature for 3 h then quenched with 10% aqueous NaHSO 3 and extracted with diethyl ether (2×). The combined organic layers were washed with 10% aqueous NaHSO 3 , three times with water and once with brine then dried over sodium sulfate, filtered and concentrated to afford 1.65 g (91%) of 5-(tert-butyl-dimethyl-silanyloxy)-3-iodo-1H-indazole as a dark brown foam.

5-(tert-Butyl-dimethyl-silanyloxy)-3-iodo-1-methyl-1H-indazole

In a round-bottomed flask, 5-(tert-butyl-dimethyl-silanyloxy)-3-iodo-1H-indazole (1.65 g, 4.41 mmol) was dissolved in THF (16 ml). The solution was cooled to 0° C. and potassium tert-butoxide (697 mg, 6.22 mmol) was added. The reaction mixture was stirred at 0° C. for 30 min then methyl iodide (0.38 ml, 6.08 mmol) was added dropwise. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 4.5 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-10% EtOAc) to give 770 mg (45%) of 5-(tert-butyl-dimethyl-silanyloxy)-3-iodo-1-methyl-1H-indazole as a light yellow solid.

5-(tert-Butyl-dimethyl-silanyloxy)-1-methyl-3-tributylstannanyl-1H-indazole

In a round-bottomed flask, 5-(tert-butyl-dimethyl-silanyloxy)-3-iodo-1-methyl-1H-indazole (140 mg, 0.36 mmol) was dissolved in THF (2 ml). The solution was cooled to −16° C. (NaCl/ice bath) and isopropylmagnesium chloride (2.0 M in THF, 0.22 ml, 0.44 mmol) was added dropwise. The reaction mixture was stirred at −16° C. for 20 min then tributylchlorostannane (0.11 ml, 0.41 mmol) was slowly added. The reaction mixture was allowed to warm to room temperature over 1.5 h then quenched with saturated aqueous NH 4 Cl and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated to provide 5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-3-tributylstannanyl-1H-indazole as a light yellow oil which was used without further purification.

2-[5-(tert-Butyl-dimethyl-silanyloxy)-1-methyl-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (100 mg, 0.24 mmol) and 5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-3-tributylstannanyl-1H-indazole (crude from Step 4) were dissolved in DMF (2 ml). The flask was evacuated and backfilled with argon then tetrakis(triphenylphosphine)palladium (0) (14 mg, 0.012 mmol) and copper (I) iodide (10 mg, 0.053 mmol) were added. The reaction mixture was stirred at 80° C. for 2 h then cooled to room temperature, quenched with water and extracted with diethyl ether (2×). The combined organic layers were washed twice with water and once with brine then dried over sodium sulfate, filtered and concentrated. The residue was chromatographed over silica gel with EtOAc/hexanes (gradient 0-30% EtOAc) to afford 104 mg (72%) of 2-[5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a light yellow solid.

2-[5-(tert-Butyl-dimethyl-silanyloxy)-1-methyl-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

In a round-bottomed flask, 2-[5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (100 mg, 0.168 mmol) was dissolved in dichloromethane (0.8 ml) and trifluoroacetic acid (0.52 ml, 6.75 mmol) was added. The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was dissolved in dichloromethane (0.8 ml) and ethylenediamine (0.68 ml, 10.1 mmol) was added. The yellow solution was stirred at room temperature for 1 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was triturated with ethyl acetate to afford 55 mg (70%) of 2-[5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a yellow powder.

2-(5-Hydroxy-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

In a round-bottomed, 2-[5-(tert-butyl-dimethyl-silanyloxy)-1-methyl-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (50 mg, 0.108 mmol) was suspended in THF (1.2 ml) and tetrabutylammonium fluoride (1.0 M in THF, 0.11 ml, 110 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with ethyl acetate. The resulting suspension was filtered and the solid was washed with hot water and ethyl acetate then dried under high vacuum to provide 33 mg (83%) of 2-(5-hydroxy-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a yellow powder. MS: (M+Na) + =373; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.77 (br. s., 1H), 9.25 (s, 1H), 9.06 (s, 1H), 8.38 (s, 1H), 8.16 (d, J=7.6 Hz, 1H), 7.73 (d, J=1.9 Hz, 1H), 7.60 (d, J=9.1 Hz, 1H), 7.10 (dd, J=9.1, 2.3 Hz, 1H), 4.23 (dq, J=13.6, 6.7 Hz, 1H), 4.13 (s, 3H), 1.35 (d, J=6.8 Hz, 6H).

2-(5-Chloro-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

2-(5-Chloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

A 5 ml microwave vial was charged with 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (252 mg, 0.45 mmol), sodium iodide (112 mg, 0.75 mmol) and copper(I) iodide (8 mg, 0.04 mmol). The vial was evacuated, backfilled with argon then toluene (0.4 ml) and trans-N,N′-dimethylcyclohexane-1,2-diamine (0.015 ml, 0.095 mmol) were added via syringe. The vial was sealed and the reaction mixture was stirred at 110° C. in an oil bath for 22 h. The reaction was cooled to room temperature and 5-chloro-1H-indazole (57 mg, 0.37 mmol) and potassium phosphate tribasic (167 mg, 0.79 mmol) were added. The vial was again evacuated, backfilled with argon, sealed and stirred at 110° C. in an oil bath for 19 h. The reaction was cooled to room temperature, filtered through Celite and washed with ethyl acetate. The filtrate was concentrated and the residue was purified by chromatography over silica gel with MeOH/CH 2 Cl 2 (0.5% NH 4 OH) (gradient 0-2.5% MeOH) to give 53 mg (22%) of 2-(5-chloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a yellow oil and 76 mg (33%) of 2-iodo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a light brown solid.

2-(5-Chloro-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(5-chloro-indazol-1-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (51 mg, 0.08 mmol) was dissolved in dichloromethane (0.5 ml) and trifluoroacetic acid (0.25 ml, 3.24 mmol) was added. The yellow reaction mixture was stirred at room temperature for 2.5 h then concentrated. The residue was dissolved in dichloromethane (0.5 ml) and ethylenediamine (0.33 ml, 4.89 mmol) was added. The reaction was stirred at room temperature for 1.5 h then quenched with water and extracted with EtOAc (2×30 ml). The combined organic layers were washed with water and brine then dried over sodium sulfate, filtered and concentrated. The residue was purified by chromatography over silica gel with EtOAc/hexanes (gradient 0-100% EtOAc) followed by trituration with EtOAc/hexanes (1:1) to provide 22 mg (52%) of 2-(5-chloro-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a yellow solid. MS: (M+H) + =503; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.01 (br. s., 1H), 9.10 (s, 1H), 8.94 (dd, J=8.9, 5.1 Hz, 1H), 8.54 (d, J=0.8 Hz, 1H), 8.51 (d, J=6.8 Hz, 1H), 8.29 (d, J=8.3 Hz, 1H), 8.07 (d, J=1.9 Hz, 1H), 7.56 (t, J=6.6 Hz, 1H), 4.92-5.02 (m, 1H), 3.70-4.06 (m, 2H), 3.09-3.68 (m, 3H), 1.50-2.08 (m, 4H), 1.20-1.39 (m, 1H), 0.31-0.61 (m, 4H).

2-(5,6-Dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

4,5-Dichloro-2-methylaniline

To a partial suspension of 1,2-dichloro-4-methyl-5-nitrobenzene (2.0 g, 9.71 mmol) in MeOH (25 ml), water (25 ml), and THF (10 ml) was added NH 4 Cl (5.19 g, 97.1 mmol) followed by iron powder (2.71 g, 48.5 mmol). The heterogeneous reaction mixture was heated at 100° C. for 3 h then cooled to room temperature and filtered over a Buchner funnel, rinsing with MeOH. The filtrate was diluted with water and saturated aqueous NaHCO 3 then extracted with CH 2 Cl 2 (3×). The combined organics were dried over MgSO 4 and concentrated to afford 1.69 g (99%) of 4,5-dichloro-2-methylaniline as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.10 (s, 1H), 6.75 (s, 1H), 3.74 (br. s., 2H), 2.12 (s, 3H).

5,6-Dichloro-1H-indazole

To a solution of 4,5-dichloro-2-methylaniline (1.69 g, 9.6 mmol) in CHCl 3 (25 ml) at 0° C. was slowly added acetic anhydride (2.09 ml, 22.1 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. A thick white precipitate had gradually formed. Potassium acetate (283 mg, 2.88 mmol) was added followed by slow addition of isoamyl nitrite (2.78 ml, 20.6 mmol). The reaction mixture was heated at reflux overnight. The homogeneous deep orange reaction mixture was cooled to room temperature and concentrated. Water (10 mL) was added and the mixture was reconcentrated to an orange solid. This solid was suspended in conc. HCl (15 mL) and heated at 60° C. for 2 h then cooled to 0° C. and neutralized with 50% NaOH. Extracted with EtOAc, dried over MgSO 4 and concentrated to an orange solid. This solid was dissolved in THF/MeOH (1:1, 25 mL) and 10% NaOH (3 mL) was added. The deep maroon reaction mixture was stirred at room temperature for 5 min then neutralized with 1.0 M HCl and diluted with water. The mixture was extracted with EtOAc (2×) then dried over MgSO 4 and concentrated. The residue was absorbed onto silica gel and purified by chromatography with 30% to 50% EtOAc/hexanes to afford 1.50 g (84%) of 5,6-dichloro-1H-indazole as a light orange solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.04 (s, 1H), 7.89 (s, 1H), 7.68 (s, 1H).

5,6-Dichloro-3-iodo-1H-indazole

To a solution of 5,6-dichloro-1H-indazole (0.50 g, 2.67 mmol) in DMF (8 ml) at room temperature was added powdered potassium hydroxide (450 mg, 8.02 mmol) and iodine (1.02 g, 4.01 mmol). The maroon reaction mixture was stirred at room temperature for 45 min then quenched with 10% aqueous Na 2 S 2 O 3 and diluted with water. The mixture was extracted with EtOAc (2×). The combined organics were washed with water (3×), dried over MgSO 4 and concentrated to afford 827 mg (99%) of 5,6-dichloro-3-iodo-1H-indazole as a pale yellow solid. 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 13.79 (s, 1H), 7.94 (s, 1H), 7.72 (s, 1H).

5,6-Dichloro-3-iodo-1-methyl-1H-indazole

To a solution of 5,6-dichloro-3-iodo-1H-indazole (820 mg, 2.62 mmol) in THF (8 ml) at 0° C. was added KOt-Bu (412 mg, 3.67 mmol). The reaction mixture was stirred at 0° C. for 30 min then added iodomethane (0.23 ml, 3.67 mmol). Stirred at 0° C. for 30 min then warmed to room temperature and stirred for 1.5 hr. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were dried over MgSO 4 and concentrated. The crude residue was absorbed on silica gel and purified by chromatography with 20% to 30% EtOAc/hexanes to afford 585 mg (68%) of 5,6-dichloro-3-iodo-1-methyl-1H-indazole as a light yellow solid. 1 H NMR (CDCl 3 , 400 MHz): δ (ppm) 7.61 (s, 1H), 7.56 (s, 1H), 4.09 (s, 3H). The minor 5,6-dichloro-3-iodo-2-methyl-1H-indazole regioisomer was also observed but not isolated.

5,6-Dichloro-1-methyl-3-tributylstannanyl-1H-indazole

To a solution of 5,6-dichloro-3-iodo-1-methyl-1H-indazole (150 mg, 0.44 mmol) in THF (3 mL) at −10° C. (ice/acetone) was slowly added isopropylmagnesium chloride (2.0 M in THF, 0.26 mL, 0.52 mmol). The bright yellow heterogeneous reaction mixture was stirred at −10° C. for 15 min then tributylchlorostannane (0.14 mL, 0.52 mmol) was added dropwise. Stirring was continued at −10° C. for 30 min then at room temperature for 1 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organics were dried over MgSO 4 and concentrated to afford 5,6-dichloro-1-methyl-3-tributylstannanyl-1H-indazole as a pale yellow oil which was used in the next step without further purification.

2-(5,6-Dichloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

To a solution of 5,6-dichloro-1-methyl-3-tributylstannyl-1H-indazole (crude from Step 5, 218 mg, 0.44 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (125 mg, 0.22 mmol) in DMF (2 mL) were added Pd(PPh 3 ) 4 (12.9 mg, 0.011 mmol) and copper(I) iodide (8 mg, 0.044 mmol). The yellow reaction mixture was heated at 90° C. for 1.5 h then cooled to room temperature, quenched with water and extracted with EtOAc (2×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 50% to 100% EtOAc/hexanes to isolate 130 mg (86%) of 2-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a pale yellow foamy solid.

2-(5,6-Dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

To a solution of 2-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (130 mg, 0.19 mmol) in CH 2 Cl 2 (4 mL) was added TFA (2.0 mL, 26.0 mmol). The reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (4 mL) and ethylenediamine (0.4 mL, 5.92 mmol) was added. The reaction mixture was stirred at room temperature for 0.5 h then quenched with water and extracted with CH 2 Cl 2 (3×). The combined organics were concentrated. The residue was purified by silica gel chromatography with 0% to 4% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) followed by trituration with Et 2 O to afford a white solid. This solid was further purified by recrystallization from MeOH/EtOAc to afford 22 mg of 2-(5,6-dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a white solid. MS: (M+Na) + =573; 1 H NMR (DMSO-d 6 ,300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.14 (s, 1H), 8.88 (s, 1H), 8.69 (d, J=8.7 Hz, 1H), 8.46 (d, J=8.7 Hz, 1H), 8.24 (s, 1H), 4.93 (t, J=7.4 Hz, 1H), 4.18 (s, 3H), 3.45-3.94 (m, 3H), 3.15 (d, J=4.9 Hz, 2H), 1.35-1.91 (m, 5H), 0.51 (br. s., 4H).

2-(5,6-Dichloroindazolz-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

2-Iodo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

In a 5 mL microwave vial were placed copper(I) iodide (5 mg, 0.027 mmol), sodium iodide (120 mg, 0.80 mmol), 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (150 mg, 0.27 mmol), 1,4-dioxane (1 mL) and trans-N,N′-dimethylcyclohexane-1,2-diamine (8 mg, 0.054 mmol). The vial was purged with a stream of nitrogen then sealed and heated in an oil bath at 110° C. for 20 h. The reaction mixture was cooled to room temperature and quenched with sat'd aqueous NH 4 OH (3 mL) then diluted with water and extracted with CH 2 Cl 2 . The organics were dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% to 80% EtOAc/hexanes to isolate 130 mg (80%) of 2-iodo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as an orange foamy solid.

2-(5,6-Dichloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

In a 5 mL microwave vial were placed copper(I) iodide (6 mg, 0.033 mmol), K 3 PO 4 (146 mg, 0.69 mmol), 5,6-dichloro-1H-indazole (74 mg, 0.39 mmol), 2-iodo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (200 mg, 0.33 mmol), toluene (1.2 mL), and trans-N,N′-dimethylcyclohexane-1,2-diamine (9 mg, 0.066 mmol). The vial was purged with a stream of nitrogen then sealed and heated in an oil bath at 110° C. for 48 h. The reaction mixture was cooled to room temperature and diluted with EtOAc then filtered over a Buchner funnel, rinsing with EtOAc. The filtrate was concentrated and the resultant residue was purified by silica gel chromatography with 0% to 2% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) to afford 215 mg (98%) of 2-(5,6-dichloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a light yellow foam.

2-(5,6-Dichloro-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide

To a solution of 2-(5,6-dichloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide (220 mg, 0.33 mmol) in CH 2 Cl 2 (4 mL) was added TFA (2.0 mL, 26.0 mmol). The yellow reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (4 mL) and ethylenediamine (0.4 mL, 5.92 mmol) was added. The reaction mixture was stirred at room temperature for 0.5 h then quenched with water and extracted with CH 2 Cl 2 (3×). The combined organics were concentrated and the residue was purified by silica gel chromatography with 0% to 5% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) then triturated with Et 2 O to afford 95 mg (54%) of 2-(5,6-dichloro-indazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(4-cyano-piperidin-1-yl)-1-cyclopropyl-2-oxo-ethyl]-amide as a light yellow solid. MS: (M+Na) + =559; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.91 (br. s., 1H), 8.91 (s, 1H), 8.79 (s, 1H), 8.44 (s, 1H), 8.41 (d, J=7.9 Hz, 1H), 8.29 (d, J=7.9 Hz, 1H), 8.18 (s, 1H), 4.77 (t, J=7.6 Hz, 1H), 3.59-3.86 (m, 2H), 3.32-3.46 (m, 1H), 2.95-3.05 (m, 2H), 1.45-1.92 (m, 4H), 1.24 (br. s., 1H), 0.32-0.48 (m, 4H).

2-(5-Chloroindazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-Iodo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a 5 mL microwave vial were placed copper(I) iodide (6 mg, 0.03 mmol), sodium iodide (133 mg, 0.89 mmol), 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (150 mg, 0.30 mmol), 1,4-dioxane (1 mL) and trans-N,N′-dimethylcyclohexane-1,2-diamine (9 mg, 0.06 mmol). The vial was purged with a stream of nitrogen then sealed and heated in an oil bath at 110° C. for 48 h. The reaction mixture was cooled to room temperature and quenched with sat'd aqueous NH 4 OH (3 mL) then diluted with water and extracted with CH 2 Cl 2 . The organics were dried over MgSO 4 and concentrated to afford 2-iodo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a maroon oil which was used without further purification.

2-(5-Chloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a 5 mL microwave vial were placed copper(I) iodide (6 mg, 0.033 mmol), K 3 PO 4 (132 mg, 0.62 mmol), 5-chloro-1H-indazole (54 mg, 0.36 mmol), 2-iodo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (164 mg, 0.30 mmol), toluene (1.2 mL), and trans-N,N′-dimethylcyclohexane-1,2-diamine (9 mg, 0.066 mmol). The vial was purged with a stream of nitrogen then sealed and heated in an oil bath at 110° C. for 24 h. The reaction mixture was cooled to room temperature and diluted with EtOAc then filtered over a Buchner funnel, rinsing with EtOAc. The filtrate was concentrated and the resultant residue was purified by silica gel chromatography with 50% to 80% EtOAc/hexanes to afford 100 mg (58%) of 2-(5-chloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow foam.

2-(5-Chloroindazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-(5-chloro-indazol-1-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (100 mg, 0.17 mmol) in CH 2 Cl 2 (4 mL) was added TFA (2.0 mL, 26.0 mmol). The yellow reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (4 mL) and ethylenediamine (0.4 mL, 5.92 mmol) was added. The reaction mixture was stirred at room temperature for 0.5 h then quenched with water and extracted with CH 2 Cl 2 (3×). The combined organics were concentrated and the residue was triturated with EtOAc to afford 45 mg (58%) of 2-(5-chloroindazol-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow solid. MS: (M+Na) + =471; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.88 (s, 1H), 8.95 (s, 1H), 8.72 (dd, J=9.1, 4.5 Hz, 1H), 8.36-8.43 (m, 2H), 7.99-8.07 (m, 1H), 7.94 (d, J=1.9 Hz, 1H), 7.41-7.52 (m, 1H), 4.36-4.66 (m, 3H), 4.06-4.18 (m, 1H), 3.94-4.04 (m, 1H), 3.66-3.81 (m, 1H), 1.26 (t, J=6.0 Hz, 3H).

2-(1,6,6-Trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-[1-Hydroxy-meth-(Z)-ylidene]-5,5-dimethyl-cyclohexanone

To a suspension of sodium hydride (60% dispersion in mineral oil, 475 mg, 11.9 mmol) in diethyl ether (25 mL) at 0° C. was added ethanol (0.06 ml, 1.03 mmol) dropwise. The grey suspension was stirred at 0° C. for 20 min. A solution of 3,3-dimethylcyclohexanone (1.50 g, 11.9 mmol) and ethyl formate (1.45 ml, 17.8 mmol) in diethyl ether (3 mL) was added dropwise over 10 min. The yellow heterogeneous reaction mixture was stirred at 0° C. for 1 h then warmed to room temperature and stirred for 2 h. Ethanol (1 mL) was added and the mixture was stirred at room temperature for 1 h then quenched with water (25 mL). The layers were separated and the aqueous phase was washed with diethyl ether. The aqueous layer was acidified with 1M HCl until pH=2 and then extracted with diethyl ether (2×). The combined organic layers were dried over MgSO 4 and concentrated to afford 1.64 g (90%) of 2-[1-hydroxy-meth-(Z)-ylidene]-5,5-dimethyl-cyclohexanone as a light yellow oil. 1 H NMR (CDCl 3 , 400 MHz): δ (ppm) 14.38 (br. s., 1H), 8.79 (s, 1H), 2.34-2.47 (m, 2H), 2.16 (s, 2H), 1.42-1.53 (m, 2H), 1.00 (s, 6H).

6,6-Dimethyl-4,5,6,7-tetrahydro-1H-indazole

To a solution of 2-[1-hydroxy-meth-(Z)-ylidene]-5,5-dimethyl-cyclohexanone (1.64 g, 10.6 mmol) in MeOH (10 mL) was added hydrazine (0.33 mL, 10.6 mmol) dropwise. The exothermic reaction was controlled by intermitant use of an ice bath. The yellow reaction mixture was stirred at room temperature for 30 min then concentrated. The residue was dissolved in CH 2 Cl 2 and washed with water. The organic layer was dried over MgSO 4 and concentrated to afford 1.53 g (96%) of 6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole as a yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.32 (s, 1H), 2.55 (t, J=6.4 Hz, 2H), 2.44 (s, 2H), 1.53 (t, J=6.4 Hz, 2H), 1.01 (s, 6H).

3-Iodo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole

To a solution of 6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole (0.50 g, 3.33 mmol) in DMF (8 mL) at room temperature was added powdered potassium hydroxide (560 mg, 10.0 mmol) and iodine (1.69 g, 6.66 mmol). The maroon reaction mixture was stirred at room temperature for 45 min then quenched with 10% aqueous Na 2 S 2 O 3 , diluted with water and extracted with EtOAc (2×). The combined organics were washed with water (3×), dried over MgSO 4 and concentrated to afford 920 mg (99%) of 3-iodo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole as a light yellow waxy solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 2.44 (s, 2H), 2.35 (t, J=6.4 Hz, 2H), 1.55 (t, J=6.4 Hz, 2H), 1.01 (s, 6H).

3-Iodo-1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazole and 3-Iodo-2,6,6-trimethyl-4,5,6,7-tetrahydro-2H-indazole

To a solution of 3-iodo-6,6-dimethyl-4,5,6,7-tetrahydro-1H-indazole (919 mg, 3.33 mmol) in THF (8 mL) at 0° C. was added KOt-Bu (523 mg, 4.66 mmol). The reaction mixture was stirred at 0° C. for 30 min then iodomethane (0.29 mL, 4.66 mmol) was added. The reaction mixture was stirred at 0° C. for 30 min then warmed to room temperature and stirred for 1.5 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were dried over MgSO 4 and concentrated. The residue was absorbed onto SiO 2 and purified by chromatography with 10% to 20% EtOAc/hexanes to afford 523 mg (54%) of 3-iodo-1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazole as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 3.72 (s, 3H), 2.33 (t, J=6.4 Hz, 2H), 2.29 (s, 2H), 1.51 (t, J=6.4 Hz, 2H), 1.02 (s, 6H). Also isolated 160 mg (17%) of 3-iodo-2,6,6-trimethyl-4,5,6,7-tetrahydro-2H-indazole as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 3.87 (s, 3H), 2.41 (s, 2H), 2.36 (t, J=6.6 Hz, 2H), 1.54 (t, J=6.6 Hz, 2H), 1.00 (s, 6H).

1,6,6-Trimethyl-3-tributylstannanyl-4,5,6,7-tetrahydro-1H-indazole

To a solution of 3-iodo-1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazole (0.150 g, 0.49 mmol) in THF (3 mL) at 0° C. was slowly added isopropylmagnesium chloride (2.0 M in THF) (0.30 mL, 0.59 mmol). The reaction mixture was stirred at 0° C. for 20 min then tributylchlorostannane (0.16 mL, 0.59 mmol) was added dropwise. The reaction mixture was stirred at 0° C. for 30 min then warmed to room temperature and stirred for 1 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 0% to 10% EtOAc/hexanes (0.5% Et 3 N) to afford 116 mg (52%) of 1,6,6-trimethyl-3-tributylstannanyl-4,5,6,7-tetrahydro-1H-indazole as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 3.74 (s, 3H), 2.49 (t, J=6.4 Hz, 2H), 2.30 (s, 2H), 1.45-1.61 (m, 8H), 1.25-1.41 (m, 6H), 1.04-1.13 (m, 6H), 1.01 (s, 6H), 0.89 (t, J=7.2 Hz, 9H).

5-(2-Trimethylsilanyl-ethoxymethyl)-2-(1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 1,6,6-trimethyl-3-tributylstannyl-4,5,6,7-tetrahydro-1H-indazole (110 mg, 0.24 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (95 mg, 0.19 mmol) in DMF (2 mL) were added Pd(PPh 3 ) 4 (11 mg, 0.01 mmol) and copper(I) iodide (7 mg, 0.037 mmol). The reaction mixture was heated at 90° C. for 2 h then cooled to room temperature and stirred overnight. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The crude brown oil was purified by silica gel chromatography with 0% to 3% MeOH/CH 2 Cl 2 to afford 43 mg (38%) of 5-(2-trimethylsilanyl-ethoxymethyl)-2-(1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a pale orange foam.

2-(1,6,6-Trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 5-(2-trimethylsilanyl-ethoxymethyl)-2-(1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (40 mg, 0.068 mmol) in CH 2 Cl 2 (3 mL) was added TFA (1.5 mL, 19.5 mmol). The yellow reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (3 mL) and ethylenediamine (0.3 mL, 4.44 mmol) was added. The reaction mixture was stirred at room temperature for 0.5 h then quenched with water and extracted with CH 2 Cl 2 (3×). The combined organics were concentrated to a yellow oily solid. Trituration with EtOAc/Et 2 O gave 17 mg (55%) of 2-(1,6,6-trimethyl-4,5,6,7-tetrahydro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as an off-white solid. MS (M+H) + =461; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 8.94 (d, J=2.0 Hz, 1H), 8.34-8.44 (m, 2H), 4.46-4.74 (m, 3H), 4.10-4.21 (m, 1H), 4.02 (dd, J=9.9, 6.4 Hz, 1H), 3.78-3.86 (m, 1H), 3.77 (s, 3H), 2.98-3.08 (m, 1H), 2.85-2.94 (m, 1H), 2.45 (s, 2H), 1.52 (t, J=6.4 Hz, 2H), 1.29-1.39 (m, 3H), 1.03 (s, 6H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(1-methanesulfonyl-azetidin-3-yl)-ethyl]-amide

3-{[(E)-2-Methyl-propane-2-sulfinylimino]-methyl}-azetidine-1-carboxylic acid tert-butyl ester

To a solution of 3-formyl-azetidine-1-carboxylic acid tert-butyl ester (1.0 g, 5.4 mmol) and 2-methylpropane-2-sulfinamide (654 mg, 5.4 mmol) in dry CH 2 Cl 2 (10 mL) was added anhydrous CuSO 4 (1.9 g, 11.9 mmol). The heterogeneous reaction mixture was stirred at room temperature overnight then filtered over Celite, rinsing with CH 2 Cl 2 . The filtrate was concentrated and the resultant residue was absorbed onto SiO 2 and purified by column chromatography with 20% to 40% EtOAc/hexanes to provide 1.26 g (81%) of 3-{[(E)-2-methyl-propane-2-sulfinylimino]-methyl}-azetidine-1-carboxylic acid tert-butyl ester as a white solid.

1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.20 (d, J=4.5 Hz, 1H), 4.14-4.23 (m, 2H), 4.00-4.13 (m, 2H), 3.53-3.65 (m, 1H), 1.45 (s, 9H), 1.21 (s, 9H).

3-[1-(2-Methyl-propane-2-sulfinylamino)-ethyl]-azetidine-1-carboxylic acid tert-butyl ester

To a solution of 3-{[(E)-2-methyl-propane-2-sulfinylimino]-methyl}-azetidine-1-carboxylic acid tert-butyl ester (0.25 g, 0.87 mmol) in CH 2 Cl 2 (4 mL) at 0° C. was added dropwise methylmagnesium bromide (3.0 M in Et 2 O, 0.35 mL, 1.04 mmol). The reaction mixture was stirred at 0° C. for 1 h then quenched with saturated aqueous NH 4 Cl, diluted with water and extracted with EtOAc (2×). The combined organics were dried over MgSO 4 and concentrated to afford 273 mg of 3-[1-(2-methyl-propane-2-sulfinylamino)-ethyl]-azetidine-1-carboxylic acid tert-butyl ester as an off-white foamy solid which was used without further purification.

3-(1-Amino-ethyl)-azetidine-1-carboxylic acid tert-butyl ester

To a solution 3-[1-(2-methyl-propane-2-sulfinylamino)-ethyl]-azetidine-1-carboxylic acid tert-butyl ester (crude from step 2, 264 mg, 0.87 mmol) in MeOH at 0° C. was added 4.0 M HCl in dioxane (0.28 mL, 1.13 mmol) dropwise. The reaction mixture was stirred at 0° C. for 1 h then quenched with saturated aqueous NaHCO 3 , diluted with water and extracted with CH 2 Cl 2 (3×). The combined organics were dried over MgSO 4 and concentrated to afford 3-(1-amino-ethyl)-azetidine-1-carboxylic acid tert-butyl ester as a thick colorless oil which was used without further purification.

3-(1-{[2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-azetidine-1-carboxylic acid tert-butyl ester

To a solution of 3-(1-amino-ethyl)-azetidine-1-carboxylic acid tert-butyl ester (crude from step 3, 63 mg, 0.31 mmol) in DMF (2 mL) were added N,N-diisopropylethylamine (69 μL, 0.39 mmol), 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.26 mmol), and HATU (110 mg, 0.29 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 30% to 60% EtOAc/hexanes to afford 158 mg (94%) of 3-(1-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-azetidine-1-carboxylic acid tert-butyl ester as a white foam. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 9.23 (s, 1H), 8.36 (t, J=4.3 Hz, 2H), 8.18 (d, J=9.1 Hz, 1H), 7.52 (s, 1H), 7.24-7.29 (m, 1H), 5.73 (s, 2H), 4.57-4.68 (m, 1H), 4.18 (s, 3H), 3.87-4.08 (m, 3H), 3.79 (dd, J=8.7, 6.0 Hz, 1H), 3.55-3.65 (m, 2H), 2.73 (br. s., 1H), 1.39 (s, 9H), 1.36 (d, J=6.8 Hz, 6H), 0.89-1.01 (m, 2H), −0.03 (s, 9H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-azetidin-3-yl-ethyl)-amide hydrochloride

To a solution of 3-(1-{[2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-azetidine-1-carboxylic acid tert-butyl ester (150 mg, 0.23 mmol) in MeOH (4 mL) at 0° C. was added acetyl chloride (0.33 mL, 4.69 mmol) dropwise over 5 min. The reaction mixture was stirred at room temperature for 1 h as a thick precipitate gradually formed. The solvent was evaporated at room temperature and the residue was dried under high vacuum to isolate 145 mg of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-azetidin-3-yl-ethyl)-amide hydrochloride as a yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(1-methanesulfonyl-azetidin-3-yl)-ethyl]-amide

To a suspension of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1-azetidin-3-yl-ethyl)-amide hydrochloride (65 mg, 0.11 mmol) in CH 2 Cl 2 (2 mL) at 0° C. was added triethylamine (47 μL, 0.33 mmol) followed by methanesulfonyl chloride (10 μL, 0.12 mmol). The reaction mixture was stirred at 0° C. for 30 min then at room temperature for 1 h. The reaction was quenched with water and extracted with CH 2 Cl 2 . The combined organics were dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 0% to 5% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) to afford 35 mg (50%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(1-methanesulfonyl-azetidin-3-yl)-ethyl]-amide as a pale yellow solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(1-methanesulfonyl-azetidin-3-yl)-ethyl]-amide

To a solution of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(1-methanesulfonyl-azetidin-3-yl)-ethyl]-amide (30 mg, 0.049 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.3 mL, 3.89 mmol). The yellow reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylenediamine (0.3 mL, 4.49 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and extracted with MeOH/CH 2 Cl 2 (1:9). The organic layer was washed with water and the aqueous was back-extracted with CH 2 Cl 2 . The combined organics were concentrated and the residue was triturated with MeOH/EtOAc/Et 2 O to afford 15 mg (63%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(1-methanesulfonyl-azetidin-3-yl)-ethyl]-amide as a pale yellow solid. MS (M+H) + =488; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.05 (br. s., 1H), 8.86 (s, 1H), 8.63 (s, 1H), 8.41 (d, J=8.7 Hz, 1H), 7.92 (s, 1H), 7.26 (d, J=8.7 Hz, 1H), 4.35-4.45 (m, 1H), 4.22-4.33 (m, 1H), 4.12 (s, 3H), 4.04-4.10 (m, 1H), 3.62-3.74 (m, 1H), 3.45-3.58 (m, 1H), 3.25 (s, 3H), 2.57-2.68 (m, 1H), 1.38 (d, J=6.8 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-amide

((R)-1-Methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-carbamic acid tert-butyl ester

To a solution of (R)-3-tert-butoxycarbonylamino-butyric acid (150 mg, 0.74 mmol) and HATU (309 mg, 0.81 mmol) in DMF (2 mL) was added pyrrolidine (0.19 mL, 2.21 mmol). The resultant yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (2×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated to afford ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-carbamic acid tert-butyl ester as a colorless oil which was used without further purification.

(R)-3-Amino-1-pyrrolidin-1-yl-butan-1-one trifluoroacetate

To a solution of ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-carbamic acid tert-butyl ester (crude from step 1, 189 mg, 0.74 mmol) in CH 2 Cl 2 (5 mL) was added trifluoroacetic acid (2.0 mL, 27.0 mmol). The reaction mixture was stirred at room temperature for 2 h then concentrated to give (R)-3-amino-1-pyrrolidin-1-yl-butan-1-one trifluoroacetate as a pale yellow oil which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-amide

To a solution of (R)-3-amino-1-pyrrolidin-1-yl-butan-1-one trifluoroacetate (crude from step 2, 118 mg, 0.44 mmol) in DMF (2 mL) were added N,N-diisopropylethylamine (0.19 mL, 1.09 mmol), 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.22 mmol), and HATU (91 mg, 0.24 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% to 100% EtOAc/hexanes to afford 125 mg (96%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-amide as a white solid.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-amide

To a solution of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-amide (125 mg, 0.21 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.5 mL, 6.49 mmol). The yellow reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylenediamine (0.4 mL, 6.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water. The resultant precipitate was collected via filtration and washed with water and EtOAc. The solid was dissolved in 10% MeOH/CH 2 Cl 2 and washed with water. The aqueous layer was back-extracted with CH 2 Cl 2 . The combined organics were dried over MgSO 4 and concentrated to afford 64 mg (66%) of 2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-3-oxo-3-pyrrolidin-1-yl-propyl)-amide as an off-white solid. MS: (M+H) + =466; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.07 (s, 1H), 8.57 (d, J=8.7 Hz, 1H), 8.41 (s, 1H), 8.26 (d, J=7.9 Hz, 1H), 7.97 (d, J=1.1 Hz, 1H), 7.28 (dd, J=8.7, 1.5 Hz, 1H), 4.36-4.54 (m, 1H), 4.16 (s, 3H), 3.40 (t, J=6.6 Hz, 2H), 3.10-3.25 (m, 2H), 2.52-2.76 (m, 2H), 1.61-1.90 (m, 4H), 1.38 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide

cis-3-Hydroxy-cyclobutanecarbonitrile

3-Oxocyclobutanecarbonitrile was prepared according to Elend, D.; Fengas, D.; Fray, J. M. Synthetic Communications, 2005, 35, 657. To a solution of 3-oxocyclobutanecarbonitrile (600 mg, 6.31 mmol) in MeOH (25 mL) at 0° C. was slowly added sodium borohydride (263 mg, 6.94 mmol). The reaction mixture was stirred at 0° C. for 1 h then quenched with water and brine and extracted with EtOAc (3×). The combined organics were dried over MgSO 4 and concentrated to afford 500 mg (82%) of cis-3-hydroxy-cyclobutanecarbonitrile as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 4.26 (quin, J=7.5 Hz, 1H), 2.70-2.82 (m, 2H), 2.50-2.66 (m, 1H), 2.26-2.41 (m, 2H), 2.09 (br. s., 1H).

cis-3-(tert-Butyldimethylsilanyloxy)-cyclobutanecarbonitrile

To a solution of cis-3-hydroxy-cyclobutanecarbonitrile (500 mg, 5.15 mmol in DMF (3 mL) at room temperature was added imidazole (876 mg, 12.9 mmol) followed by TBDMS-Cl (854 mg, 5.66 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (2×). The combined organics were washed with water (3×), dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 0% to 10% EtOAc/hexanes to afford 890 mg (82%) of cis-3-(tert-butyldimethylsilanyloxy)-cyclobutanecarbonitrile as a colorless oil. 1 H NMR (CDCl 3 , 400 MHz): δ (ppm) 4.10-4.19 (m, 1H), 2.57-2.67 (m, 2H), 2.43-2.54 (m, 1H), 2.22-2.34 (m, 2H), 0.84 (s, 9H), 0.00 (s, 6H).

cis-3-(tert-Butyldimethylsilanyloxy)-cyclobutanecarbaldehyde

To a solution of cis-3-(tert-butyldimethylsilyloxy)cyclobutanecarbonitrile (0.89 g, 4.21 mmol in CH 2 Cl 2 (25 mL) at −70° C. was slowly added DIBAL-H (1.05 mL, 5.89 mmol). The reaction mixture was stirred for 2.5 h as the temperature gradually rose to 0° C. The cloudy reaction mixture was quenched with MeOH (1 mL) then diluted with CH 2 Cl 2 (20 mL) and saturated aqueous Na+ K+ tartrate (25 mL) was added. The biphasic mixture was stirred vigorously at room temperature for 1 h. The layers were separated and the aqueous phase was extracted with CH 2 Cl 2 (2×). The combined organics were dried over MgSO 4 and concentrated to give cis-3-(tert-butyldimethylsilanyloxy)-cyclobutanecarbaldehyde as a colorless oil which was used without further purification.

2-Methyl-propane-2-sulfinic acid 1-[cis-3-(tert-butyldimethylsilanyloxy)-cyclobutyl]-meth-(E)-ylideneamide

To a solution of cis-3-(tert-butyldimethylsilanyloxy)-cyclobutanecarbaldehyde (crude from step 3, 900 mg, 4.2 mmol) and 2-methylpropane-2-sulfinamide (509 mg, 4.2 mmol) in dry CH 2 Cl 2 (10 mL) was added anhydrous CuSO 4 (1.47 g, 9.24 mmol). The heterogeneous reaction mixture was stirred at room temperature overnight then filtered over Celite, rinsing with CH 2 Cl 2 . The filtrate was absorbed onto SiO 2 and purified via chromatography with 0% to 20% EtOAc/hexanes to isolate 642 mg (48%) of 2-methyl-propane-2-sulfinic acid 1-[cis-3-(tert-butyldimethylsilanyloxy)-cyclobutyl]-meth-(E)-ylideneamide as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.04 (d, J=5.3 Hz, 1H), 4.25 (quin, J=7.4 Hz, 1H), 2.73-2.88 (m, 1H), 2.46-2.59 (m, 2H), 2.06-2.18 (m, 2H), 1.19 (s, 9H), 0.89 (s, 9H), 0.05 (s, 6H).

2-Methyl-propane-2-sulfinic acid {1-[cis-3-(tert-butyl-dimethyl-silanyloxy)-cyclobutyl]-ethyl}-amide

To a solution of 2-methyl-propane-2-sulfinic acid 1-[cis-3-(tert-butyldimethylsilanyloxy)-cyclobutyl]-meth-(E)-ylideneamide (640 mg, 2.02 mmol) in CH 2 Cl 2 (10 mL) at 0° C. was slowly added methylmagnesium bromide (3.0 M in Et 20 , 1.14 mL, 3.43 mmol). The reaction mixture was stirred at 0° C. for 1 h then quenched with saturated aqueous NH 4 Cl, diluted with water and extracted with EtOAc (3×). The combined organics were dried over MgSO 4 and concentrated to provide 685 mg of 2-methyl-propane-2-sulfinic acid {1-[cis-3-(tert-butyl-dimethyl-silanyloxy)-cyclobutyl]-ethyl}-amide as an off-white waxy solid which was used without further purification. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 4.05-4.18 (m, 1H), 3.16-3.31 (m, 1H), 2.85 (d, J=7.2 Hz, 1H), 2.21-2.44 (m, 2H), 1.59-1.76 (m, 3H), 1.20 (s, 9H), 1.18 (d, J=6.0 Hz, 3H), 0.88 (s, 9H), 0.03 (s, 6H).

cis-3-(1-Aminoethyl)-cyclobutanol hydrochloride

To a solution of 2-methyl-propane-2-sulfinic acid {1-[cis-3-(tert-butyl-dimethyl-silanyloxy)-cyclobutyl]-ethyl}-amide (200 mg, 0.60 mmol) in MeOH (3 mL) was added hydrogen chloride (4.0M in 1,4-dioxane, 0.30 mL, 1.2 mmol). The reaction mixture was stirred at room temperature for 20 min then concentrated to afford cis-3-(1-aminoethyl)-cyclobutanol hydrochloride as an off-white semisolid which was used without further purification. 1 H NMR (METHANOL-d 4 , 300 MHz): δ (ppm) 4.09 (quind, J=7.5, 3.8 Hz, 1H), 3.17 (dt, J=6.0, 3.0 Hz, 1H), 2.36-2.56 (m, 2H), 1.78-1.96 (m, 1H), 1.59-1.77 (m, 2H), 1.22 (dd, J=6.8, 3.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide

To a solution of cis-3-(1-aminoethyl)-cyclobutanol hydrochloride (crude from step 6, 91 mg, 0.60 mmol) in DMF (2 mL) were added N,N-diisopropylethylamine (0.24 mL, 1.36 mmol), 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.27 mmol), and HATU (114 mg, 0.30 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated to a pale yellow solid. Trituration with EtOAc/Et 2 O gave 108 mg (74%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide as a white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide (60 mg, 0.11 mmol) in CH 2 Cl 2 (2 mL) was added TFA (1 mL, 13.0 mmol). The bright yellow-orange reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylene diamine (0.4 mL, 6.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and diluted with CH 2 Cl 2 . A very fine precipitate formed which was collected via filtration. This solid was taken up in MeOH/CH 2 Cl 2 (200 mL) and filtered again, rinsing with MeOH/CH 2 Cl 2 . The filtrate was concentrated and triturated with EtOAc/MeOH to afford 28 mg (62%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide as a light yellow solid. MS: (M+H) + =409; 1 H NMR (DMSO-d 6 ,300 MHz): δ (ppm) 9.08 (s, 1H), 8.37-8.48 (m, 2H), 7.96 (d, J=8.7 Hz, 1H), 7.70 (dd, J=9.8, 1.9 Hz, 1H), 7.18 (td, J=9.1, 2.3 Hz, 1H), 4.92 (br. s., 1H), 4.14 (s, 3H), 4.04-4.13 (m, 1H), 3.87 (br. s., 1H), 2.14-2.34 (m, 2H), 1.78-1.93 (m, 1H), 1.58 (quin, J=9.8 Hz, 2H), 1.19 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-cyanocyclobutyl)-ethyl]-amide

Methanesulfonic acid cis-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester

To a partial suspension of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide (100 mg, 0.19 mmol) in CH 2 Cl 2 (3 mL) at 0° C. was added triethylamine (39 μL, 0.28 mmol) followed by methanesulfonyl chloride (16 μL, 0.21 mmol). The reaction mixture was stirred at 0° C. for 1 h then quenched with water and extracted with CH 2 Cl 2 . The organics were dried over MgSO 4 and concentrated to give methanesulfonic acid cis-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester as an off-white foam which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-cyano-cyclobutyl)-ethyl]-amide

To a solution of methanesulfonic acid cis-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester (crude from step 1, 114 mg, 0.19 mmol) in DMSO (1.5 mL) at room temperature was added potassium cyanide (48 mg, 0.74 mmol). The reaction mixture was heated at 60° C. for 2.5 h. 18-Crown-6 (10 mg, 0.04 mmol) was added and heated was continued at 80° C. for 2 h then at 100° C. overnight. The reaction was cooled to room temperature, quenched with water, and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified via chromatography with 30% to 50% EtOAc/hexanes to isolate 46 mg (45%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-cyano-cyclobutyl)-ethyl]-amide as a yellow foam.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-cyanocyclobutyl)-ethyl]-amide

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-cyano-cyclobutyl)-ethyl]-amide (44 mg, 0.08 mmol) in CH 2 Cl 2 (2 mL) was added TFA (1 mL, 13.0 mmol). The bright yellow-orange reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylene diamine (0.4 mL, 6.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and extracted with 5% MeOH/CH 2 Cl 2 (2×). The combined organics were concentrated and the residue was triturated with EtOAc to afford 19 mg (57%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-cyanocyclobutyl)-ethyl]-amide as a light yellow solid. MS: (M+H) + =418; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.08 (s, 1H), 8.43 (s, 1H), 8.40 (dd, J=8.9, 5.5 Hz, 1H), 7.96 (d, J=9.1 Hz, 1H), 7.70 (dd, J=9.8, 2.3 Hz, 1H), 7.29 (td, J=9.1, 1.9 Hz, 1H), 4.19-4.31 (m, 1H), 4.14 (s, 3H), 2.64-2.77 (m, 2H), 2.34-2.45 (m, 1H), 2.22-2.33 (m, 3H), 1.18 (d, J=6.4 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-hydroxy-cyclobutyl)-ethyl]-amide

4-Nitrobenzoic acid trans-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide (200 mg, 0.37 mmol) in THF (4 mL) was added 4-nitrobenzoic acid (124 mg, 0.74 mmol) and triphenylphosphine (204 mg, 0.78 mmol). Then the reaction mixture was cooled to 0° C. and diethyl azodicarboxylate (123 μL, 0.78 mmol) was added dropwise. The reaction was stirred at room temperature overnight then diluted with CH 2 Cl 2 (25 mL) and washed with 1.0 M aqueous NaOH. The aqueous phase was back-extracted with CH 2 Cl 2 then the combined organics were dried over MgSO 4 and concentrated. The residue was absorbed onto SiO 2 and purified via chromatography with 20% to 80% EtOAc/hexanes to provide 250 mg (98%) of 4-nitrobenzoic acid trans-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester as a white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-hydroxy-cyclobutyl)-ethyl]-amide

To a suspension of 4-nitrobenzoic acid trans-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester (250 mg, 0.36 mmol) in THF (12 mL) was added 10% aqueous sodium hydroxide (0.44 mL, 1.09 mmol), water (1 mL), and MeOH (2 mL). The reaction mixture was stirred at room temperature for 30 min then diluted with water and extracted with CH 2 Cl 2 (3×). The combined organics were dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 30% to 80% EtOAc/hexanes to afford 140 mg (72%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-hydroxy-cyclobutyl)-ethyl]-amide as an off-white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-hydroxy-cyclobutyl)-ethyl]-amide

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-hydroxy-cyclobutyl)-ethyl]-amide (50 mg, 0.09 mmol) in CH 2 Cl 2 (2 mL) was added TFA (1 mL, 13.0 mmol). The bright yellow-orange reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylene diamine (0.4 mL, 6.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and extracted with 5% MeOH/CH 2 Cl 2 (2×). The combined organics were concentrated and triturated with EtOAc to afford 19 mg (50%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-hydroxy-cyclobutyl)-ethyl]-amide as a light yellow solid. MS: (M+H) + =409; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.09 (s, 1H), 8.42 (s, 1H), 8.39 (dd, J=8.7, 5.3 Hz, 1H), 7.94 (d, J=8.7 Hz, 1H), 7.71 (dd, J=9.6, 2.1 Hz, 1H), 7.26 (td, J=9.1, 1.9 Hz, 1H), 4.96 (br. s., 1H), 4.14 (s, 3H), 4.07-4.26 (m, 2H), 2.23-2.41 (m, 1H), 1.98-2.19 (m, 3H), 1.84-1.98 (m, 1H), 1.20 (d, J=6.4 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-cyanocyclobutyl)-ethyl]-amide

Methanesulfonic acid trans-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester

To a partial suspension of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(trans-3-hydroxy-cyclobutyl)-ethyl]-amide (85 mg, 0.16 mmol) in CH 2 Cl 2 (3 mL) at 0° C. was added triethylamine (33 μL, 0.24 mmol) followed by methanesulfonyl chloride (14 μL, 0.18 mmol). The reaction mixture was stirred at 0° C. for 1 h then quenched with water and extracted with CH 2 Cl 2 . The organics were dried over MgSO 4 and concentrated to give methanesulfonic acid trans-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester as an off-white foam which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-cyano-cyclobutyl)-ethyl]-amide

To a solution of methanesulfonic acid trans-3-(1-{[2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbonyl]-amino}-ethyl)-cyclobutyl ester (crude from step 1, 97 mg, 0.16 mmol) in DMSO (1.5 mL) at room temperature was added potassium cyanide (41 mg, 0.63 mmol) and 18-crown-6 (8 mg, 0.03 mmol). The reaction mixture was heated at 100° C. overnight then cooled to room temperature, quenched with water, and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified via chromatography with 20% to 50% EtOAc/hexanes to isolate 34 mg (40%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-cyano-cyclobutyl)-ethyl]-amide as a yellow foam.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-cyanocyclobutyl)-ethyl]-amide

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-cyano-cyclobutyl)-ethyl]-amide (34 mg, 0.06 mmol) in CH 2 Cl 2 (2 mL) was added TFA (1 mL, 13.0 mmol). The bright yellow-orange reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylene diamine (0.4 mL, 6.0 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then concentrated directly purified via silica gel chromatography with 50% to 100% EtOAc/hexanes to 5% MeOH/EtOAc to afford 15 mg (58%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [1-(cis-3-cyanocyclobutyl)-ethyl]-amide as a white solid. MS: (M+H) + =418; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.86 (br. s., 1H), 9.08 (s, 1H), 8.44 (s, 1H), 8.40 (dd, J=9.1, 5.3 Hz, 1H), 7.98 (d, J=8.7 Hz, 1H), 7.70 (dd, J=9.8, 1.9 Hz, 1H), 7.25 (td, J=9.0, 2.1 Hz, 1H), 4.17-4.28 (m, 1H), 4.14 (s, 3H), 3.20 (t, J=8.7 Hz, 1H), 2.30-2.46 (m, 3H), 2.04-2.20 (m, 2H), 1.18 (d, J=6.8 Hz, 3H).

2-Isoquinolin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-Isoquinolin-1-yl-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of hexamethylditin (90 mg, 0.28 mmol) and 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (100 mg, 0.20 mmol) in toluene (2 mL) was added Pd(Ph 3 P) 4 (23 mg, 0.02 mmol). A stream of nitrogen gas was gently bubbled through the reaction mixture for 15 min then it was heated to 95° C. After 1.5 h 1-iodoisoquinoline (50 mg, 0.20 mmol) and Pd(Ph 3 P) 4 (23 mg, 0.02 mmol) were added as solids in one portion. Heating was continued at 95° C. for 1.5 h and additional 1-iodoisoquinoline (25 mg, 0.10 mmol), DMF (0.5 mL) and copper (I) iodide (5 mg) were added. The reaction mixture was heated at 95° C. overnight. Additional 1-iodoquinoline (25 mg, 0.10 mmol) and Pd(Ph 3 P) 4 (23 mg, 0.02 mmol) were added and heating was continued for 8 h. The reaction was cooled to room temperature, quenched with water, and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine, then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 30% to 80% EtOAc/hexanes to afford 52 mg (48%) of 2-isoquinolin-1-yl-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a yellow foam.

2-Isoquinolin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-isoquinolin-1-yl-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (52 mg, 0.094 mmol) in CH 2 Cl 2 (2 mL) was added TFA (1 mL, 13.0 mmol). The reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylene diamine (0.4 mL, 6.0 mmol) was added. The reaction mixture was stirred for 1 h then quenched with water and extracted with CH 2 Cl 2 . The combined organics were concentrated and the residue was purified by silica gel chromatography with 0% to 5% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) to afford 17 mg (43%) of 2-isoquinolin-1-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as an off-white solid. MS (M+H) + =426; mp=180-185° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.02 (br. s., 1H), 9.09 (s, 1H), 8.91 (d, J=8.7 Hz, 1H), 8.68 (d, J=5.7 Hz, 1H), 8.55 (d, J=9.1 Hz, 1H), 8.44 (d, J=7.6 Hz, 1H), 8.09 (d, J=7.9 Hz, 1H), 7.98 (d, J=5.7 Hz, 1H), 7.84 (t, J=7.6 Hz, 1H), 7.66-7.77 (m, 1H), 4.40-4.70 (m, 3H), 4.12 (q, J=9.7 Hz, 1H), 3.93-4.04 (m, 1H), 3.74-3.88 (m, 1H), 1.22 (t, J=6.6 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide hydrochloride

(R)-2-Methyl-propane-2-sulfinic acid ((R)-1-pyridin-2-yl-ethyl)-amide

The title compound was prepared from pyridine-2-carboxaldehyde according to the procedure outlined by Kuduk, et. al. Tetrahedron Lett. 2004, 45, 6641. The product was obtained as a 10:1 mixture favoring the R S R diastereomer as judged by NMR which is in agreement with the literature. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.55 (d, J=4.9 Hz, 1H), 7.66 (td, J=7.6, 1.7 Hz, 1H), 7.29 (d, J=7.6 Hz, 1H), 7.18 (dd, J=7.6, 4.9 Hz, 1H), 4.83 (d, J=4.9 Hz, 1H), 4.53-4.66 (m, 1H), 1.51 (d, J=6.8 Hz, 3H), 1.26 (s, 9H).

(R)-1-Pyridin-2-yl-ethylamine dihydrochloride

To a solution of (R)-2-methyl-propane-2-sulfinic acid ((R)-1-pyridin-2-yl-ethyl)-amide (1.10 g, 4.86 mmol) in MeOH (12 mL) was added 4.0 M hydrogen chloride in dioxane (3.04 mL, 12.1 mmol). The reaction mixture was stirred at room temperature for 30 min then concentrated and dried under high vacuum to afford 1.0 g of (R)-1-pyridin-2-yl-ethylamine dihydrochloride as a light yellow solid. 1 H NMR (METHANOL-d 4 , 300 MHz): δ (ppm) 8.80 (t, J=3.8 Hz, 1H), 8.32 (tdd, J=7.9, 4.5, 1.7 Hz, 1H), 7.88 (dd, J=7.9, 4.5 Hz, 1H), 7.72-7.83 (m, 1H), 4.78 (qd, J=6.9, 4.5 Hz, 1H), 1.73 (dd, J=6.9, 4.5 Hz, 3H). Assume 82% ee based on 10:1 dr of the starting material.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide

To a solution of (R)-1-pyridin-2-yl-ethylamine dihydrochloride (66 mg, 0.34 mmol) in DMF (2 mL) was added N,N-diisopropylethylamine (0.20 mL, 1.13 mmol), 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.23 mmol), and HATU (95 mg, 0.25 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% to 100% EtOAc/hexanes to give 117 mg (95%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide as a white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide hydrochloride

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide (117 mg, 0.21 mmol) in CH 2 Cl 2 (2 mL) was added TFA (1 mL, 13.0 mmol). The bright yellow-orange reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (2 mL) and ethylene diamine (0.5 mL, 7.50 mmol) was added. The reaction mixture was stirred for 1 h then chromatographed directly with 50% to 100% EtOAc/hexanes to 5% MeOH/EtOAc. The white solid thus isolated was triturated with EtOAc then suspended in CH 2 Cl 2 and MeOH (1:1, 6 mL). 1.0M HCl in MeOH (2 eq) was added which caused complete dissolution. The solution was concentrated and dried under high vacuum to afford 67 mg (69%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-pyridin-2-yl-ethyl)-amide hydrochloride as a light yellow solid. MS (M+H) + =416; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.93 (d, J=2.6 Hz, 1H), 9.13 (s, 1H), 8.83 (d, J=7.6 Hz, 1H), 8.73 (dd, J=8.9, 5.5 Hz, 1H), 8.59 (d, J=4.9 Hz, 1H), 8.44 (d, J=3.0 Hz, 1H), 8.07 (br. s., 1H), 7.76 (d, J=7.9 Hz, 1H), 7.68 (dd, J=9.6, 2.1 Hz, 1H), 7.53 (br. s., 1H), 7.05 (td, J=9.1, 1.9 Hz, 1H), 5.44 (quin, J=7.0 Hz, 1H), 4.15 (s, 3H), 1.67 (d, J=6.8 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide

(4-Trifluoromethyl-pyridin-2-yl)-methanol

To a solution of 4-trifluoromethyl-pyridine-2-carboxylic acid (500 mg, 2.62 mmol) in THF (20 mL) at 0° C. was added triethylamine (0.40 mL, 2.88 mmol) followed by ethyl chloroformate (0.28 mL, 2.88 mmol). A thick white precipitate formed. The reaction mixture was stirred at 0° C. for 15 min then a solution of sodium borohydride (297 mg, 7.85 mmol) in water (5 mL) was slowly added via pipet. Vigorous gas evolution was observed and all solids dissolved. The reaction was stirred at 0° C. for 10 min then warmed to room temperature and stirred for 1 h. The reaction was diluted with water and extracted with CH 2 Cl 2 (3×). The combined organics were dried over MgSO 4 and concentrated. The residue was purified by chromatography with 20% to 50% EtOAc/hexanes to afford 296 mg (64%) of (4-trifluoromethyl-pyridin-2-yl)-methanol as a colorless oil that freezes just below room temperature. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.76 (d, J=4.9 Hz, 1H), 7.55 (s, 1H), 7.45 (d, J=4.9 Hz, 1H), 4.87 (s, 2H).

4-Trifluoromethyl-pyridine-2-carbaldehyde

To a solution of (4-trifluoromethyl-pyridin-2-yl)-methanol (290 mg, 1.64 mmol) in CH 2 Cl 2 (15 mL) at room temperature was added Dess-Martin periodinane (764 mg, 1.8 mmol). The reaction mixture was stirred at room temperature for 1 h then quenched with saturated aqueous NaHCO 3 (10 mL) and 10% aqueous Na 2 S 2 O 3 (10 mL). The biphasic mixture was diluted with CH 2 Cl 2 and stirred vigorously for 10 min. The layers were separated and the aqueous layer was extracted with CH 2 Cl 2 . The combined organics were dried over MgSO 4 and concentrated to give 300 mg of 4-trifluoromethyl-pyridine-2-carbaldehyde as a pale yellow oil which was used without further purification. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.15 (s, 1H), 9.00 (d, J=5.3 Hz, 1H), 8.19 (s, 1H), 7.77 (dd, J=5.3, 1.3 Hz, 1H).

(R)-2-Methyl-propane-2-sulfinic acid 1-(4-trifluoromethyl-pyridin-2-yl)-meth-(E)-ylideneamide

To a solution of 4-trifluoromethyl-pyridine-2-carbaldehyde (287 mg, 1.64 mmol) and (R)-2-methylpropane-2-sulfinamide (209 mg, 1.72 mmol) in CH 2 Cl 2 (10 mL) was added anhydrous copper (II) sulfate (576 mg, 3.61 mmol). The reaction mixture was stirred at room temperature overnight then filtered over a Buchner funnel, rinsing with CH 2 Cl 2 . The filtrate was concentrated and the residue was absorbed on SiO 2 and purified by chromatography with 20% to 40% EtOAc/hexanes to give 340 mg (75%) of (R)-2-methyl-propane-2-sulfinic acid 1-(4-trifluoromethyl-pyridin-2-yl)-meth-(E)-ylideneamide as a pale yellow oil.

(R)-2-Methyl-propane-2-sulfinic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide

To a solution of (R)-2-methyl-propane-2-sulfinic acid 1-(4-trifluoromethyl-pyridin-2-yl)-meth-(E)-ylideneamide (0.34 g, 1.22 mmol) in THF (5 mL) at −78° C. was slowly added methylmagnesium bromide (3.0 M in Et 2 O) (0.73 mL, 2.2 mmol). The reaction mixture was stirred at −78° C. for 30 min then quenched cold with saturated aqueous NH 4 Cl. The mixture was warmed to room temperature, diluted with water, and extracted with EtOAc (2×). the combined organics were dried over MgSO 4 and concentrated. NMR analysis showed an approx 8:1 mixture of diastereomers. The residue was purified by chromatography with 50% to 100% EtOAc/hexanes to afford 225 mg (63%) of (R)-2-methyl-propane-2-sulfinic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide as a colorless oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.75 (d, J=5.3 Hz, 1H), 7.51 (s, 1H), 7.42 (d, J=5.3 Hz, 1H), 4.77 (d, J=4.9 Hz, 1H), 4.67 (quin, J=6.3 Hz, 1H), 1.55 (d, J=6.8 Hz, 3H), 1.27 (s, 9H). The single diastereomer obtained was assigned as R S R based on literature precedent (Kuduk, et. al. Tetrahedron Lett. 2004, 45, 6641).

(R)-1-(4-Trifluoromethyl-pyridin-2-yl)-ethylamine dihydrochloride

To a solution of (R)-2-methyl-propane-2-sulfinic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide (225 mg, 0.76 mmol) in MeOH (4 mL) was added 4.0 M hydrogen chloride in dioxane (0.48 mL, 1.9 mmol). The reaction mixture was stirred at room temperature for 30 min then concentrated and dried under high vacuum to afford 225 mg of (R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethylamine dihydrochloride as a viscous colorless oil which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide

To a solution of (R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethylamine dihydrochloride (89 mg, 0.34 mmol) in DMF (2 mL) was added N,N-diisopropylethylamine (0.20 mL, 1.13 mmol), 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (100 mg, 0.23 mmol), and HATU (95 mg, 0.25 mmol). The yellow reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (3×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% to 100% EtOAc/hexanes to give 122 mg (88%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide as a white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide (122 mg, 0.20 mmol) in CH 2 Cl 2 (3 mL) was added TFA (1 mL, 13.0 mmol). The bright yellow-orange reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (3 mL) and ethylene diamine (0.5 mL, 7.50 mmol) was added. The reaction mixture was stirred for 1 h then quenched with water and extracted with 5% MeOH/CH 2 Cl 2 (2×). The combined organics were concentrated and triturated with MeOH/CH 2 Cl 2 to isolate 65 mg (68%) of 2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(4-trifluoromethyl-pyridin-2-yl)-ethyl]-amide as an off-white solid. MS: (M+Na) + =506; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.79 (br. s., 1H), 9.12 (s, 1H), 8.86 (d, J=7.9 Hz, 1H), 8.71-8.81 (m, 2H), 8.43 (s, 1H), 7.91 (s, 1H), 7.60-7.73 (m, 2H), 7.03 (td, J=9.2, 2.1 Hz, 1H), 5.55 (quin, J=7.3 Hz, 1H), 4.15 (s, 3H), 1.64 (d, J=6.8 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide

(R)-2-Methyl-propane-2-sulfinic acid (E)-ethylideneamide

In a flask (R)-2-methyl-propane-2-sulfinic acid amide (4.00 g, 33.0 mmol) was dissolved in CH 2 Cl 2 (14.0 mL). Acetaldehyde (16.7 mL, 297 mmol), MgSO 4 (11.9 g, 99.0 mmol) and pyridinium tosylate (415 mg, 1.65 mmol) were added. The reaction mixture was stirred overnight at room temperature, filtered and concentrated to give 5.21 g of (R)-2-methyl-propane-2-sulfinic acid (E)-ethylideneamide as a yellow oil which was used without further purification.

(R)-2-Methyl-propane-2-sulfinic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide

In a flask, isobutyronitrile (6.39 g, 92.4 mmol) was dissolved in diethyl ether (190 mL) and cooled at −78° C. NaHMDS (1.0 M in THF, 99.0 mL, 99.0 mmol) was added and the mixture stirred for 30 min at −78° C. A solution of (R)-2-methyl-propane-2-sulfinic acid (E)-ethylideneamide (crude from step 1, 5.21 g, 33.0 mmol) in THF (50.0 mL) was slowly added. The mixture was stirred at −78° C. for 2 h then allowed to warm to room temperature overnight. The reaction mixture was quenched with saturated aqueous ammonium chloride and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (20-100% EtOAc/hexane) to afford 2.93 g (41%) (R)-2-methyl-propane-2-sulfinic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide as a light yellow oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 3.28 (dq, J=8.7, 6.4 Hz, 1H), 3.08 (d, J=8.7 Hz, 1H), 1.45 (d, J=6.4 Hz, 3H), 1.39 (s, 3H), 1.34 (s, 3H), 1.26 (s, 9H).

(S)-3-Amino-2,2-dimethyl-butyronitrile hydrochloride

(R)-2-Methyl-propane-2-sulfinic acid (2-cyano-1,2,2-trimethyl-ethyl)-amide (2.93 g, 13.6 mmol) was dissolved in MeOH and HCl (4.0 M in 1,4-dioxane, 6.8 mL, 27.2 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then concentrated to give 1.90 g (94%) of (S)-3-amino-2,2-dimethyl-butyronitrile hydrochloride as a white solid which was used without further purification.

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide

In a flask were combined 2-bromo-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (1.10 g, 2.95 mmol), (S)-3-amino-2,2-dimethyl-butyronitrile hydrochloride (439 mg, 2.95 mmol), EDC (1.3 g, 6.8 mmol) and HOBt (1.15 g, 6.8 mmol). DMF (27 mL) was added followed by i-Pr 2 NEt (3.6 mL, 20.7 mmol). The reaction mixture was stirred at room temperature for 18 h and then quenched with water and extracted with EtOAc. The organics were washed with 10% citric acid, sat'd NaHCO 3 , sat'd LiCl, and sat'd NaCl then dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (50-100% EtOAc/hexane) to give 1.32 g (96%) of 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide as an off-white powder.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide

To a solution of 6-tert-butyl-1-methyl-3-tributylstannyl-1H-indazole (222 mg, 0.49 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide (110 mg, 0.24 mmol) in DMF (1.5 mL) were added Pd(PPh 3 ) 4 (14 mg, 0.012 mmol) and copper(I) iodide (9 mg, 0.05 mmol). The yellow reaction mixture was purged with argon then heated at 80° C. for 2 h then cooled to room temperature, quenched with sat NH 4 Cl and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 20% to 50% EtOAc/heptane to isolate 120 mg (92%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide as a white powder.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide

To a solution of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide (120 mg, 0.22 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.75 mL). The reaction mixture was stirred at room temperature for 2 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h then concentrated. The residue was taken up in 10% MeOH/CH 2 Cl 2 and water was added. The resultant precipitate was collected via filtration then triturated with EtOAc to afford 77 mg (84%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-cyano-1,2,2-trimethyl-ethyl)-amide as a light yellow powder. MS: (M+H) + =422; mp=322-328° C.; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.78 (s, 1H), 8.99 (s, 1H), 8.38 (s, 1H), 8.34 (d, J=9.1 Hz, 1H), 8.01 (d, J=9.6 Hz, 1H), 7.86 (d, J=1.5 Hz, 1H), 7.19 (dd, J=8.6, 1.5 Hz, 1H), 4.20-4.34 (m, 1H), 4.04 (s, 3H), 1.31 (d, J=6.6 Hz, 3H), 1.28 (s, 3H), 1.25 (s, 3H).

2-(6-tert-Butyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

5-tert-Butyl-2-methylaniline

To a solution of 4-tert-butyl-1-methyl-2-nitrobenzene (3.58 g, 18.5 mmol) in MeOH (80 ml) was added 10% Pd on carbon (wet, 358 mg). The reaction mixture was stirred under an atmosphere of hydrogen (balloon) for 4 h then filtered over Celite, rinsing with EtOAc. The filtrate was concentrated to afford 2.48 g (82%) of 5-tert-butyl-2-methylaniline as a brown oil which was used without further purification.

6-tert-Butyl-1H-indazole

To a solution of 5-tert-butyl-2-methylaniline (2.48 g, 15.2 mmol) in CHCl 3 (40 ml) at 0° C. was slowly added acetic anhydride (3.3 ml, 34.9 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. Potassium acetate (446 mg, 4.55 mmol) was added followed by slow addition of isoamyl nitrite (4.4 ml, 32.6 mmol). The reaction mixture was heated at reflux overnight. The reaction mixture was cooled to room temperature and concentrated. The residue was dissolved in EtOAc and washed with water, sat'd NaHCO 3 and brine then dried over MgSO 4 and concentrated. The residue was dissolved in THF/MeOH (1:1, 40 mL) and 10% NaOH (4.5 mL) was added. The reaction mixture was stirred at room temperature for 10 min then neutralized with 1.0 M HCl, diluted with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 20% to 50% EtOAc/heptane to afford 1.02 g (39%) of 6-tert-butyl-1H-indazole as an off-white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.03 (s, 1H), 7.70 (d, J=8.7 Hz, 1H), 7.48 (s, 1H), 7.29 (dd, J=8.7, 1.5 Hz, 1H), 1.40 (s, 9H).

6-tert-Butyl-3-iodo-1H-indazole

To a solution of 6-tert-butyl-1H-indazole (1.02 g, 5.84 mmol) in DMF (20 ml) at room temperature was added potassium hydroxide (983 mg, 17.5 mmol) and iodine (2.22 g, 8.76 mmol). The maroon reaction mixture was stirred at room temperature for 1 h then quenched with 10% aqueous Na 2 S 2 O 3 and diluted with water. The mixture was extracted with EtOAc (2×). The combined organics were washed with water, sat LiCl, and sat NaCl, then dried over MgSO 4 and concentrated to afford 1.92 g 6-tert-butyl-3-iodo-1H-indazole as a light brown solid.

6-tert-Butyl-3-iodo-1-methyl-1H-indazole

To a solution of 6-tert-butyl-3-iodo-1H-indazole (820 mg, 2.73 mmol) in THF (8 ml) at 0° C. was added KOt-Bu (429 mg, 3.82 mmol). The reaction mixture was stirred at 0° C. for 30 min then added iodomethane (0.24 ml, 3.82 mmol). Stirred at 0° C. for 30 min then warmed to room temperature and stirred for 1.5 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 10% to 50% EtOAc/heptane to afford 592 mg (69%) of 6-tert-butyl-3-iodo-1-methyl-1H-indazole as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.37-7.43 (m, 1H), 7.31 (d, J=9.8 Hz, 2H), 4.10 (s, 3H), 1.41 (s, 9H). The minor 6-tert-butyl-3-iodo-2-methyl-1H-indazole regioisomer was also observed but not isolated.

6-tert-Butyl-1-methyl-3-tributylstannanyl-1H-indazole

To a solution of 6-tert-butyl-3-iodo-1-methyl-1H-indazole (150 mg, 0.45 mmol) in THF (3 mL) at 0° C. was slowly added isopropylmagnesium chloride (2.0 M in THF, 0.27 mL, 0.54 mmol). The bright yellow heterogeneous reaction mixture was stirred at 0° C. for 1 h then tributylchlorostannane (0.15 mL, 0.54 mmol) was added dropwise. Stirring was continued at 0° C. for 20 min then at room temperature for 3 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated to afford 6-tert-butyl-1-methyl-3-tributylstannanyl-1H-indazole as a viscous yellow oil which was used in the next step without further purification.

2-(6-tert-Butyl-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 6-tert-butyl-1-methyl-3-tributylstannyl-1H-indazole (crude from Step 5, 217 mg, 0.45 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (125 mg, 0.25 mmol) in DMF (1.5 mL) were added Pd(PPh 3 ) 4 (14 mg, 0.012 mmol) and copper(I) iodide (9 mg, 0.05 mmol). The yellow reaction mixture was purged with argon then heated at 80° C. for 1.5 h then cooled to room temperature, quenched with sat NH 4 Cl and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to isolate 129 mg (85%) of 2-(6-tert-butyl-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white solid.

2-(6-tert-Butyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-(6-tert-butyl-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (129 mg, 0.21 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.75 mL). The reaction mixture was stirred at room temperature for 4 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography with 0% to 5% MeOH/EtOAc to afford 74 mg (73%) of 2-(6-tert-butyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow powder. MS: (M+H) + =485; mp=180-195° C.; 1 H NMR (CDCl 3 , 400 MHz): δ (ppm) 10.08-10.28 (m, 1H), 9.02-9.14 (m, 1H), 8.65 (d, J=7.1 Hz, 1H), 8.46 (d, J=8.6 Hz, 1H), 7.99-8.13 (m, 1H), 7.40-7.49 (m, 1H), 7.36 (s, 1H), 4.86-5.08 (m, 1H), 4.23-4.76 (m, 4H), 4.11 (s, 3H), 3.52-3.59 (m, 1H), 1.55-1.71 (m, 3H), 1.48 (s, 9H).

6-Chloro-1-ethyl-3-iodo-1H-indazole

To a solution of 6-chloro-3-iodo-1H-indazole (913 mg, 3.28 mmol) in THF (12 ml) at 0° C. was added KOt-Bu (429 mg, 3.82 mmol). The reaction mixture was stirred at 0° C. for 30 min then added iodoethane (0.37 ml, 4.6 mmol). Stirred at 0° C. for 30 min then warmed to room temperature and stirred for 48 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 10% to 50% EtOAc/heptane to afford 622 mg (62%) of 6-chloro-1-ethyl-3-iodo-1H-indazole as a white powder. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.37-7.43 (m, 2H), 7.17 (dd, J=8.7, 1.1 Hz, 1H), 4.41 (q, J=7.2 Hz, 2H), 1.51 (t, J=7.2 Hz, 3H). Also isolated 174 mg (17%) of 6-chloro-2-ethyl-3-iodo-2H-indazole as a more polar, minor regioisomer. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.66-7.70 (m, 1H), 7.35 (d, J=9.1 Hz, 1H), 7.04-7.12 (m, 1H), 4.56 (q, J=7.2 Hz, 2H), 1.58 (t, J=7.2 Hz, 3H).

6-Chloro-1-ethyl-3-tributylstannanyl-1H-indazole

To a solution of 6-chloro-1-ethyl-3-iodo-1H-indazole (150 mg, 0.47 mmol) in THF (3 mL) at 0° C. was slowly added isopropylmagnesium chloride (2.0 M in THF, 0.28 mL, 0.56 mmol). The bright yellow heterogeneous reaction mixture was stirred at 0° C. for 20 min then tributylchlorostannane (0.15 mL, 0.56 mmol) was added dropwise. Stirring was continued at 0° C. for 20 min then at room temperature for 2 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The exact reaction was repeated once more on the same scale. The residues from the two runs were combined and purified by silica gel chromatography with 10% to 50% EtOAc/heptane (0.5% Et 3 N) to provide 128 mg (29%) of 6-chloro-1-ethyl-3-tributylstannanyl-1H-indazole as a colorless oil.

2-(6-Chloro-1-ethyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 6-chloro-1-ethyl-3-tributylstannyl-1H-indazole (125 mg, 0.27 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (125 mg, 0.25 mmol) in DMF (1.5 mL) were added Pd(PPh 3 ) 4 (14 mg, 0.012 mmol) and copper(I) iodide (9 mg, 0.05 mmol). The yellow reaction mixture was purged with argon then heated at 80° C. for 0.5 h then cooled to room temperature, quenched with sat NH 4 Cl and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to isolate 156 mg of 2-(6-chloro-1-ethyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a viscous colorless oil.

2-(6-Chloro-1-ethyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-(6-chloro-1-ethyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (150 mg, 0.25 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.75 mL). The reaction mixture was stirred at room temperature for 5 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography with 0% to 5% MeOH/EtOAc followed by trituration with MeOH to afford 88 mg (75%) of 2-(6-chloro-1-ethyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white powder. MS: (M+Na) + =499; mp=248-255° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.14 (s, 1H), 8.71 (d, J=8.7 Hz, 1H), 8.47 (dd, J=7.6, 3.4 Hz, 2H), 8.02 (s, 1H), 7.25 (d, J=8.7 Hz, 1H), 4.48-4.79 (m, 5H), 4.04-4.28 (m, 2H), 3.77-3.92 (m, 1H), 1.47 (t, J=7.2 Hz, 3H), 1.39 (dd, J=6.8, 4.5 Hz, 3H).

2-(6,7-Difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

6,7-Difluoro-1H-indazole

In a microwave vial 2,3,4-trifluorobenzaldehyde (1.5 g, 9.4 mmol) was dissolved in 1,4-dioxane (6 mL) and hydrazine (6 mL, 191 mmol) was added. The vial was sealed and heated under microwave irradiation at 150° C. for 30 min. The reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 20% to 50% EtOAc/heptane to provide 664 mg (46%) of 6,7-difluoro-1H-indazole as a light brown powder. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.10 (d, J=3.4 Hz, 1H), 7.47 (dd, J=8.9, 4.0 Hz, 1H), 7.05 (ddd, J=10.6, 8.9, 6.6 Hz, 1H).

2-(6,7-Difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 81, Steps 3-7, substituting 6,7-difluoro-1H-indazole for 6-tert-butyl-1H-indazole in Step 3. MS: (M+Na) + =487; mp=240-250° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (s, 1H), 9.11 (s, 1H), 8.53 (dd, J=9.1, 4.2 Hz, 1H), 8.48 (d, J=6.8 Hz, 1H), 8.38 (d, J=7.6 Hz, 1H), 7.18-7.33 (m, 1H), 4.48-4.78 (m, 3H), 4.28 (s, 3H), 4.16-4.26 (m, 1H), 4.05-4.14 (m, 1H), 3.84 (dd, J=9.3, 5.1 Hz, 1H), 1.38 (t, J=5.9 Hz, 3H).

2-(6-Ethyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

6-Vinyl-1H-indazole

To a suspension of 6-bromo-1H-indazole (600 mg, 3.05 mmol) in toluene (18 ml) and 1,2-dimethoxyethane (6 ml) were added tributyl(vinyl)tin (1.33 ml, 4.57 mmol) and PdCl 2 (PPh 3 ) 2 (214 mg, 0.31 mmol). The reaction was purged with argon then heated at reflux for 3 h. Additional tributyl(vinyl)tin (0.66 ml, 2.28 mmol) and PdCl 2 (PPh 3 ) 2 (107 mg, 0.15 mmol) were added and heating was continued for 1 h. The same reaction was performed on an additional batch of 6-bromo-1H-indazole (200 mg, 1.02 mmol) and the two crude batches were combined. The reactions were diluted with ethyl acetate, washed with water and brine, dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 5% to 50% EtOAc/heptane to isolate 350 mg (60%) of 6-vinyl-1H-indazole as a yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.07 (s, 1H), 7.72 (d, J=8.3 Hz, 1H), 7.48 (s, 1H), 7.35 (d, J=8.3 Hz, 1H), 6.85 (dd, J=17.4, 11.0 Hz, 1H), 5.86 (d, J=17.4 Hz, 1H), 5.35 (d, J=11.0 Hz, 1H).

6-Ethyl-1H-indazole

To a solution of 6-vinyl-1H-indazole (350 mg, 2.42 mmol) in MeOH (24 ml) was added 10% Pd on carbon (wet, 443 mg). The reaction mixture was stirred under an atmosphere of hydrogen (balloon) for 2.5 h then filtered over Celite, rinsing with EtOAc. The filtrate was concentrated to afford 305 mg (86%) of 6-ethyl-1H-indazole as a white semi-solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.04 (s, 1H), 7.67 (d, J=8.3 Hz, 1H), 7.32 (s, 1H), 7.06 (d, J=8.3 Hz, 1H), 2.80 (q, J=7.6 Hz, 2H), 1.31 (t, J=7.6 Hz, 3H).

2-(6-Ethyl-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 81, Steps 3-7, substituting 6-ethyl-1H-indazole for 6-tert-butyl-1H-indazole in Step 3. MS: (M+Na) + =479; mp=185-190° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.87 (br. s., 1H), 9.13 (s, 1H), 8.50-8.58 (m, 2H), 8.41-8.49 (m, 2H), 7.54 (s, 1H), 7.15 (dd, J=8.3, 3.0 Hz, 1H), 4.63-4.80 (m, 2H), 4.44-4.63 (m, 2H), 4.00-4.28 (m, 4H), 3.74-3.94 (m, 1H), 2.80 (q, J=7.6 Hz, 2H), 1.43 (dd, J=6.8, 4.2 Hz, 3H), 1.29 (t, J=7.6 Hz, 3H).

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

4,6-Difluoro-1H-indazole

To a solution of 2,4,6-trifluorobenzaldehyde (0.80 g, 5.0 mmol) in 1,2-dimethoxyethane (10 mL) were added potassium carbonate (1.04 g, 7.5 mmol) and O-methylhydroxylamine hydrochloride (438 mg, 5.25 mmol). The reaction mixture was heated at 50° C. for 5 h then cooled to room temperature and filtered, rinsing with dichloromethane. The filtrate was concentrated. The residue was dissolved in 1,2-dimethoxyethane (10 mL) and hydrazine (0.17 mL, 5.5 mmol) was added. The reaction mixture was heated at 100° C. for 1.5 h. Additional hydrazine (0.17 mL, 5.5 mmol) was added and heating was continued for 30 min. Thereaction was cooled to room temperature, poured into water, and extracted with ethyl acetate. The organic layer was washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 20% to 50% EtOAc/heptane to provide 358 mg (47%) of 4,6-difluoro-1H-indazole as a light yellow solid. 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.47 (br. s., 1H), 8.19 (s, 1H), 7.22 (d, J=9.1 Hz, 1H), 6.96 (td, J=10.0, 1.9 Hz, 1H).

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 81, Steps 3-7, substituting 4,6-difluoro-1H-indazole for 6-tert-butyl-1H-indazole in Step 3. MS: (M+Na) + =487; mp=235-265° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.94 (br. s., 1H), 8.99 (s, 1H), 8.54 (d, J=7.2 Hz, 1H), 8.47 (dd, J=10.8, 3.2 Hz, 1H), 7.55-7.63 (m, 1H), 7.09 (t, J=10.2 Hz, 1H), 4.40-4.68 (m, 3H), 4.15 (s, 3H), 4.08-4.17 (m, 1H), 3.93-4.03 (m, 1H), 3.73-3.86 (m, 1H), 1.35 (t, J=5.7 Hz, 3H).

2-(1,6-Dimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-Chloro-6-methylpyridine-3-carbaldehyde

To a solution of 2-chloro-6-methylnicotinonitrile (2.0 g, 13.1 mmol) in dichloromethane (40 mL) at −78° C. was added DIBAL-H (2.92 mL, 16.4 mmol) dropwise. The reaction was stirred at −78° C. for 5 min then allowed to warm to room temperature and stirred for 6 h. The reaction was carefully quenched with 1N HCl (40 mL) and the mixture was heated at reflux for 30 min. After cooling the reaction was made basic with aqueous 10% NaOH and extracted with EtOAc (3×). The combined organics were washed with brine then dried over MgSO 4 and concentrated to afford 1.98 g (97%) of 2-chloro-6-methylpyridine-3-carbaldehyde as a light yellow solid.

6-Methyl-1H-pyrazolo[3,4-b]pyridine

In a microwave vial 2-chloro-6-methylpyridine-3-carbaldehyde (1.98 g, 12.7 mmol) was dissolved in 1,4-dioxane (12 mL) and hydrazine (6.0 mL, 191 mmol) was added. The vial was sealed and heated under microwave irradiation at 150° C. for 1 h. The reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to provide 863 mg (41%) of 6-methyl-1H-pyrazolo[3,4-b]pyridine as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.06 (s, 1H), 8.03 (d, J=8.3 Hz, 1H), 7.07 (d, J=8.3 Hz, 1H), 2.79 (s, 3H).

2-(1,6-Dimethyl-1H-pyrazolo[3,4-b]pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 81, Steps 3-7, substituting 6-methyl-1H-pyrazolo[3,4-b]pyridine for 6-tert-butyl-1H-indazole in Step 3. MS: (M+Na) + =466; mp=275-285° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.14 (s, 1H), 8.98 (d, J=8.3 Hz, 1H), 8.47 (d, J=6.4 Hz, 2H), 7.22 (dd, J=8.3, 3.4 Hz, 1H), 4.46-4.80 (m, 3H), 4.17-4.30 (m, 1H), 4.13 (s, 3H), 4.07-4.15 (m, 1H), 3.77-3.93 (m, 1H), 2.66 (s, 3H), 1.31-1.48 (m, 3H).

2-[6-Chloro-1-(2-hydroxy-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-{6-Chloro-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indazol-3-yl}-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (see Example 23, 120 mg, 0.21 mmol) was dissolved in DMF (1.3 ml). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 10 mg, 0.25 mmol) was added. The reaction mixture was stirred at 0° C. for 30 min then 2-(2-bromoethoxy)tetrahydro-2H-pyran (47 μl, 0.31 mmol) was added. The reaction mixture was stirred at 0° C. for 1 h and then at room temperature for 4 h. The reaction mixture was quenched with water and extracted with ethyl acetate (2×). The combined organic layers were washed with water, sat LiCl, and brine then dried over MgSO 4 and concentrated. The residue was chromatographed over silica gel with 50% to 100% EtOAc/heptane to afford 138 mg (94%) of 2-{6-chloro-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indazol-3-yl}-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a viscous yellow oil.

2-[6-Chloro-1-(2-hydroxy-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-{6-chloro-1-[2-(tetrahydro-pyran-2-yloxy)-ethyl]-1H-indazol-3-yl}-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (138 mg, 0.20 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.75 mL). The reaction mixture was stirred at room temperature for 6 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography with 0% to 10% MeOH/CH 2 Cl 2 to afford 63 mg (65%) of 2-[6-chloro-1-(2-hydroxy-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white solid. MS: (M+Na) + =515; mp=225-250° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.14 (s, 1H), 8.69 (d, J=8.7 Hz, 1H), 8.47 (d, J=7.2 Hz, 2H), 7.95 (d, J=1.5 Hz, 1H), 7.24 (d, J=8.7 Hz, 1H), 4.92 (t, J=5.5 Hz, 1H), 4.49-4.78 (m, 5H), 4.17-4.27 (m, 1H), 4.05-4.15 (m, 1H), 3.83-3.93 (m, 3H), 1.39 (dd, J=6.6, 4.7 Hz, 3H).

2-(6-Chloro-1-isopropyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 90, substituting 2-bromopropane for 2-(2-bromoethoxy)tetrahydro-2H-pyran in Step 1. MS: (M+H) + =491; mp=204-208° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.91 (br. s., 1H), 9.16 (s, 1H), 8.70 (d, J=8.3 Hz, 1H), 8.47 (dd, J=7.6, 2.6 Hz, 2H), 8.03 (d, J=1.1 Hz, 1H), 7.19-7.29 (m, 1H), 5.14 (quin, J=6.6 Hz, 1H), 4.46-4.79 (m, 3H), 4.15-4.27 (m, 1H), 4.03-4.14 (m, 1H), 3.78-3.92 (m, 1H), 1.56 (dd, J=6.6, 3.0 Hz, 6H), 1.39 (dd, J=6.6, 4.7 Hz, 3H).

2-[6-Chloro-1-propyl-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-(1-Allyl-6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (see Example 23, 396 mg, 0.68 mmol) was dissolved in DMF (4.5 ml). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 33 mg, 0.83 mmol) was added. The reaction mixture was stirred at 0° C. for 20 min then allyl bromide (65 μl, 0.75 mmol) was added. The reaction mixture was stirred at 0° C. for 20 min and then at room temperature for 1 h. The reaction mixture was quenched with water and extracted with ethyl acetate (2×). The combined organic layers were washed with water, sat LiCl, and brine then dried over MgSO 4 and concentrated. The residue was chromatographed over silica gel with 50% to 100% EtOAc/heptane to afford 388 mg (92%) of 2-(1-allyl-6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light yellow foam.

2-(6-Chloro-1-propyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-(1-allyl-6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (50 mg, 0.08 mmol) in MeOH (6 ml) was added 10% Pd on carbon (wet, 17 mg). The reaction mixture was stirred under an atmosphere of hydrogen (balloon) for 1.5 h then filtered over Celite, rinsing with EtOAc. The filtrate was concentrated and the residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to afford 38 mg (76%) of 2-(6-chloro-1-propyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a viscous colorless oil.

2-[6-Chloro-1-propyl-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-(6-chloro-1-propyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (38 mg, 0.06 mmol) in CH 2 Cl 2 (1.5 mL) was added TFA (0.5 mL). The reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography with 0% to 10% MeOH/CH 2 Cl 2 to afford 10 mg (32%) of 2-[6-chloro-1-propyl-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white solid. MS: (M+Na) + =513; mp=219-221° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.93 (s, 1H), 9.13 (s, 1H), 8.71 (d, J=9.1 Hz, 1H), 8.46 (dd, J=7.6, 2.6 Hz, 2H), 8.03 (s, 1H), 7.25 (d, J=9.1 Hz, 1H), 4.43-4.78 (m, 5H), 4.16-4.27 (m, 1H), 4.05-4.13 (m, 1H), 3.78-3.91 (m, 1H), 1.86-1.96 (m, 2H), 1.39 (dd, J=6.6, 4.3 Hz, 3H), 0.89 (t, J=7.4 Hz, 3H).

2-(6-Chloro-1-cyanomethyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 90, substituting 2-iodoacetonitrile for 2-(2-bromoethoxy)tetrahydro-2H-pyran in Step 1. MS: (M+Na) + =510; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.00 (br. s., 1H), 9.14 (s, 1H), 8.79 (dd, J=8.7, 2.3 Hz, 1H), 8.52 (d, J=6.4 Hz, 1H), 8.42 (d, J=7.9 Hz, 1H), 8.15 (s, 1H), 7.36 (d, J=9.1 Hz, 1H), 5.94 (s, 2H), 4.48-4.78 (m, 3H), 4.17-4.28 (m, 1H), 4.06-4.15 (m, 1H), 3.80-3.89 (m, 1H), 1.33-1.44 (m, 3H).

2-[6-Chloro-1-(2,3-dihydroxy-propyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Methanesulfonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester

To a solution of (2,2-dimethyl-[1,3]dioxolan-4-yl)-methanol (1.25 g, 9.46 mmol) and triethylamine (9.2 ml, 66.2 mmol) in dichloromethane (60 ml) at 0° C. was slowly added methanesulfonyl chloride (2.2 ml, 28.4 mmol). The reaction mixture was stirred at 0° C. for 2 h then quenched with water and the aqueous layer was extracted with dichloromethane. The combined organics were washed with 10% citric acid, sat NaHCO 3 , and brine then dried over MgSO 4 and concentrated to afford methanesulfonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester as a light brown oil which was used without further purification.

2-[6-Chloro-1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

In a round-bottomed flask, 2-(6-chloro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (see Example 23, 120 mg, 0.21 mmol) was dissolved in DMF (1.3 ml). The reaction mixture was cooled to 0° C. and sodium hydride (60% dispersion in mineral oil, 12 mg, 0.31 mmol) was added. The reaction mixture was stirred at 0° C. for 30 min then a solution of methanesulfonic acid 2,2-dimethyl-[1,3]dioxolan-4-ylmethyl ester (131 mg, 0.62 mmol) in DMF (0.5 ml) was added. The reaction mixture was stirred at 0° C. for 1 h and then at room temperature for 48 h. The reaction mixture was quenched with water and extracted with ethyl acetate (2×). The combined organic layers were washed with water, sat LiCl, and brine then dried over MgSO 4 and concentrated to give 2-[6-chloro-1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a light brown viscous oil which was used without further purification.

2-[6-Chloro-1-(2,3-dihydroxy-propyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-[6-chloro-1-(2,2-dimethyl-[1,3]dioxolan-4-ylmethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (crude from Step 2) in CH 2 Cl 2 (3 mL) was added TFA (1 mL). The reaction mixture was stirred at room temperature for 48 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography with 0% to 10% MeOH/CH 2 Cl 2 to afford 22 mg (20%, 2 steps) of 2-[6-Chloro-1-(2,3-dihydroxy-propyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white solid. MS: (M+Na) + =545; mp=165-180° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.14 (s, 1H), 8.69 (d, J=8.7 Hz, 1H), 8.47 (d, J=7.6 Hz, 2H), 7.91 (s, 1H), 7.23 (d, J=6.8 Hz, 1H), 5.15 (d, J=5.3 Hz, 1H), 5.03 (dd, J=5.3, 3.0 Hz, 1H), 4.84 (t, J=5.5 Hz, 1H), 4.35-4.80 (m, 5H), 4.18-4.26 (m, 1H), 3.93-4.15 (m, 2H), 3.79-3.90 (m, 1H), 3.34-3.49 (m, 2H), 1.33-1.45 (m, 3H).

2-[6-Chloro-1-(2-hydrox-ypropyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-(2-Bromo-1-methyl-ethoxy)-tetrahydro-2H-pyran

To a solution of 1-bromopropan-2-ol (1.25 g, 9.0 mmol) and 3,4-dihydro-2H-pyran (2.04 ml, 22.5 mmol) in dichloromethane (50 ml) at 0° C. was added p-toluenesulfonic acid monohydrate (85 mg, 0.45 mmol). The reaction mixture was stirred at 0° C. for 15 min then warmed to room temperature and stirred for 2 h. The reaction was diluted with EtOAc and washed with water, sat NaHCO 3 , and brine then dried over MgSO 4 and concentrated to afford 2-(2-bromo-1-methyl-ethoxy)-tetrahydro-2H-pyran as a light brown oil which was used without further purification.

2-[6-Chloro-1-(2-hydroxy-propyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 90, substituting 2-(2-bromo-1-methyl-ethoxy)-tetrahydro-2H-pyran for 2-(2-bromoethoxy)tetrahydro-2H-pyran in Step 1. MS: (M+Na) + =529; mp=160-165° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.91 (br. s., 1H), 9.13 (s, 1H), 8.69 (d, J=8.7 Hz, 1H), 8.47 (d, J=7.6 Hz, 2H), 7.95 (s, 1H), 7.17-7.27 (m, 1H), 4.93 (dd, J=5.1, 2.8 Hz, 1H), 4.49-4.78 (m, 3H), 4.42 (d, J=6.0 Hz, 2H), 4.06-4.27 (m, 3H), 3.80-3.87 (m, 1H), 1.39 (dd, J=6.6, 4.7 Hz, 3H), 1.11-1.21 (m, 3H).

2-[6-Chloro-1-(3-hydroxy-propyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-(3-Bromopropoxy)-tetrahydro-2H-pyran

To a solution of 3-bromopropan-1-ol (1.25 g, 9.0 mmol) and 3,4-dihydro-2H-pyran (2.04 ml, 22.5 mmol) in dichloromethane (50 ml) at 0° C. was added p-toluenesulfonic acid monohydrate (85 mg, 0.45 mmol). The reaction mixture was stirred at 0° C. for 15 min then warmed to room temperature and stirred for 2 h. The reaction was diluted with EtOAc and washed with water, sat NaHCO 3 , and brine then dried over MgSO 4 and concentrated to afford 2-(3-bromopropoxy)-tetrahydro-2H-pyran as a light brown oil which was used without further purification.

2-[6-Chloro-1-(3-hydroxy-propyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 90, substituting 2-(3-bromopropoxy)-tetrahydro-2H-pyran for 2-(2-bromoethoxy)tetrahydro-2H-pyran in Step 1. MS: (M+Na) + =529; mp=240-250° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.92 (br. s., 1H), 9.14 (s, 1H), 8.71 (d, J=9.1 Hz, 1H), 8.47 (dd, J=7.4, 4.0 Hz, 2H), 7.96 (d, J=1.5 Hz, 1H), 7.20-7.30 (m, 1H), 4.49-4.79 (m, 6H), 4.17-4.28 (m, 1H), 4.04-4.14 (m, 1H), 3.78-3.89 (m, 1H), 3.44 (q, J=5.9 Hz, 2H), 2.05 (t, J=6.6 Hz, 2H), 1.39 (dd, J=6.8, 4.5 Hz, 3H).

2-(4,6-Dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2,4,6-Trichlorobenzaldehyde

2,4,6-Trichlorobenzaldehyde was prepared according to the procedure outlined in Synthesis 2008, 279. To a solution of 1,3,5-trichlorobenzene (10.0 g, 55.1 mmol) in THF (200 ml) at −78° C. was slowly added n-BuLi (1.6 M in hexanes, 34.4 ml, 55.1 mmol) over 20 min. The reaction mixture was stirred at −78° C. for 30 min then DMF (7.5 ml, 96.4 mmol) was added dropwise. The reaction was stirred at −78° C. for an additional 1.5 h then quenched with 3 N HCl (200 ml) and warmed to room temperature. The mixture was extracted with EtOAc. The organic layer was washed with sat NaHCO 3 and brine then dried over MgSO 4 and concentrated to afford 10.7 g (93%) of 2,4,6-trichlorobenzaldehyde as a white solid.

4,6-Dichloro-1H-indazole

In a microwave vial 2,4,6-trichlorobenzaldehyde (4.0 g, 19.1 mmol) was dissolved in 1,4-dioxane (8 mL) and hydrazine (7.2 mL, 229 mmol) was added. The vial was sealed and heated under microwave irradiation at 160° C. for 30 min. The reaction was quenched with water and extracted with EtOAc. The organic layer was washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to provide 1.38 g (38%) of 4,6-dichloro-1H-indazole as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 8.14 (s, 1H), 7.44 (s, 1H), 7.20 (d, J=1.5 Hz, 15H).

2-(4,6-Dichloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 81, Steps 3-7, substituting 4,6-dichloro-1H-indazole for 6-tert-butyl-1H-indazole in Step 3. MS: (M+Na) + =519; mp=196-200° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 8.75 (s, 1H), 8.45-8.56 (m, 2H), 8.03 (s, 1H), 7.42 (s, 1H), 4.38-4.66 (m, 3H), 4.17 (s, 3H), 3.91-4.14 (m, 2H), 3.73-3.86 (m, 1H), 1.23-1.32 (m, 3H).

2-(1-Methyl-1H-pyrazolo[4,3-b]pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

1-Pyrazolo[4,3-b]pyridin-1-yl-ethanone

To a solution of 3-amino-2-methylpyridine (1.0 g, 9.25 mmol) in CHCl 3 (24 ml) at 0° C. was slowly added acetic anhydride (2.0 ml, 21.3 mmol). The reaction mixture was warmed to room temperature and stirred for 1 h. Potassium acetate (272 mg, 2.77 mmol) was added followed by slow addition of isoamyl nitrite (2.7 ml, 19.9 mmol). The reaction mixture was heated at reflux overnight. The reaction mixture was cooled to room temperature and concentrated. The residue was dissolved in EtOAc and washed with water, sat'd NaHCO 3 and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 20% to 100% EtOAc/heptane to give 973 mg (65%) of 1-pyrazolo[4,3-b]pyridin-1-yl-ethanone as a light yellow solid.

1H-Pyrazolo[4,3-b]pyridine

Pyrazolo[4,3-b]pyridin-1-yl-ethanone (973 mg, 6.04 mmol) was dissolved in THF/MeOH (1:1, 16 mL) and 10% NaOH (1.8 mL) was added. The reaction mixture was stirred at room temperature for 30 min then neutralized with 1.0 M HCl, diluted with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated to afford 687 mg (96%) of 1H-pyrazolo[4,3-b]pyridine as a light yellow solid. 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.29 (br. s., 1H), 8.50 (d, J=4.5 Hz, 1H), 8.27 (s, 1H), 8.00 (d, J=8.7 Hz, 1H), 7.34 (dd, J=8.7, 4.5 Hz, 1H).

2-(1-Methyl-1H-pyrazolo[4,3-b]pyridin-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

Prepared according to the procedure outlined in Example 81, Steps 3-7, substituting 1H-pyrazolo[4,3-b]pyridine for 6-tert-butyl-1H-indazole in Step 3. MS: (M+H) + =430; mp=194-198° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.86 (br. s., 1H), 9.32 (s, 1H), 9.05 (t, J=7.9 Hz, 1H), 8.68 (d, J=4.2 Hz, 1H), 8.44 (d, J=12.1 Hz, 1H), 8.27 (d, J=8.3 Hz, 1H), 7.52 (dd, J=8.7, 4.2 Hz, 1H), 4.40-4.79 (m, 3H), 4.21 (s, 3H), 3.98-4.05 (m, 2H), 3.74-3.84 (m, 1H), 1.49 (d, J=6.8 Hz, 3H).

2-(1-Methyl-1H-thieno[3,2-c]pyrazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

N-Benzhydrylidene-N′-[1-(3-bromo-thiophen-2-yl)-meth-(E)-ylidene]-hydrazine

To a solution of 3-bromothiophene-2-carbaldehyde (5.57 g, 29.2 mmol) in EtOH (90 mL) was added (diphenylmethylene)hydrazine (6.3 g, 32.1 mmol). The reaction mixture was heated at 65° C. for 4 h then concentrated. The residue was purified by silica gel chromatography with 10% to 20% EtOAc/heptane to afford 11 g of N-benzhydrylidene-N′-[1-(3-bromo-thiophen-2-yl)-meth-(E)-ylidene]-hydrazine as a viscous yellow oil.

N-Benzhydrylidene-N′-[2-(benzhydrylidene-hydrazonomethyl)-thiophen-3-yl]-hydrazine

To a solution of N-benzhydrylidene-N′-[1-(3-bromo-thiophen-2-yl)-meth-(E)-ylidene]-hydrazine (10.8 g, 29.2 mmol) in toluene (200 mL) was added (diphenylmethylene)hydrazine (6.9 g, 35.1 mmol), cesium carbonate (16.2 g, 49.7 mmol), Pd(OAc) 2 (1.31 g, 5.85 mol), and 1,1′-bis(diphenylphosphino)ferrocene (2.43 g, 4.4 mmol). The reaction mixture was heated at 100° C. for 8.5 h then cooled to room temperature, diluted with EtOAc and filtered over Celite, rinsing with EtOAc. The filtrate was concentrated and the residue was purified by silica gel chromatography with 10% to 20% EtOAc/heptane to give 12.8 g of N-benzhydrylidene-N′-[2-(benzhydrylidene-hydrazonomethyl)-thiophen-3-yl]-hydrazine as a viscous brown oil.

1H-Thieno[3,2-c]pyrazole

To a solution of N-benzhydrylidene-N′-[2-(benzhydrylidene-hydrazonomethyl)-thiophen-3-yl]-hydrazine (12.8 g, 26.4 mmol) in EtOH (300 mL) was added conc. HCl (150 mL). the deep red reaction mixture was stirred at 85° C. for 1 h then cooled to room temperature, diluted with water and neutralized with Na 2 CO 3 . The mixture was extracted with EtOAc. The organic layer was washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 20% to 100% EtOAc/heptane to afford 2.0 g (60%) of 1H-thieno[3,2-c]pyrazole as a brown solid. The NMR appears to display a mixture of 1H and 2H tautomers: major 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.00 (br. s., 1H), 7.74 (s, 1H), 7.60 (d, J=5.3 Hz, 1H), 7.09 (d, J=5.3 Hz, 1H); minor 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.32 (s, 1H), 8.02 (s, 1H), 7.56 (d, J=4.9 Hz, 1H), 7.13 (d, J=4.9 Hz, 1H).

3-Iodo-1H-thieno[3,2-c]pyrazole

To a solution of 1H-thieno[3,2-c]pyrazole (1.0 g, 8.05 mmol) in DMF (65 ml) at room temperature was added potassium hydroxide (1.36 g, 24.2 mmol) and iodine (3.07 g, 12.1 mmol). The maroon reaction mixture was stirred at room temperature for 3 h then quenched with 10% aqueous Na 2 S 2 O 3 and diluted with water. The mixture was extracted with EtOAc (2×). The combined organics were washed with water, sat LiCl, and sat NaCl, then dried over MgSO 4 and concentrated to afford 2.0 g (99%) of 3-iodo-1H-thieno[3,2-c]pyrazole as a light brown solid. 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 13.38 (br. s., 1H), 7.68 (d, J=5.3 Hz, 1H), 7.21 (d, J=5.3 Hz, 1H).

3-Iodo-1-methyl-1H-thieno[3,2-c]pyrazole

To a solution of 3-iodo-1H-thieno[3,2-c]pyrazole (500 mg, 2.0 mmol) in THF (7 ml) at 0° C. was added KOt-Bu (314 mg, 2.8 mmol). The reaction mixture was stirred at 0° C. for 30 min then added iodomethane (0.17 ml, 2.8 mmol). Stirred at 0° C. for 30 min then warmed to room temperature and stirred for 1.5 h. The reaction was quenched with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 20% to 50% EtOAc/heptane to afford 292 mg (55%) of 3-iodo-1-methyl-1H-thieno[3,2-c]pyrazole as a light brown viscous oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.41 (d, J=5.3 Hz, 1H), 6.97 (d, J=5.3 Hz, 1H), 4.05 (s, 3H). Also isolated 141 mg (27%) of 3-iodo-2-methyl-2H-thieno[3,2-c]pyrazole as an off-white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.36 (d, J=5.3 Hz, 1H), 7.16 (d, J=5.3 Hz, 1H), 4.13 (s, 3H).

1-Methyl-3-tributylstannanyl-1H-thieno[3,2-c]pyrazole

To a solution of 3-iodo-1-methyl-1H-thieno[3,2-c]pyrazole (290 mg, 1.10 mmol) in THF (6 mL) at −15° C. was slowly added isopropylmagnesium chloride (2.0 M in THF, 0.66 mL, 1.32 mmol). The bright yellow heterogeneous reaction mixture was stirred at −15° C. for 20 min then tributylchlorostannane (0.36 mL, 1.32 mmol) was added dropwise. Stirring was continued at −15° C. for 20 min then at room temperature for 2 h. The reaction mixture was quenched with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 10% to 20% EtOAc/heptane (0.5% Et 3 N) gave 298 mg (63%) of 1-methyl-3-tributylstannanyl-1H-thieno[3,2-c]pyrazole as a pale yellow oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.36 (d, J=5.3 Hz, 1H), 6.90 (d, J=5.3 Hz, 1H), 4.06 (s, 3H), 1.54-1.67 (m, 6H), 1.36 (dq, J=14.7, 7.3 Hz, 6H), 1.13-1.22 (m, 6H), 0.90 (t, J=7.3 Hz, 9H).

2-(1-Methyl-1H-thieno[3,2-c]pyrazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 1-methyl-3-tributylstannanyl-1H-thieno[3,2-c]pyrazole (111 mg, 0.26 mmol) and 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (120 mg, 0.24 mmol) in DMF (1.2 mL) were added Pd(PPh 3 ) 4 (14 mg, 0.012 mmol) and copper(I) iodide (9 mg, 0.05 mmol). The yellow reaction mixture was purged with argon then heated at 80° C. for 1.5 h then cooled to room temperature, quenched with sat NH 4 Cl and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to provide 131 mg (98%) of 2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as an off-white solid.

2-(1-Methyl-1H-thieno[3,2-c]pyrazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

To a solution of 2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (131 mg, 0.23 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.75 mL). The reaction mixture was stirred at room temperature for 5 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h. The reaction mixture was concentrated and the residue was purified by silica gel chromatography with 0% to 10% MeOH/CH 2 Cl 2 to afford 83 mg (83%) of 2-(1-methyl-1H-thieno[3,2-c]pyrazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide as a white solid. MS (M+Na) + =457; mp=310-320° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.93 (br. s., 1H), 9.07 (s, 1H), 8.46 (d, J=11.0 Hz, 1H), 8.19 (d, J=7.9 Hz, 1H), 7.82 (d, J=5.3 Hz, 1H), 7.32 (d, J=5.3 Hz, 1H), 4.42-4.77 (m, 3H), 4.13-4.21 (m, 1H), 4.12 (s, 3H), 3.97-4.08 (m, 1H), 3.76-3.89 (m, 1H), 1.51 (dd, J=6.8, 2.6 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide

(S)-2-Methyl-propane-2-sulfinic acid (E)-ethylideneamide

In a flask (S)-2-methyl-propane-2-sulfinic acid amide (1.50 g, 12.4 mmol) was dissolved in CH 2 Cl 2 (6 mL). Acetaldehyde (6.25 mL, 111 mmol), MgSO 4 (4.47 g, 37.1 mmol) and pyridinium tosylate (156 mg, 0.62 mmol) were added. The reaction mixture was stirred overnight at room temperature, filtered and concentrated to give (S)-2-methyl-propane-2-sulfinic acid (E)-ethylideneamide as a pale red oil which was used without further purification.

(S)-2-Methyl-propane-2-sulfinic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide

In a flask, cyclopentanecarbonitrile (3.53 g, 37.1 mmol) was dissolved in THF (40 mL) and cooled at −78° C. LiHMDS (1.0 M in THF, 41 mL, 41 mmol) was added and the mixture stirred for 30 min at −78° C. A solution of (S)-2-methyl-propane-2-sulfinic acid (E)-ethylideneamide (crude from step 1, 1.82 g, 12.4 mmol) in THF (10 mL) was slowly added. The mixture was stirred at −78° C. for 2 h then allowed to warm to room temperature overnight. The reaction mixture was quenched with saturated aqueous ammonium chloride and extracted with EtOAc. The combined organics were washed with brine, dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (50-100% EtOAc/heptane) to afford 1.96 g (65%) of (S)-2-methyl-propane-2-sulfinic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide as a white solid.

1-((R)-1-Amino-ethyl)-cyclopentanecarbonitrile hydrochloride

(S)-2-Methyl-propane-2-sulfinic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide (1.96 g, 8.07 mmol) was dissolved in MeOH (16 mL) and HCl (4.0 M in 1,4-dioxane, 4.0 mL, 16.0 mmol) was added. The reaction mixture was stirred at room temperature for 30 min then concentrated to give 1-((R)-1-amino-ethyl)-cyclopentanecarbonitrile hydrochloride as an off-white solid which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide

In a flask were combined 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (120 mg, 0.27 mmol), 1-((R)-1-amino-ethyl)-cyclopentanecarbonitrile hydrochloride (48 mg, 0.27 mmol), EDC (120 mg, 0.63 mmol) and HOBt (106 g, 0.63 mmol). DMF (3 mL) was added followed by i-Pr 2 NEt (0.28 mL, 1.63 mmol). The reaction mixture was stirred at room temperature for 3 h then quenched with water and extracted with EtOAc. The organics were washed with 10% citric acid, sat'd NaHCO 3 , sat'd LiCl, and sat'd NaCl then dried over MgSO 4 and concentrated. The residue was purified by SiO 2 chromatography (20-100% EtOAc/heptane) to give 140 mg (92%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide as a white solid.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide

To a solution of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide (140 mg, 0.25 mmol) in CH 2 Cl 2 (2 mL) was added TFA (0.75 mL). The reaction mixture was stirred at room temperature for 4 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h then concentrated. The residue was purified by silica gel chromatography with 0% to 5% MeOH/EtOAc to afford 92 mg (86%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-1-(1-cyano-cyclopentyl)-ethyl]-amide as a light yellow powder. MS (M+Na) + =454; mp=300-315° C.; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.96 (br. s., 1H), 9.11 (s, 1H), 8.51-8.56 (m, 1H), 8.50 (s, 1H), 8.19 (d, J=9.1 Hz, 1H), 7.67 (dd, J=9.8, 1.9 Hz, 1H), 7.15 (td, J=9.1, 2.3 Hz, 1H), 4.34-4.50 (m, 1H), 4.14 (s, 3H), 1.92-2.14 (m, 3H), 1.63-1.90 (m, 5H), 1.46 (d, J=6.8 Hz, 3H).

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

4,6-Difluoro-3-iodo-1H-indazole

To a solution of 4,6-difluoro-1H-indazole (1.16 g, 7.53 mmol) in DMF (60 ml) at room temperature was added potassium hydroxide (1.27 g, 22.6 mmol) and iodine (2.87 g, 11.3 mmol). The maroon reaction mixture was stirred at room temperature for 2 h then quenched with 10% aqueous Na 2 S 2 O 3 and diluted with water. The mixture was extracted with EtOAc (2×). The combined organics were washed with water, sat LiCl, and sat NaCl, then dried over MgSO 4 and concentrated to afford 2.18 g of 4,6-difluoro-3-iodo-1H-indazole as a light brown solid.

4,6-Difluoro-3-tributylstannanyl-1H-indazole

To a solution of 4,6-difluoro-3-iodo-1H-indazole (2.11 g, 7.53 mmol) in THF (45 mL) at 0° C. was slowly added sodium hydride (60% in mineral oil, 362 mg, 9.04 mmol). The reaction mixture was stirred at room temperature for 10 min then cooled to −10° C. and isopropylmagnesium chloride (2.0 M in THF, 4.52 mL, 9.04 mmol) was added. The reaction mixture was stirred at −10° C. for 30 min then tributylchlorostannane (2.66 mL, 9.8 mmol) was added dropwise. Stirring was continued at −10° C. for 20 min then at room temperature for 3 h. The reaction mixture was quenched with saturated aqueous NH 4 Cl then diluted with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 10% to 20% EtOAc/heptane (0.5% Et 3 N) to afford 1.94 g (58%) of 4,6-difluoro-3-tributylstannanyl-1H-indazole as a pale yellow viscous oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.03 (dd, J=8.9, 2.1 Hz, 1H), 6.60 (td, J=9.8, 2.1 Hz, 1H), 1.51-1.64 (m, 6H), 1.29-1.42 (m, 6H), 1.20-1.29 (m, 6H), 0.88 (t, J=7.4 Hz, 9H).

2-(4,6-Difluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (1.56 g, 4.38 mmol) and 4,6-difluoro-3-tributylstannanyl-1H-indazole (1.94 g, 4.38 mmol) were dissolved in DMF (40 mL) and tetrakis(triphenylphosphine)palladium(0) (253 mg, 0.22 mmol) and copper(I) iodide (167 mg, 0.88 mmol) were added. The reaction mixture was purged with argon, stirred at room temperature for 4 h, then heated at 80° C. for 1 h. The reaction was cooled to room temperature, quenched with sat NH 4 Cl and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to provide 1.89 g of 2-(4,6-difluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a brown solid.

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

To a solution of 2-(4,6-difluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (890 mg, 2.1 mmol) in DMF (9 ml) at 0° C. was added sodium hydride (60% in mineral oil, 279 mg, 2.49 mmol). The reaction mixture was stirred at 0° C. for 10 min then iodomethane (0.18 ml, 2.9 mmol) was slowly added. The mixture was stirred at 0° C. for 30 min then at room temperature for 30 min. The reaction was quenched with sat'd NH 4 Cl, diluted with water and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 20% to 100% EtOAc/heptane to provide 226 mg (22%) of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a yellow solid.

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

To a solution of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (226 mg, 0.51 mmol) in 1,4-dioxane (15 ml) and water (3 ml) at 0° C. was added sulfamic acid (297 mg, 3.06 mmol). Then a solution of sodium chlorite (80%, 75 mg, 0.66 mmol) and potassium dihydrogen phosphate (834 mg, 6.13 mmol) in water (12 ml) was added via dropping funnel over ˜15 min. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 3 h. The reaction mixture was diluted with water and extracted with EtOAc (3×). The combined organic layers were washed with brine then dried over MgSO 4 and concentrated to afford 230 mg (98%) of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid as a light yellow powder.

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

To a solution of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (75 mg, 0.16 mmol), HOBt (63 mg, 0.38 mmol) and EDC (72 mg, 0.38 mmol) in DMF was added isopropylamine (84 ul, 0.98 mmol). The reaction mixture was stirred at room temperature for 1.5 h then additional HOBt, EDC, and isopropylamine were added. The reaction mixture was stirred at room temperature overnight then diisopropylethylamine (170 ul, 0.98 mmol) was added. The reaction was stirred for 1 h then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with 10% citric acid, sat NaHCO 3 , sat LiCl, and brine then dried over MgSO 4 and concentrated. The residue was chromatographed over silica gel with 20% to 100% EtOAc/heptane to afford 30 mg (37%) of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a white solid.

2-(4,6-Difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

To a solution of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (30 mg, 0.06 mmol) in CH 2 Cl 2 (1.5 mL) was added TFA (0.5 mL). The reaction mixture was stirred at room temperature for 4 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h then concentrated. The residue was purified by silica gel chromatography with 0% to 5% MeOH/EtOAc to afford 18 mg (82%) of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a light yellow powder. MS (M+Na) + =393; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.83 (s, 1H), 8.99 (s, 1H), 8.40 (s, 1H), 8.27 (d, J=7.9 Hz, 1H), 7.59 (dd, J=9.1, 1.9 Hz, 1H), 7.12-7.23 (m, 1H), 4.16-4.27 (m, 1H), 4.14 (s, 3H), 1.22 (d, J=6.4 Hz, 6H).

2-(6-Fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

6-Fluoro-3-iodo-1H-indazole

To a solution of 6-fluoro-1H-indazole (5.50 g, 40.4 mmol) in DMF (150 ml) at room temperature was added potassium hydroxide (6.8 g, 121 mmol) and iodine (15.4 g, 60.6 mmol). The maroon reaction mixture was stirred at room temperature for 8 h then quenched with 10% aqueous Na 2 S 2 O 3 and diluted with water. The mixture was extracted with EtOAc (2×). The combined organics were washed with water, sat LiCl, and sat NaCl, then dried over MgSO 4 and concentrated to afford 8.6 g (81%) of 6-fluoro-3-iodo-1H-indazole as a light yellow solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.48 (dd, J=8.9, 5.1 Hz, 1H), 7.20 (dd, J=8.9, 2.1 Hz, 1H), 7.02 (td, J=9.1, 2.1 Hz, 1H)

6-Fluoro-3-tributylstannanyl-1H-indazole

To a solution of 6-fluoro-3-iodo-1H-indazole (8.6 g, 32.8 mmol) in THF (200 mL) at 0° C. was slowly added portionwise sodium hydride (60% in mineral oil, 1.58 g, 39.4 mmol). The reaction mixture was stirred at room temperature for 10 min then cooled to −10° C. and isopropylmagnesium chloride (2.0 M in THF, 19.7 mL, 39.4 mmol) was added. The reaction mixture was stirred at −10° C. for 30 min then additional isopropylmagnesium chloride (2.0 M in THF, 8.2 mL, 16.4 mmol) was added. The reaction mixture was stirred at −10° C. for 30 min then tributylchlorostannane (11.6 mL, 42.7 mmol) was slowly added. Stirring was continued at −10° C. for 20 min then at room temperature for 3 h. The reaction mixture was quenched with saturated aqueous NH 4 Cl then diluted with water and extracted with EtOAc (2×). The combined organics were washed with brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 10% to 20% EtOAc/heptane (0.5% Et 3 N) to afford 6.53 g (47%) of 6-fluoro-3-tributylstannanyl-1H-indazole as a light brown viscous oil. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 7.65 (dd, J=8.7, 5.3 Hz, 1H), 7.20 (dd, J=9.3, 2.1 Hz, 1H), 6.92 (td, J=9.0, 2.1 Hz, 1H), 1.53-1.67 (m, 6H), 1.28-1.43 (m, 6H), 1.20-1.28 (m, 6H), 0.89 (t, J=7.4 Hz, 9H).

2-(6-Fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a round-bottomed flask, 2-bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (5.47 g, 15.4 mmol) and 6-fluoro-3-tributylstannanyl-1H-indazole (6.53 g, 15.4 mmol) were dissolved in DMF (140 mL) and tetrakis(triphenylphosphine)palladium(0) (888 mg, 0.76 mmol) and copper(I) iodide (585 mg, 3.07 mmol) were added. The reaction mixture was purged with argon then heated at 80° C. for 1 h. The reaction was cooled to room temperature, quenched with sat NH 4 Cl and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was recrystallized from EtOAc to afford 3.74 g of a white solid. The mother liquor was purified by silica gel chromatography with 50% to 100% EtOAc/heptane to provide an additional 1.75 g white solid. Overall yield was 5.49 g (87%) of 2-(6-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.49 (s, 1H), 9.34 (s, 1H), 8.83 (dd, J=9.1, 5.3 Hz, 1H), 8.32 (s, 1H), 7.08-7.25 (m, 2H), 5.77 (s, 2H), 3.55-3.71 (m, 2H), 0.87-1.03 (m, 2H), −0.03 (s, 9H).

2-(6-Fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a microwave vial 2-(6-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (300 mg, 0.73 mmol) was dissolved in DMF (5 ml) and cesium carbonate (714 mg, 2.19 mmol) and 3-iodooxetane (200 mg, 1.08 mmol) were added. The vial was sealed and heated at 100° C. under microwave irradiation for 2 h. The reaction was cooled, quenched with water and extracted with EtOAc (2×). The combined organics were washed with sat LiCl and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 20% to 100% EtOAc/heptane to provide 295 mg (86%) of 2-(6-fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as a white solid. 1 H NMR (CDCl 3 , 300 MHz): δ (ppm) 10.48 (s, 1H), 9.40 (s, 1H), 8.86 (dd, J=9.1, 5.3 Hz, 1H), 8.31 (s, 1H), 7.11-7.25 (m, 2H), 5.72-5.86 (m, 3H), 5.41 (t, J=6.6 Hz, 2H), 5.20 (t, J=7.4 Hz, 2H), 3.56-3.70 (m, 2H), 0.85-1.06 (m, 2H), −0.02 (s, 9H).

2-(6-Fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

To a solution of 2-(6-fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (293 mg, 0.63 mmol) in 1,4-dioxane (20 ml) and water (4 ml) at 0° C. was added sulfamic acid (365 mg, 3.76 mmol). Then a solution of sodium chlorite (80%, 92 mg, 0.82 mmol) and potassium dihydrogen phosphate (1.02 g, 7.52 mmol) in water (16 ml) was added over ˜15 min. After the addition was complete, the ice bath was removed and the reaction mixture was stirred at room temperature for 30 min. THF (20 ml) was added and stirred was continued for 2 h. The reaction mixture was diluted with water and extracted with EtOAc (3×). The combined organic layers were washed with brine then dried over MgSO 4 and concentrated to afford 340 mg of 2-(6-fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid as an off-white powder.

2-(6-Fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

To a solution of 2-(4,6-difluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (115 mg, 0.23 mmol), HOBt (92 mg, 0.55 mmol) and EDC (105 mg, 0.55 mmol) in DMF (3 ml) was added isopropylamine (41 ul, 0.48 mmol) and N,N-diisopropylethylamine (0.17 ml, 0.95 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (2×). The combined organic layers were washed with 10% citric acid, sat NaHCO 3 , sat LiCl, and brine then dried over MgSO 4 and concentrated. The residue was chromatographed over silica gel with 20% to 100% EtOAc/heptane to afford 98 mg (78%) of 2-(6-fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a white solid.

2-(6-Fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

To a solution of 2-(6-fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (98 mg, 0.18 mmol) in CH 2 Cl 2 (1.5 mL) was added TFA (0.5 mL). The reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in 10:90:0.5 MeOH/CH 2 Cl 2 /NH 4 OH (3 mL) and stirred at room temperature for 3 h then concentrated. The residue was portioned between water and 10% MeOH/CH 2 Cl 2 . The aqueous layer was extracted with 10% MeOH/CH 2 Cl 2 (3×). The combined organics were concentrated and the residue was purified by silica gel chromatography with 0% to 5% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) to afford 30 mg (41%) of 2-(6-fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a white solid. MS (M+Na) + =417; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 12.87 (br. s., 1H), 9.20 (s, 1H), 8.45-8.51 (m, 1H), 8.44 (s, 1H), 8.04 (d, J=7.6 Hz, 1H), 7.73 (dd, J=9.8, 1.9 Hz, 1H), 7.22 (td, J=9.1, 1.9 Hz, 1H), 6.13 (quin, J=7.0 Hz, 1H), 5.11-5.20 (m, 2H), 4.99-5.10 (m, 2H), 4.21 (dq, J=13.5, 6.4 Hz, 1H), 1.30 (d, J=6.4 Hz, 6H).

2-(6-Fluoro-1-oxetan-3-yl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-1-methyl-ethyl)-amide

Prepared according to the procedure outlined in Example 102, Steps 6-7, substituting (S)-1-methoxypropan-2-amine hydrochloride for isopropylamine in Step 6. MS: (M+Na) + =447; 1 H NMR (DMSO-d 6 , 400 MHz): δ (ppm) 12.87 (br. s., 1H), 9.25 (s, 1H), 8.56 (dd, J=9.0, 5.2 Hz, 1H), 8.47 (s, 1H), 8.21 (d, J=8.3 Hz, 1H), 7.74 (dd, J=9.7, 2.1 Hz, 1H), 7.20 (td, J=9.0, 2.1 Hz, 1H), 6.09-6.22 (m, 1H), 5.18 (q, J=6.1 Hz, 2H), 5.03-5.11 (m, 2H), 4.34-4.44 (m, 1H), 3.40-3.57 (m, 2H), 3.31 (s, 3H), 1.32 (d, J=6.8 Hz, 3H).

2-(1-Azetidin-3-yl-6-fluoro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-[1-(1-Benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

In a microwave vial 2-(6-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (300 mg, 0.73 mmol) was dissolved in DMF (6 ml) and cesium carbonate (713 mg, 2.19 mmol) and methanesulfonic acid 1-benzhydryl-azetidin-3-yl ester (347 mg, 1.09 mmol) were added. The vial was sealed and heated in a microwave reactor at 100° C. 3 h. The reaction was cooled, quenched with water and extracted with EtOAc (2×). The combined organics were washed with water and brine then dried over MgSO 4 and concentrated. The crude residue was purified by silica gel chromatography with 20% to 30% EtOAc/hexanes to provide 176 mg (38%) of 2-[1-(1-benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde as an orange foam.

2-[1-(1-Benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

To a solution of 2-[1-(1-benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (170 mg, 0.27 mmol) in 1,4-dioxane (10 mL) and water (2 mL) at 0° C. was added sulfamic acid (157 mg, 1.61 mmol). Then added a solution of NaClO 2 (43 mg, 0.37 mmol) and KH 2 PO 4 (439 mg, 3.22 mmol) in water (4 mL) dropwise over 5 min. The ice bath was removed and the yellow cloudy reaction mixture was stirred at room temperature overnight. The mixture was diluted with water and extracted with EtOAc (2×). The combined organic layers were dried over MgSO 4 and concentrated. The residue was triturated with petroleum ether to isolate 45 mg (26%) of 2-[1-(1-benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid as a light yellow solid.

2-[1-(1-Benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

To a solution of 2-[1-(1-benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (130 mg, 0.20 mmol) in DMF (2 mL) were added HATU (84 mg, 0.22 mmol) and isopropylamine (86 μL, 1.00 mmol). The reaction mixture was stirred at room temperature overnight then quenched with water and extracted with EtOAc (2×). The combined organics were washed with water (3×) and brine then dried over MgSO 4 and concentrated. The residue was purified by silica gel chromatography with 50% EtOAc/hexanes to isolate 74 mg (54%) of 2-[1-(1-benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as an off-white foamy solid.

2-(1-Azetidin-3-yl-6-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

In a round-bottomed flask ammonium formate (135 mg, 2.15 mmol) was dissolved in MeOH (1.5 mL). This solution was added to a solution of 2-[1-(1-benzhydryl-azetidin-3-yl)-6-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (74 mg, 0.107 mmol) in THF (1.5 mL) which caused a white precipitate to form. This slurry was transferred via pipet to a pressure tube containing 10% palladium on carbon (wet, 23 mg) in MeOH (1 mL). The tube was sealed and heated at 50° C. for 4 h then cooled to room temperature overnight. The mixture was filtered over Celite, rinsing with CH 2 Cl 2 . The filtrate was concentrated and the residue was absorbed onto SiO 2 and chromatographed with 0% to 10% MeOH/CH 2 Cl 2 (0.5% NH 4 OH) to afford 38 mg (68%) of 2-(1-azetidin-3-yl-6-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a pale yellow foamy solid.

2-(1-Azetidin-3-yl-6-fluoro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

To a solution of 2-(1-azetidin-3-yl-6-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (36 mg, 0.69 mmol) in CH 2 Cl 2 (1 mL) was added TFA (0.5 mL, 6.5 mmol). The reaction mixture was stirred at room temperature for 3 h then concentrated. The residue was redissolved in CH 2 Cl 2 (1 mL) and ethylene diamine (0.2 mL, 3.00 mmol) was added. The reaction mixture was stirred at room temperature for 1 h then quenched with water and extracted with 5% MeOH/CH 2 Cl 2 (3×). The combined organic layers were dried over MgSO 4 and concentrated. The residue was triturated with EtOAc to afford 17 mg (63%) of 2-(1-azetidin-3-yl-6-fluoro-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide as a pale yellow powder. MS: (M+H) + =394; 1 H NMR (DMSO-d 6 , 300 MHz): δ (ppm) 9.14 (s, 1H), 8.40-8.50 (m, 2H), 8.04 (d, J=7.6 Hz, 1H), 7.78-7.86 (m, 1H), 7.13-7.24 (m, 1H), 5.65-5.76 (m, 1H), 4.12-4.28 (m, 3H), 3.86 (t, J=7.9 Hz, 2H), 1.30 (d, J=6.4 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methanesulfonyl-1-methyl-ethyl)-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methanesulfonyl-1-methyl-ethyl)-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (80 mg, 0.175 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (84 mg, 0.26 mmol) and N,N-diisopropylethylamine (0.076 ml, 0.44 mmol) were dissolved in acetonitrile (1.75 ml). (R)-1-(Methylsulfonyl)propan-2-amine hydrochloride (36 mg, 0.21 mmol) was added and the mixture was stirred at room temperature for 3 h. Water and ethyl acetate were added, the layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 65 mg (64%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methanesulfonyl-1-methyl-ethyl)-amide. (M+H) + =578.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methanesulfonyl-1-methyl-ethyl)-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methanesulfonyl-1-methyl-ethyl)-amide (65 mg, 0.113 mmol) was dissolved in dichloromethane (0.8 ml) and then stirred in an ice bath. Trifluoroacetic acid (0.4 ml) was slowly added and the ice bath was removed. The reaction was stirred at room temperature for 3 h then cooled in ice bath. Sodium bicarbonate solution was added and the mixture was extracted three times with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was dissolved in absolute ethanol (7 ml) and sodium acetate (185 mg, 2.25 mmol) was added. The mixture was stirred for 20 h at 60° C. The reaction was cooled, and water and ethyl acetate were added. The aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and evaporated to a residue. After purification by silica gel chromatography (methanol/dichloromethane), 18.6 mg (37%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-methanesulfonyl-1-methyl-ethyl)-amide was obtained. MS: (M+H) + =447; mp=287-290° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ ppm 12.91 (s, 1H) 9.10 (s, 1H) 8.54 (d, J=8.7 Hz, 1H) 8.47 (s, 1H) 8.26 (d, J=7.9 Hz, 1H) 7.97-8.02 (m, 1H) 7.35 (dd, J=8.7, 1.5 Hz, 1H) 4.60-4.72 (m, 1H) 4.18 (s, 3H) 3.45-3.63 (m, 2H) 3.06 (s, 3H) 1.52 (d, J=6.8 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (80 mg, 0.175 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (84 mg, 0.26 mmol) and N,N-diisopropylethylamine (0.076 ml, 0.44 mmol) were dissolved in acetonitrile (1.75 ml). Isopropylamine (0.018 ml, 0.21 mmol) was added and the mixture was stirred at room temperature overnight. Water and ethyl acetate were added, the layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 45 mg (52%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide. (M+H) + =500.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (45 mg, 0.09 mmol) was dissolved in dichloromethane (0.9 ml) and cooled in ice bath. Trifluoroacetic acid (0.3 ml) was added slowly and the reaction was stirred at room temperature for 3.5 h. The reaction was evaporated and the residue was dissolved in dichloromethane (2 ml). Ethylenediamine (0.36 ml, 5.4 mmol) was added and the mixture was stirred at room temperature for 18 h. Water and then ethyl acetate were added to the mixture. The resulting precipitate was filtered off, rinsed with water and dried under high vacuum to give 21 mg (81%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide. (M+Na) + =391; mp=356-362° C. 1 H NMR (400 MHz, DMSO-d 6 ) δ ppm 12.79-12.90 (m, 1H) 9.09 (s, 1H) 8.44 (d, J=9.1 Hz, 1H) 8.42 (s, 1H) 8.02 (d, J=7.6 Hz, 1H) 8.00 (d, J=1.5 Hz, 1H) 7.30 (dd, J=8.8, 1.8 Hz, 1H) 4.19-4.27 (m, 1H) 4.17 (s, 3H) 1.32 (d, J=6.6 Hz, 6H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (80 mg, 0.18 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (87 mg, 0.27 mmol) and N,N-diisopropylethylamine (0.16 ml, 0.91 mmol) were dissolved in acetonitrile (1.8 ml). 3-Amino-2,2-dimethylpropan-1-ol (22 mg, 0.22 mmol) was added and the mixture was stirred at room temperature overnight. Water and ethyl acetate were added, the layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 85 mg (89%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide. (M+Na) + =549.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide (82 mg, 0.156 mmol) was suspended in dichloromethane (1.1 ml) and cooled in ice bath. Trifluoroacetic acid (0.5 ml) was added slowly and the reaction was stirred at room temperature for 3.5 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1.6 ml). Ethylenediamine (0.63 ml, 9.3 mmol) was added and the mixture was stirred at room temperature for 18 h. Water and then ethyl acetate were added to the mixture, the layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and concentrated. The residue was purified by silica gel chromatography (methanol/dichloromethane) to give 39 mg (63%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (3-hydroxy-2,2-dimethyl-propyl)-amide as an off-white solid. (M+Na) + =419; mp=291-293° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 9.10 (s, 1H), 8.45 (s, 1H), 8.41-8.49 (m, 1H), 8.19-8.27 (m, 1H), 7.67 (dd, J=9.8, 2.3 Hz, 1H), 7.14-7.23 (m, 1H), 4.63-4.72 (m, 1H), 4.14 (s, 3H), 3.37-3.43 (m, 2H), 3.16-3.24 (m, 2H), 0.90 (s, 6H).

[(R)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

(R)-2-tert-Butoxycarbonylamino-propionic acid (1.0 g, 5.3 mmol), 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide (2.33 g, 12.2 mmol) and hydroxybenzotriazole (1.64 g, 12.2 mmol) were dissolved in DMF (50 ml). (S)-3-Fluoropyrrolidine hydrochloride (1.66 g, 13.2 mmol) and N,N-diisopropylethylamine (2.95 ml, 16.9 mmol) were added and the mixture was stirred at room temperature for 16 h. Ethyl acetate was added and the solution was washed with 10% citric acid solution three times. The organic layer was washed with sodium bicarbonate solution which was then back-extracted with ethyl acetate four times. The combined organic layers were then washed further with lithium chloride solution, sodium chloride solution, and dried over magnesium sulfate. Concentration of the solution gave 1.3 g (94%) of [(R)-2-((S)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester.

(R)-2-Amino-1-((S)-3-fluoro-pyrrolidin-1-yl)-propan-1-one trifluoroacetate

[(R)-2-((S)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (43 mg, 0.127 mmol) was dissolved in dichloromethane (1.6 ml) and cooled in an ice bath. Trifluoroacetic acid (0.8 ml) was slowly added and the reaction was stirred at room temperature for 3 h then evaporated and dried under high vacuum to afford (R)-2-amino-1-((S)-3-fluoro-pyrrolidin-1-yl)-propan-1-one trifluoroacetate which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((S)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

(R)-2-Amino-1-((S)-3-fluoro-pyrrolidin-1-yl)-propan-1-one trifluoroacetate (crude from Step 2) was dissolved in acetonitrile (4 ml) to which was then added 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (60 mg, 0.13 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (63 mg, 0.197 mmol) and N,N-diisopropylethylamine (0.092 ml, 0.52 mmol). The reaction was stirred at room temperature for 18 h and then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (ethyl acetate/hexanes) to afford 55 mg (70%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((S)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-amide. 1 H NMR (300 MHz, CDCl 3 ) δ: 9.29 (s, 1H), 8.88-8.93 (m, 1H), 8.85 (d, J=8.1 Hz, 1H), 8.32 (s, 1H), 7.43-7.46 (m, 1H), 7.35-7.39 (m, 1H), 5.70-5.74 (m, 2H), 5.21-5.26 (m, 1H), 4.15 (s, 3H), 3.61-4.00 (m, 5H), 3.54-3.61 (m, 2H), 2.06-2.46 (m, 2H), 1.59 (d, J=6.6 Hz, 3H), 0.90-0.97 (m, 2H), −0.05 (s, 9H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((S)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((S)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (54 mg, 0.09 mmol) was dissolved in dichloromethane (0.9 ml) and cooled in ice bath. Trifluoroacetic acid (0.45 ml) was slowly added and the reaction was stirred at room temperature for 2.5 h. The reaction was evaporated and the residue was suspended in dichloromethane (0.9 ml). Ethylenediamine (0.36 ml, 5.4 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The resulting precipitate was filtered off, rinsed with water and dried under high vacuum to give 24 mg (58%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((S)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-amide. MS: (M+H) + =470; mp=269-271° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 9.16 (s, 1H), 8.81-8.91 (m, 1H), 8.53-8.62 (m, 1H), 8.47 (d, J=2.0 Hz, 1H), 7.97 (s, 1H), 7.25-7.33 (m, 1H), 5.27-5.52 (m, 1H), 4.95-5.11 (m, 1H), 4.18 (s, 3H), 3.96-4.12 (m, 1H), 3.73-3.92 (m, 1H), 3.61-3.72 (m, 1H), 2.08-2.35 (m, 1H), 1.38-1.48 (m, 3H).

[(R)-2-((R)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester

(R)-2-tert-Butoxycarbonylamino-propionic acid (1.0 g, 5.3 mmol), 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide (2.33 g, 12.2 mmol) and hydroxybenzotriazole (1.64 g, 12.2 mmol) were dissolved in DMF (50 ml). (R)-3-Fluoropyrrolidine hydrochloride (1.66 g, 13.2 mmol) and N,N-diisopropylethylamine (2.95 ml, 16.9 mmol) were added and the mixture was stirred at room temperature for 16 h. Ethyl acetate was added and the solution was washed with 10% citric acid solution three times. The organic layer was washed with sodium bicarbonate solution which was then back-extracted with ethyl acetate four times. The combined organic layers were then washed further with lithium chloride solution, sodium chloride solution, and dried over magnesium sulfate. Concentration of the solution gave 1.3 g (94%) of [(R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester.

[(R)-2-((R)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-carbamic acid tert-butyl ester

[(R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (50 mg, 0.19 mmol) was dissolved in diethyl ether (0.8 ml) and stirred in an ice/water bath. Lithium aluminum hydride (1.0 M in diethyl ether, 0.38 ml, 0.38 mmol) was added dropwise. The reaction was stirred at 0° C. and monitored by TLC. When the reaction was judged to be complete, water (15 ul), then 10% sodium hydroxide solution (23 ul), and then water (45 ul) were added. The reaction mixture was warmed to room temperature then filtered. The filtrate was evaporated to give 47 mg (99%) of [(R)-2-(R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-carbamic acid tert-butyl ester.

(R)-2-(R)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-ethylamine bistrifluoroacetate

[(R)-2-((R)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-carbamic acid tert-butyl ester (48 mg, 0.185 mmol) was dissolved in dichlormethane (1.2 ml) and cooled in an ice bath. Trifluoroacetic acid (0.74 ml) was slowly added and the reaction was stirred at room temperature for 2 h then evaporated to afford (R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethylamine bistrifluoroacetate which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-amide

(R)-2-((R)-3-Fluoro-pyrrolidin-1-yl)-1-methyl-ethylamine bistrifluoroacetate (crude from Step 3) was dissolved in acetonitrile (4 ml) to which was then added 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (65 mg, 0.14 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (68 mg, 0.21 mmol) and N,N-diisopropylethylamine (0.12 ml, 0.71 mmol). The reaction was stirred at room temperature for 18 h and then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 65 mg (78%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-amide. (M+H) + =586.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-amide (65 mg, 0.11 mmol) was dissolved in dichloromethane (0.7 ml) and cooled in ice bath. Trifluoroacetic acid (0.4 ml) was slowly added and the reaction was stirred at room temperature for 3 h. The reaction was evaporated and the residue was suspended in dichloromethane (1.1 ml). Ethylenediamine (0.45 ml, 6.65 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 33 mg (65%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-((R)-3-fluoro-pyrrolidin-1-yl)-1-methyl-ethyl]-amide. MS (M+H) + =456; mp=233-234° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 12.81-12.93 (m, 1H), 9.10 (s, 1H), 8.44 (s, 1H), 8.38-8.46 (m, 1H), 8.07 (d, J=8.3 Hz, 1H), 7.99-8.03 (m, 1H), 7.28-7.36 (m, 1H), 4.97-5.24 (m, 1H), 4.20-4.33 (m, 1H), 4.17 (s, 3H), 2.54-2.90 (m, 1H), 2.54-2.90 (m, 4H), 2.32-2.44 (m, 1H), 1.66-2.13 (m, 2H), 1.32 (d, J=6.4 Hz, 3H).

6-Chloro-4-fluoro-1H-indazole

4-Chloro-2,6-difluoro-benzaldehyde (15 g, 85 mmol) was dissolved in 1,2-dimethoxyethane 170 ml). O-Methyl-hydroxylamine hydrochloride (7.1 g, 85 mmol) and potassium carbonate (12.9 g, 93.5 mmol) were then added and the mixture was stirred at 35° C. for 24 h. The reaction was filtered, rinsed with dichloromethane, evaporated and redissolved in DMF (170 ml). Hydrazine (2.9 ml 93.5 mmol) was added and the reaction was stirred at 100° C. for 1 h. After cooling, water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with water and sodium chloride solution then dried over sodium sulfate. The solvent was evaporated to leave a solid which was purified by silica gel chromatography (diethyl ether/hexanes) to give 7 g (49%) of 6-chloro-4-fluoro-1H-indazole. (M+H) + =171.

6-Chloro-4-fluoro-3-iodo-1H-indazole

6-Chloro-4-fluoro-1H-indazole (7.6 g, 44.6 mmol) was dissolved in DMF (110 ml). Iodine (22.6 g, 89.1 mmol) was added followed by potassium hydroxide (9.5 g, 169 mmol). The reaction was stirred at room temperature for 1.5 h. Water, 1 M sodium thiosulfate solution and diethyl ether were added. The layers were separated and the aqueous layer was extracted once more with ether. The organic layers were washed with water and sodium chloride solution, and then dried over sodium sulfate. Evaporation of the solvent gave 11.16 g (85%) of 6-chloro-4-fluoro-3-iodo-1H-indazole as a light brown solid (M−H) − =295.

6-Chloro-4-fluoro-3-tributylstannanyl-1H-indazole

6-Chloro-4-fluoro-3-iodo-1H-indazole (10.1 g, 34.1 mmol) was dissolved in THF (170 ml). The reaction flask was stirred in a water bath and sodium hydride (60% dispersion, 1.64 g, 40.9 mmol) was added. The mixture was stirred for 15 min then cooled in an ice/salt bath to −15° C. Isopropylmagnesium chloride (2.0 M in THF, 20.6 ml, 41.2 mmol) was added dropwise. After 40 min, tributyltin chloride (11.6 ml, 42.6 mmol) was slowly added and the reaction was allowed to warm to room temperature. After an additional 2 h stirring, ammonium chloride solution and ethyl acetate were added. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. Evaporation of the solvent provided 6-chloro-4-fluoro-3-tributylstannanyl-1H-indazole as an oil which was used directly in the next step.

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

2-Bromo-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (7.6 g, 18.6 mmol) and 6-chloro-4-fluoro-3-tributylstannanyl-1H-indazole (crude from Step 3) were dissolved in DMF (180 ml) and purged with Ar gas. Tetrakis(triphenylphosphine)pallladium (1.07 g, 0.93 mmol) and then copper iodide (707 mg, 3.71 mmol) were added and the flask was stoppered and stirred in a 90° C. oil bath for 20 h. The reaction was cooled and water, ethyl acetate and sodium bicarbonate solution were added. The layers were separated, and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with water and sodium chloride solution, then dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) followed by trituration with diethyl ether/hexanes to give 3.9 g (47%) of 2-(6-chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde. (M+H) + =446.

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (0.5 g, 1.12 mmol) was dissolved in DMF (5.6 ml) and cooled in an ice bath. Sodium hydride (60% dispersion, 67 mg, 1.68 mmol) was carefully added. The mixture was stirred for 10 min then iodomethane (84 ul, 1.35 mmol) was added and the reaction was warmed to room temperature and stirred for 18 h. Water and ethyl acetate were added to the reaction. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed water and sodium chloride solution and dried over sodium sulfate. After evaporation the remaining residue was purified by silica gel chromatography (ethyl acetate/dichloromethane) to give 257 mg (50%) of 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde. (M+H) + =460.

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (255 mg, 0.55 mmol) was dissolved in THF (8.3 ml) and water (2.8 ml). Sulfamic acid (517 mg, 5.3 mmol) was added. The reaction flask was cooled in an ice/water bath and a solution of sodium chlorite (104 mg, 1.15 mmol) and potassium phosphate monobasic (1.45 g, 10.6 mmol) in water (8 ml) was slowly added. After 1 h the reaction mixture was poured into ethyl acetate and water. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were washed with water and sodium chloride solution, and dried over sodium sulfate. Evaporation of the solvent gave 270 mg of 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid as a light yellow solid. (M+H) + =476.

1-((R)-2-Amino-propionyl)-azetidine-3-carbonitrile trifluoroacetate

[(R)-2-(3-cyanoazetidin-1-yl)-1-methyl-2-oxo-ethyl]-carbamic acid tert-butyl ester (47 mg, 0.185 mmol) was dissolved in dichloromethane (1 ml) and cooled in an ice bath. Trifluoroacetic acid (0.5 ml) was slowly added and the reaction was stirred at room temperature for 2 h then evaporated and dried under high vacuum to afford 1-((R)-2-amino-propionyl)-azetidine-3-carbonitrile trifluoroacetate which was used without further purification.

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

1-((R)-2-Amino-propionyl)-azetidine-3-carbonitrile trifluoroacetate (crude from Step 7) was dissolved in acetonitrile (2 ml) to which was then added 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (80 mg, 0.168 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (81 mg, 0.252 mmol) and N,N-diisopropylethylamine (0.15 ml, 0.84 mmol). The reaction was stirred at room temperature for 18 h and then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 84 mg (82%) of 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide. (M+Na) + =633.

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide (84 mg, 0.137 mmol) was suspended in dichloromethane (2 ml) and cooled in an ice bath. Trifluoroacetic acid (0.9 ml) was slowly added and the reaction was stirred at room temperature for 3 h then evaporated. The residue was dissolved in dichloromethane (1.4 ml) and ethylenediamine (0.55 ml, 8.25 mmol) was added. The reaction was stirred for 8 h. Water was added giving a cloudy mixture, which was extracted with ethyl acetate eight times. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. Drying agent was filtered off and rinsed with 10% methanol/dichloromethane, and evaporated to a residue. This was combined with solid which had appeared in the aqueous layer. The combined material was purified by silica gel chromatography (methanol/dichloromethane) to give 32 mg (48%) of 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-2-oxo-ethyl]-amide. (M+H) + =481; mp=267-268° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 9.00 (s, 1H), 8.54 (d, J=7.2 Hz, 1H), 8.49 (d, J=10.6 Hz, 1H), 7.86-7.90 (m, 1H), 7.18 (d, J=10.2 Hz, 1H), 4.42-4.69 (m, 3H), 4.18 (s, 3H), 4.07-4.17 (m, 1H), 3.95-4.05 (m, 1H), 3.76-3.87 (m, 1H), 1.32-1.41 (m, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [2-(3-cyano-pyrrolidin-1-yl)-1-methyl-ethyl]-amide

[2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-(2-methyl-aziridin-1-yl)-methanone

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxylic acid (100 mg, 0.218 mmol) was suspended in dichloromethane (2.2 ml). 4-Dimethylaminopyridine (5.3 mg, 0.044 mmol), N,N-diisopropylethylamine (76 ul, 0.44 mmol) and then 1-(3-(dimethylamino)-propyl)-3-ethylcarbodiimide (84 mg, 0.44 mmol) were added. The solution was stirred for 5 min then cooled in an ice bath. 2-Methylaziridine (23 ul, 0.33 mmol) was added and the reaction was warmed to room temperature. Stirring was continued until judged to be complete by TLC then water, dilute HCl and ethyl acetate were added. The aqueous layer was extracted once more with ethyl acetate and the combined organic layers were washed with sodium bicarbonate solution and dried over sodium sulfate. After evaporation the residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 70 mg (64%) of [2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-(2-methyl-aziridin-1-yl)-methanone. 1 H NMR (300 MHz, CDCl 3 ) δ ppm 9.23 (s, 1H) 8.76 (d, J=8.7 Hz, 1H) 8.33 (s, 1H) 7.44 (s, 1H) 7.24 (d, J=8.7 Hz, 1H) 5.73 (s, 2H) 4.14 (s, 3H) 3.56-3.65 (m, 6H) 2.80-2.91 (m, 1H) 2.59 (d, J=6.0 Hz, 1H) 2.33 (d, J=3.8 Hz, 1H) 1.41 (d, J=5.3 Hz, 3H) 0.89-0.99 (m, 2H)-0.05 (s, 9H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [2-(3-cyano-pyrrolidin-1-yl)-1-methyl-ethyl]-amide

[2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazin-7-yl]-(2-methyl-aziridin-1-yl)-methanone (70 mg, 0.14 mmol) was dissolved in 1:1 THF: acetonitrile (1.5 ml). 3-Cyanopyrrolidine hydrochloride (28 mg, 0.21 mmol) and N,N-diisopropylethylamine (37 ul, 0.21 mmol) were added and the reaction was heated in a microwave reactor at 120° C. for 2 h. An additional 0.5 eq of 3-cyanopyrrolidine hydrochloride and N,N-diisopropylethylamine were added and the heating was repeated twice more. Water and ethyl acetate were then added to the cooled solution. The aqueous layer was extracted twice more with ethyl acetate and the combined organics were washed with sodium chloride solution and dried over sodium sulfate. After evaporation of solvent the crude residue was purified by silica gel chromatography (ethyl acetate/dichloromethane) to give 21 mg (25%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [2-(3-cyano-pyrrolidin-1-yl)-1-methyl-ethyl]-amide. (M+H) + =593.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [2-(3-cyano-pyrrolidin-1-yl)-1-methyl-ethyl]-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [2-(3-cyano-pyrrolidin-1-yl)-1-methyl-ethyl]-amide (37 mg, 0.062 mmol) was dissolved in dichloromethane (0.8 ml) and cooled in ice bath. Trifluoroacetic acid (0.4 ml) was slowly added and the reaction was stirred at room temperature for 2 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1.2 ml). Ethylenediamine (0.25 ml, 3.7 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 15 mg (52%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [2-(3-cyano-pyrrolidin-1-yl)-1-methyl-ethyl]-amide. MS: (M+H) + =463; mp=206-209° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 12.83-12.94 (m, 1H), 9.10 (s, 1H), 8.38-8.51 (m, 2H), 8.04-8.13 (m, 1H), 7.99-8.04 (m, 1H), 7.30-7.39 (m, 1H), 4.20-4.36 (m, 1H), 4.18 (s, 3H), 3.07-3.22 (m, 1H), 2.53-2.88 (m, 5H), 1.99-2.15 (m, 1H), 1.74-1.92 (m, 1H), 1.33 (d, J=6.4 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-amide

(R)-2-methyl-1-(4-nitro-benzenesulfonyl)-aziridine

4-Nitrobenzene-1-sulfonyl chloride (6.9 g, 31 mmol) was dissolved in acetonitrile (8 ml) and stirred in an ice bath. A solution of (R)-2-aminopropan-1-ol (1 g, 13.3 mmol) in pyridine (5 ml) was added slowly and the reaction was stirred for 2 h. Ethyl acetate (25 ml) and water (10 ml) were added and the reaction was stirred for 10 min. The layers were separated and the organic layer was washed with 1M citric acid solution twice and with water once. The organic layer was cooled to 10° C. and 7 ml of water was added followed by dropwise addition of N,N-diisopropylethylamine (3.7 ml, 21.3 mmol). After stirring for 1 h the layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organics were washed twice with 1M citric acid solution and twice with water. Isopropanol (70 ml) was then added and the solvents were evaporated slowly leaving mostly isopropanol. (R)-2-Methyl-1-(4-nitro-benzenesulfonyl)-aziridine 2.2 g (69%) was obtained after crystallization from isopropanol. 1 H NMR (300 MHz, CDCl 3 ) δ: 8.40 (d, J=9.1 Hz, 2H), 8.16 (d, J=9.1 Hz, 2H), 2.92-3.04 (m, 1H), 2.74 (d, J=7.2 Hz, 1H), 2.13 (d, J=4.5 Hz, 1H), 1.30 (d, J=5.7 Hz, 3H).

N—[(R)-2-(3-Cyano-azetidin-1-yl)-1-methyl-ethyl]-4-nitro-benzenesulfonamide

(R)-2-Methyl-1-(4-nitro-benzenesulfonyl)-aziridine (0.2 g, 0.83 mmol) was dissolved in THF (1 ml). 3-Cyanoazetidinine hydrochloride (117 mg, 0.99 mmol) and N,N-diisopropylethylamine (0.2 ml, 1.16 mmol) were added and the reaction was stirred for 64 h. Water and ethyl acetate were then added. The aqueous layer was extracted twice more with ethyl acetate, the combined organics were washed with sodium chloride solution and dried over sodium sulfate. After evaporation the residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 133 mg (49%) of N—[(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-4-nitro-benzenesulfonamide. (M+H) + =325.

N—[(R)-2-(3-Cyano-azetidin-1-yl)-1-methyl-ethyl]-4-nitro-benzenesulfonamide

N—[(R)-2-(3-Cyano-azetidin-1-yl)-1-methyl-ethyl]-4-nitro-benzenesulfonamide (133 mg, 0.41 mmol) was dissolved in DMF (2 ml). Di-tert-butyldicarbonate (98 mg, 0.45 mmol) and 4-dimethylaminopyridine (55 mg, 0.45 mmol) were added and the reaction was stirred for 6 h. Thiophenol (63 ul, 0.615 mmol) and potassium carbonate (170 mg, 1.23 mmol) were then added and the reaction was allowed to stand for 16 h at 0° C. Water, sodium hydroxide solution and ethyl acetate were then added. The aqueous layer was extracted once more with ethyl acetate and the combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 75 mg (76%) of [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-carbamic acid tert-butyl ester. (M+H) + =240.

1-((R)-2-Amino-propyl)-azetidine-3-carbonitrile bistrifluoroacetate

[(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-carbamic acid tert-butyl ester (35 mg, 0.146 mmol) was dissolved in dichloromethane (1 ml) and cooled in an ice bath. Trifluoroacetic acid (0.45 ml) was slowly added and the reaction was stirred at room temperature for 2 h then evaporated and dried under high vacuum to afford 1-((R)-2-amino-propyl)-azetidine-3-carbonitrile bistrifluoroacetate which was used without further purification.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-amide

1-((R)-2-Amino-propyl)-azetidine-3-carbonitrile bistrifluoroacetate (crude from Step 4) was dissolved in acetonitrile (1.5 ml) to which was then added 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (60 mg, 0.132 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (70 mg, 0.22 mmol) and N,N-diisopropylethylamine (0.13 ml, 0.73 mmol). The reaction was stirred at room temperature for 18 h and then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 58 mg (64%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-amide. (M+H) + =579.

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-amide

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-amide (58 mg, 0.10 mmol) was dissolved in dichloromethane (1.4 ml) and cooled in ice bath. Trifluoroacetic acid (0.6 ml) was slowly added and the reaction was stirred at room temperature for 5 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1 ml). Ethylenediamine (0.40 ml, 6.0 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 29 mg (64%) of 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid [(R)-2-(3-cyano-azetidin-1-yl)-1-methyl-ethyl]-amide. MS: (M+H) + =449; mp=235-238° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 9.10 (s, 1H), 8.44 (d, J=8.7 Hz, 1H), 8.43 (s, 1H), 8.01 (d, J=1.5 Hz, 1H), 8.02 (d, J=8.3 Hz, 1H), 7.34 (dd, J=8.7, 1.5 Hz, 1H), 4.18 (s, 3H), 4.04-4.16 (m, 1H), 3.36-3.53 (m, 4H), 3.28 (d, J=7.9 Hz, 1H), 2.60-2.68 (m, 2H), 1.28 (d, J=6.8 Hz, 3H).

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (59 mg, 0.124 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (60 mg, 0.186 mmol), N,N-diisopropylethylamine (0.11 ml, 0.62 mmol) and isopropylamine (11 ul, 0.124 mmol) were added together in acetonitrile (1.3 ml). The reaction was stirred at room temperature for 18 h then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (ethyl acetate/hexanes) to give 46 mg (72%) of 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide. (M+H) + =517.

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (46 mg, 0.09 mmol) was dissolved in dichloromethane (1.2 ml) and cooled in ice bath. Trifluoroacetic acid (0.6 ml) was slowly added and the reaction was stirred at room temperature for 2 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1 ml). Ethylenediamine (0.36 ml, 5.3 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The resulting precipitate was filtered off, rinsed with water diethyl ether and ethyl acetate and set aside. The organic filtrate was separated, washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was combined with the precipitate collected above. The solids were dried under high vacuum to afford 34 mg (98%) of 2-(6-chloro-4-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide. MS: (M+H) + =387; mp=347-349° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 9.01 (s, 1H), 8.42 (s, 1H), 8.22-8.33 (m, 1H), 7.88 (s, 1H), 7.20-7.32 (m, 1H), 4.13-4.30 (m, 1H), 4.18 (s, 3H), 1.24 (d, J=6.4 Hz, 6H).

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide hydrochloride

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (100 mg, 0.22 mmol) was dissolved in DMF (0.5 ml) and cooled in an ice bath. Sodium hydride (60% dispersion, 22 mg, 0.56 mmol) was carefully added. The mixture was stirred for 10 min then dimethylaminoethyl chloride hydrochloride (36 mg, 0.25 mmol) and potassium iodide (4 mg, 0.022 mmol) were added and the reaction was warmed to room temperature then stirred at 50° C. overnight. After cooling to room temperature, water and ethyl acetate were added to the reaction. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed water and sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to give 46 mg (40%) of 2-[6-chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde. (M+H) + =517.

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (46 mg, 0.09 mmol) was dissolved in THF (1.3 ml) and water (0.4 ml) and sulfamic acid (83 mg, 0.85 mmol) was added. A solution of sodium chlorite (17 mg, 0.185 mmol) and potassium phosphate monobasic (232 mg, 1.7 mmol) in water (1.4 ml) was slowly added. After 1 h the reaction mixture was poured into ethyl acetate and water. The pH was adjusted to 6, the layers were separated and the aqueous layer was extracted five times with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated to give 53 mg of 2-[6-chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid.

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (50 mg, 0.094 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (45 mg, 0.14 mmol), N,N-diisopropylethylamine (0.08 ml, 0.47 mmol) and isopropylamine (10 ul, 0.11 mmol) were added together in acetonitrile (1 ml). The reaction was stirred at room temperature for 18 h then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to give 35 mg (65%) of 2-[6-chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide.

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide hydrochloride

2-[6-Chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (35 mg, 0.06 mmol) was dissolved in dichloromethane (1.6 ml) and cooled in ice bath. Trifluoroacetic acid (0.8 ml) was slowly added and the reaction was stirred at room temperature for 2 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1 ml). Ethylenediamine (0.25 ml, 3.7 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography (methanol/dichloromethane). The product thus isolated was dissolved in methanol/dichloromethane and treated with 4 eq of 4 M HCl in 1,4-dioxane. Evaporation of the solvent provided a solid which was dried under high vacuum to afford 18 mg (62%) of 2-[6-chloro-1-(2-dimethylamino-ethyl)-4-fluoro-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide hydrochloride. MS: (M+H) + =444; mp=281-283° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 10.17-10.33 (m, 1H), 9.08 (s, 1H), 8.44 (d, J=3.0 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 8.03-8.08 (m, 1H), 7.34 (d, J=10.6 Hz, 1H), 4.94-5.05 (m, 2H), 4.14-4.30 (m, 1H), 3.66-3.77 (m, 2H), 2.89 (d, J=4.5 Hz, 6H), 1.24 (d, J=6.8 Hz, 6H).

2-[6-Chloro-4-fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide hydrochloride

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carbaldehyde (139 mg, 0.31 mmol) was dissolved in THF (4.7 ml) and water (1.6 ml) and sulfamic acid (291 mg, 3.0 mmol) was added. A solution of sodium chlorite (17 mg, 0.185 mmol) and potassium phosphate monobasic (232 mg, 1.7 mmol) in water (1.4 ml) was slowly added. After 1 h the reaction mixture was poured into ethyl acetate and water. The layers were separated and the aqueous layer was extracted once more with ethyl acetate. The combined organic layers were dried over sodium sulfate and concentrated to give 136 mg of 2-(6-chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid.

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (140 mg, 0.30 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (146 mg, 0.46 mmol), N,N-diisopropylethylamine (0.27 ml, 1.52 mmol) and isopropylamine (31 ul, 0.36 mmol) were added together in acetonitrile (1 ml). The reaction was stirred at room temperature for 18 h then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted twice more with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to give 77 mg (51%) of 2-(6-chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide.

2-[6-Chloro-4-fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide

2-(6-Chloro-4-fluoro-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (77 mg, 0.15 mmol) was dissolved in DMF (2.5 ml) and cooled in an ice bath. Sodium hydride (60% dispersion, 8 mg, 0.20 mmol) was carefully added. The mixture was stirred for 15 min then additional sodium hydride (60% dispersion, 10 mg, 0.25 mmol) and 4-(2-bromoethyl)morpholine hydrochloride (42 mg, 0.18 mmol) were added. The reaction was warmed to room temperature and stirred overnight. Water, sodium bicarbonate solution and ethyl acetate were added to the reaction. The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed water and sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to give 66 mg (70%) of 2-[6-chloro-4-fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide.

2-[6-Chloro-4-fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide hydrochloride

2-[6-Chloro-4-fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indazol-3-yl]-5-(2-trimethylsilanylethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide (66 mg, 0.107 mmol) was dissolved in dichloromethane (1.4 ml) and cooled in ice bath. Trifluoroacetic acid (0.7 ml) was slowly added and the reaction was stirred at room temperature for 2 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1 ml). Ethylenediamine (0.43 ml, 6.4 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sodium chloride solution, dried over sodium sulfate and evaporated. The residue was purified by silica gel chromatography (methanol/dichloromethane). The product thus isolated was dissolved in methanol/dichloromethane and treated with 2 eq of 4 M HCl in 1,4-dioxane. Evaporation of the solvent provided a solid which was dried under high vacuum to afford 40 mg (72%) of 2-[6-chloro-4-fluoro-1-(2-morpholin-4-yl-ethyl)-1H-indazol-3-yl]-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid isopropylamide hydrochloride. MS: (M+H) + =486; mp=190-195° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 12.86-12.98 (m, 1H), 10.92-11.17 (m, 1H), 9.06 (s, 1H), 8.45 (d, J=3.0 Hz, 1H), 8.26 (d, J=7.9 Hz, 1H), 8.05 (s, 1H), 7.35 (d, J=10.6 Hz, 1H), 5.05 (br. s., 2H), 4.14-4.30 (m, 1H), 3.93-4.09 (m, 2H), 3.68-3.85 (m, 4H), 3.54-3.64 (m, 2H), 3.11-3.30 (m, 2H), 1.24 (d, J=6.4 Hz, 6H).

((R)-2-Hydroxy-1-methyl-ethyl)-carbamic acid tert-butyl ester

R-(−)-2-Aminopropan-1-ol (2.0 g, 26.6 mmol) was dissolved in dichloromethane (133 ml) and di-tert-butyldicarbonate (11.6 g, 53.3 mmol) was added in portions. The reaction was stirred at room temperature for 16 h. Water was added and the aqueous layer was extracted once with dichloromethane. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to give 4.0 g (85%) of ((R)-2-hydroxy-1-methyl-ethyl)-carbamic acid tert-butyl ester. (M+Na) + =198.

Methanesulfonic acid (R)-2-tert-butoxycarbonylamino-propyl ester

((R)-2-Hydroxy-1-methyl-ethyl)-carbamic acid tert-butyl ester (0.5 g, 2.85 mmol) was dissolved in dichloromethane (14 ml) and stirred in an ice bath. N,N-diisopropylethylamine (0.75 ml, 4.28 mmol) and then methanesulfonyl chloride (0.27 ml, 3.4 mmol) were slowly added and the reaction was warmed to room temperature over 16 h. Ammonium chloride solution was added to the reaction and it was extracted two times with ethyl acetate. The combined organics were washed with sodium chloride solution and dried over sodium sulfate. Evaporation gave 0.73 g of methanesulfonic acid (R)-2-tert-butoxycarbonylamino-propyl ester as a waxy white solid. 1 H NMR (CDCl 3 ) δ: 4.51-4.68 (m, 1H), 4.19-4.28 (m, 1H), 4.11-4.18 (m, 1H), 3.90-4.04 (m, 1H), 3.03 (s, 3H), 1.24 (d, J=6.8 Hz, 3H).

((R)-1-Methyl-2-pyrazol-1-yl-ethyl)-carbamic acid tert-butyl ester

1H-Pyrazole (70 mg, 1.03 mmol) was dissolved in DMF (5 ml) and cooled in an ice bath. Sodium hydride (60% dispersion in mineral oil, 41 mg, 1.03 mmol) was added and the reaction was stirred for 15 min. Methanesulfonic acid (R)-2-tert-butoxycarbonylamino-propyl ester (200 mg, 0.79 mmol) was then added and the mixture was stirred at 50° C. for 16 h. The reaction was cooled to room temperature and water and ethyl acetate were added. The aqueous layer was extracted twice more with ethyl acetate and the combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to give 129 mg (72%) of ((R)-1-methyl-2-pyrazol-1-yl-ethyl)-carbamic acid tert-butyl ester. (M+H) + =226.

(R)-1-Methyl-2-pyrazol-1-yl-ethylamine trifluoroacetate

((R)-1-Methyl-2-pyrazol-1-yl-ethyl)-carbamic acid tert-butyl ester (49 mg, 0.22 mmol) was dissolved in dichloromethane (2.4 ml) and cooled in an ice bath. Trifluoroacetic acid (1.2 ml) was slowly added and the reaction was stirred at room temperature for 2 h then evaporated and dried under high vacuum to afford (R)-1-methyl-2-pyrazol-1-yl-ethylamine trifluoroacetate which was used without further purification.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-pyrazol-1-yl-ethyl)-amide

(R)-1-Methyl-2-pyrazol-1-yl-ethylamine trifluoroacetate (crude from Step 4) was dissolved in acetonitrile (1.8 ml) to which was then added 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid (80 mg, 0.18 mmol), O-benzotriazol-1-yl-N,N,N′,N′-tetramethyluronium tetrafluoroborate (87 mg, 0.27 mmol) and N,N-diisopropylethylamine (0.16 ml, 0.91 mmol). The reaction was stirred at room temperature for 18 h and then water and ethyl acetate were added. The layers were separated and the aqueous layer was extracted three times with ethyl acetate. The combined organic layers were washed with sodium chloride solution and dried over sodium sulfate. After evaporation, the residue was purified by silica gel chromatography (methanol/dichloromethane) to afford 89 mg (81%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-pyrazol-1-yl-ethyl)-amide.

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-pyrazol-1-yl-ethyl)-amide

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-pyrazol-1-yl-ethyl)-amide (86 mg, 0.16 mmol) was dissolved in dichloromethane (2.2 ml) and cooled in ice bath. Trifluoroacetic acid (1 ml) was slowly added and the reaction was stirred at room temperature for 2 h. The reaction was evaporated and the residue was dissolved in dichloromethane (1 ml). Ethylenediamine (0.63 ml, 9.4 mmol) was added and the mixture was stirred for 18 h. Water and then ethyl acetate were added to the mixture. The resulting precipitate was filtered off, rinsed with water and diethyl ether and dried under high vacuum to give 37 mg (57%) of 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-1-methyl-2-pyrazol-1-yl-ethyl)-amide. MS: (M+Na) + =441; mp=252-253° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 9.08 (s, 1H), 8.46 (s, 1H), 8.21-8.33 (m, 1H), 8.12 (d, J=7.9 Hz, 1H), 7.63-7.75 (m, 2H), 7.31-7.40 (m, 1H), 6.97-7.10 (m, 1H), 6.12-6.23 (m, 1H), 4.46-4.63 (m, 1H), 4.32-4.44 (m, 2H), 4.14 (s, 3H), 1.23 (d, J=6.4 Hz, 3H).

2-(6-Chloro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((R)-2-imidazol-1-yl-1-methyl-ethyl)-amide

Prepared according to the procedure outlined in Example 133, substituting 1H-imidazole for 1H-pyrazole in Step 3 and substituting 2-(6-chloro-1-methyl-1H-indazol-3-yl)-5-((2-(trimethylsilyl)ethoxy)methyl)-5H-pyrrolo[3,2-b]pyrazine-7-carboxylic acid for 2-(6-fluoro-1-methyl-1H-indazol-3-yl)-5-(2-trimethylsilanyl-ethoxymethyl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid in Step 5. MS: (M+H) + =435; mp=276-279° C. 1 H NMR (300 MHz, DMSO-d 6 ) δ: 12.76-13.03 (m, 1H), 9.08 (s, 1H), 8.47 (s, 1H), 8.01-8.14 (m, 2H), 7.98 (br. s., 1H), 7.62 (br. s., 1H), 7.18-7.27 (m, 1H), 7.15 (br. s., 1H), 6.82 (s, 1H), 4.36-4.50 (m, 1H), 4.16 (br. s., 3H), 4.09-4.36 (m, 2H), 1.26 (d, J=6.4 Hz, 3H).

2-(6-Fluoro-1-methyl-1H-indazol-3-yl)-5H-pyrrolo[2,3-b]pyrazine-7-carboxylic acid ((S)-2-methoxy-propyl)-amide

((S)-2-Hydroxy-propyl)-carbamic acid tert-butyl ester

(S)-1-Aminopropan-2-ol (1.0 g, 13.3 mmol) was dissolved in dichloromethane (67 ml) and di-tert-butyldicarbonate (5.8 g, 26.6 mmol) was added in portions. The reaction was stirred at room temperature for 16 h. Ammonium chloride solution and water were added and the aq